var title_f14_31_14832="Mandibular advan splint III";
var content_f14_31_14832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mandibular advancement splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Another example of a two-piece device, with full occlusal coverage, and a titratable slot and flange coupling mechanism in the vicinity of the posterior teeth, permitting mouth opening and closing whilst in advancement (SomnoMed MAS&reg;, SomnoMed Ltd, Australia).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: SomnoMed, Inc. file://www.somnomed.com.au/index.php?id=281.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14832=[""].join("\n");
var outline_f14_31_14832=null;
var title_f14_31_14833="Toe osteo";
var content_f14_31_14833=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteomyelitis of the toe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 366px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFuAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKdGjSMERSzHgADJNADaK6DT/AA5NJiS9IiiHVQcsf6CussPD0CBDHbwr6hxubHrk0AeZ08xuBkowHqRXrsWm7QAiIv0HGPrTZLCTZnaSBQB5DRXpF/o9tKcTwIT64wf0rl9T8PSQ7pLMmROuxvvfh60Ac/RSsCGIYEEcEHtSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU5FZ3VEGWY4A9TQBJa28lzOsUK7nb9K7bRdHis+QN8xGGc/yFN0TTEs4cY3Snl3A/Qe1boGyMBT8x4Ax60APt7cST7cApHgsT0+lbcSdCQcY7daqWUQhjCjDE/MxxW7pGnS3Ub3DRf6NFnJYcSEYz9cZ7UAVYo3kXMUcjgdcDgUpQKOcgdgeMV0M8QiARNgVSy4PAAOfmx9McVnukLqSIg4G1jjjqOf6UAYd1DGwIYf8AAhWLeWpXOcAHo1dHfRNDJtJDIfunBJHtWVc8Kw69jQB5z4nsyH+0IOB8r8frXPV3l8qzCRD905Uj1FcIeODQAlWbexurgjyIJHB6ELx+dbeiacscQnlQNK3Kgj7g/wAa6eCD5Bk57Z7UAcMdE1HGfszY/wB4f41DNpt7CMyW0o+gz/KvTY4B6fjSNartPAOOvYigDygjBwQRSV6HqWi210p3xqH7MvUVx2raVLp75PzQk4Vx/WgDNooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACul8M6d0uZVJZuI1x29axtLtDe3ixdFHLH2r0O1hWNAqqFX0xQBLBGRgAH2q7aRl5S7DhQB1qELnAGCDwTjpWhbKI4wcjsaALEUbOyhSAWO0e2a7DT4PldU3mGKPamM9wP6g1ycAbzMqCcN+teh6NbImnWT3rkMAzOVXqo3HB9e35UAZTWcsayu7Ijop+Vj/HuwBwem3moGgDH7NGqMzZVzJxtUnrnsf8a2wsXmM0SRyRO4LFz83vu/DHFUtSWK1s54pQHcL5iq2c4OdoJzzQByesHYgUOu04CbOenHXvwM1gXjYQ85HpWtqjERBQyEIFGEGBnHasC/fjbwB1/SgDGmA5JPFcpbWnnazIhGUSQsfcZ4rrJwdnbPORWTpkB+2TysP9YQw+nNAGzax5AA+p9614EPBzVS0i4BI68e9bulWzTXUQABVWySTjigCOG3klO1EywGTnjFSvaTLwU3AddpDH8utdBZW8Sv5UrSrErbmZQMgZ4yT15/nT7m3SOOV8uSFDKSoxjGSBg5zzkUAchKnJBHzDt0rPvLZJInVwrIRhlIzmui1KMFVYjDZ24Jyce/rWLeLiIgD7x4HtQB5tq9gbG5+XJhfJQ+3ofes+u38QW6zWEi/3AZB9QK4igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApQCcAck9qSug8NaYZXF1MmVB/dg9z60Aa/hjTDawPJMB5zkZH90DtXSRjGVHXofaorOLaCpByT07GrqLgYHrnnvQAsUYD/ADDGBV1Rjrx359KiVCG3Y3Ant2qeCMzTpH83zHnjt3oA29BtR5sLOuWuGwgH3uO4H0rsYwkWjyKyN5i7IVG7Lc5AFZmnwNGrTxKj3DDZHhf9Wp6n6+9aaW5JvUA/ehlMjYxsGP6D+dADYriOCQRttBiiSM+gc9z6msrW5D80IQtbocBx/Fjk59uTUurTDzIZFVQJizgkdcHGf061k+L7wwI0WAkkqrsQHlTj5if5UActfziaX5QAoOeP51iXYLHGDjJNaMsg2AHIGeuO9Z0o5yDznvQBl3YYptXO5ztHrmpZLdYbmOPpiMDPrzVixh87UFHVIssT2z0H9amvVJ1RQGx8gHr370AWrOMZAxyPaum8L2wuLm6LAtFbxBnIHdmAArI0yy88geY5z/Ci4P612Nra+Ton2ezAgikdXbOWaRhnk/QD6UARs0JfaisXctljgrg8fhk85ptztnKujDdApRiBwgP9MYpwtWQyTOGZI03KUOcg8Z9ucVUvWZfDtxEi4Z3V5XHBKhsY/M5NAHP3rrJKWjysa4CDPYd6zLo7exJ9avyuQCehxWZcsCTgk85xQBkaqwS3mY42hSc9+lcBXW+IZ3eMW0ILSynkDjA71XtvDaMoM07A99g4H4mgDmqK6OfwvKFLW06ydwrLtrCubaa1k2XEbRt6EdaAIaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiinKCxCqCSeAB3oAvaNYG/uwpz5ScuR/L8a9CsrYIoCqFVQAFHYVT0HTBZ2qRDliNzkdz/niuiggGc4HtQBFFEFORyfUirUaBRnnpmpkQEAtwPWphE+wssb7PXbQBVPJ78ck9MV0vhbTTOfOkDRxyLlmzjCDt9TVLRtIN4VuLtXisVPGRhpyP4VB/U11F1flH8gKioECbVGQD1/SgC3b35muI44T5EMURkCHgSN/Dz1PGTiqKagzLczSM4zkDA6scYOD2NV4Lp4pGulMiui7Qz4PzMT+mOKragxZbcSkt5cmAeoOBk/zFAGrLD5n2aLaFRNjNucEkA8fh1rg9SuXvb+a63ZDMdnqFzXVPdeT4RvnwglVsgn/a7D6VxZXbCoxjaAPrQBWlyBydxJ796oznCkk8VduApBIbA64NUnjM7rEMDeefXHegC3okO23eV85kbJGOnpVW7wdSkOckIADjp1rb2bI1RV2qBjA/rXPbhLfSEkhDIAR6jOKAOw0UiGzQywAXUnzK4Yg//W4rpRd3UMqGG4cxlh8koDYwORntXM20pjM7FiVA5HoOwHfsBVuO6AEZTBO8kgOc853ZP4cUAdGs0JR21PTWWLZvMsIwoGSOx/HFYt+Y/soeCaNkY8uuQW3NwGHara3hdJHVWVfugBSOrAEjscYJrF1y6fYTtEcjEDKnHp/SgDG1ELBO6hSoXOAT09qw7pmkfy4uXI5P90Vdu5ZJpyFJaSQ5OefxprRLa27sSSQNzH1NAHP+QrXzbBlUOzPqepNasKYOQMD+lVrWPkEj3Pvmta1tZHXcAFQjhm7/AEoAYiccZ4/lVXULKG+g8q4UMCCQehB9RWw9m6nC4cgbiucEj1xVVlx7c9T3oA8w1Swk0+5aKTlc/K+OGFU677VbJby1libALMWVsZwa4SRWjdkcYZTgg0AMooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArb8J2f2rU/MYfLCN349qxK7rwTahdO8wjmVyfwHFAHVWcOVU45FakUXHtUNpHgDA6cVqWduJriONlLKcllXqQOeKAJdNsmZFmeMgN9zIxkDuM9a1LDTd8hdyWKglfmwWHY/57itCe0lk8lok82JVCqR056nHbHOa1PJm+xuiSKWYABnYAcdycc4oAz7yeVFEkylrhUK89EzyT9cdqyWy7kMymMqCGPdiO/8An0ralikjtpo5oldhCPL2sSSTwSf16fhUV7Yie2tjaB0kjH713XIPHX17HqKAKMRASGRkjSLzR5qrhuQo24z0BNN1EvFZWTzCKRpFkyONwA4GQO/apZYHjukSFdpkJAPc7TwfzP6VFqbGW4O0/utwG1cDdgEg/wDfTUAZWquV0W+twBkMsg7/AMQB/rXPXBwAF6D1Nbl9IgJ8w/KQ28KecE/41z03yNtLBj1X3FAFOcnO0jHce9LpC+ZcSyMDx8oPr61VunOzAPOePY5rV0+NYrdU/wBnLe570AT3cojgeRuVCE/X2rm7WM+UC5yWHT0zWnrtxlVtwxO8gkAdutU12qM84HcUAdLpUZuLBZWYoq8M2M9D3qaJt7y4wYjFwF+XAzz+NT6faG20a0SVisjqZXiPB+Y5HJ4zjt71Ddjbbful4UlVUcknHXNADIZnjhmLkpMVaTBbGBnFZms3JWO0QkHyw2fxxir91AsFvFlgW8sqQcEkBsj9cVzt+Wl1eOFyTjGTjGe9AFvT4SsQd+JH5PsPSq+stmNYxjLt+grRV/unNZVwfOveFG1BtBHQmgB1hbCSeNXBCk7m46DuK6WzjkPzqVkV/k254AAJIwe/pWdpVuZboIikyeWSo65P/wCquotrfMeySRBEgYSuwx2JOPXjAoAqSwo8jRiIiTDDGMMAoHFc3drumbbgqVBz2ziuz1LfaC7Yhfm3AZHQNg/y/lXHuCFyxzQBkzpxjHbg1w/iWDyr/wAwcCUZP1HB/pXeT8A/T1rkPFajyoW6MHIx9R/9agDm6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK9Q8MIBplkAOTED9c815fXq/hwY02zyORAnX6CgDpLVcKOPqPetTTpIob+FpiQj5iJAyRuGAQO5zWbbngZrovCcXmXrvCwMyKdwx8yrjkj3oA6fT4r0C6mljRVkOFiLhT025x1HFMZY3hmiiDF43YyRsAZA2MEAGkledWYW88RG7iMD7w28f/rpn7m+VHnAS4RQyTRtuKjPG4HqKAJBGrpGFWRzCgXyyxOOTycev6UXNjeQvCiNAEZCHyMKCQcNkdcCq0lxq1qyLNAl1HnAkjHmZXPqOR6USapfvKwh0N1xvO7ymbk9sHj/OaAJoIJ1ISOSCUxxhEcg7gxz0PucGse/t5YGaR0hCKCQY24XHfH5VqHU9d80NFpyByBuIhQemMZNZmq6trKQSC9slSNx8xaABQM84Ye1AHKagNkjKyggYAPTgD/69Yd+xVkcptbBXB9u/6102oBJpt8SI8bjIEDBgO/X1rjdRnzLKH+XacUAQRYkvArcqnzdep7VsQtjg8Jjk9BWLpn+sdyPvNtBPp3q5qk2yAQoctIcc9hQBVaQXNzJPkbGOF47Cug0LTQZorjUUYQKfMEQPLAc8+grEhTBUD5QCOnbmu5tVsJxNFPczWNxPwDPGVXbn16c+vT86AIZ5J72KS4mVpGlfjd90c9h6AVVuRul83yysYAzgdW9cjtitidJLSQJ50ZRVYxllGGz0OO/tUE0M4EQ8syIVCl4gOXPzfngjjtQBkOrSTxJhnC/K7EcqM/8A165pZRJqrTYP8TAE9ug/SuluMQwXE67iBGXbJPDEFR29f5Vy33LiL3Ujj86ANOSTYCP4gM1QtMcuxIBOeTRdSkQEevGfarWlAtMFQKGZCFJ9e3WgDd8Pxst2L47lhijO3szswwAPb3rYjRWMUaKm+TcUGc7Vx/n86is4lV1+1TLHFIAPMkBIPTjPTPFasWltOu5FEynMQlicdevTt8wAoAz/ABHPI+k2hAystzJHI+ecKBtH8+a5efONvPORg10urxou+2boCcqTzjdxg+uOa5u8QxhWVxJG/Kt0J9iPWgDKnIIJz09a4XxRNvvEiHRVyee5rs9RnWOJiTj61xQsZdRvpZZCyR7scjk4oAyERpGCopZj2AzVttLvVTebd8D0wT+VdppumQW8ICIBkf8AfX1NXvs0e3gce3WgDzIgqSCMEdQabXe6tosd5GdoUTdFfGDXEXVvJazvDOu116igCGiiigAooooAKKKKACiiigAooooAKKKKACiiigCazRZLuBJPuM6hvpmvWNOAWMBcFTwPpXlVhCbi6RAGbnJA9K9O0qG5IUJHtXj7xxQB0UUm1SfQZrvNB+y6PpHmGVRc3aAbiQTkjP4DkVwtrYy4/ezRquMbQOcV2mh28E2naf5iiVo3ljbIySAPy6HpQBLFcSMiwsziPOzCJ+8IGQQx7AnGDUU9re4aZV8ncNu1uDnJC4x26fma2rVCkdtA+GbkAfdyBjgkfgabPEJCjcjYsb8EnaA3Tnrx/OgCrZpOblIgpcogB2tt+bofxzV+WzklCiIbAz7OZckHJ5zVdFUz+XE/yxys7yDgIOoB71filZXITy1JJ2lmIwc5yQOnAFAFVLeRrtXimZU2AKJHHbJ7n9azvEMktrBes1qwMeI0YP1zzyB9a3YAn2iQrtLRsFCjJUjHGc1W1Erh3Y+azrkbU5JxgYz+FAHi89wyI6iQjczduck+tY93ImCARtHQCu7v7OOJ5hhGQMQcisHUbCOSOTzFB4IPHagDD0tQtoHLLzyQaktrW91O7cWls8ix/Lv6KPxNdTY6ZbxW0JECblQBeK27a2WC3EKAKgyzADvnnpQBh6P4YllvLWK5lG6SQDahx9a9HXSreK3W3mYzQj+GQbu3TmszQ4FbV7Zu0e6Q8+2P610s6HzdrK7NnOeg298ev40AYdvpFtBEkMMa7BlzDKomVD6DPI49DRJp7upWFdPTewfiBk5xjPftirt1lIZSIzk9CDyc8DkdKtpC8TOjYDqgUkMSQx5Jx9OKAOG8S6FePZeSZLJIQVx5OegPAwa4XU9IvYCjEJIA3Ye1er+JJC1zHbcEr+8kPb/ZX8ua5y5jBiyAd3Uf1oA81u5GWdI5kKEDPI49ua1NNIkuIAxO3O4t7AVu3FikkshKqQeMEdhVM6Gi3ERsyY3dgoQchsnGAKAOo0bU4oIJZLhSyEcqCB0+taDS2ckrGNEBByWikMZHtt6Hv+Fc3JFNA3lSLIpRmRpAOMjHQnjimoZC0qRK5ByBhuSOM/n3oA3b9iIpDPqMbSJnKvFk+ucjv0riNSullkZhxGmQFx0/ya25blXljjwVUkrkdB6/r/KuXQmW5Ab+Ekt7nNAEK229vMlAL8EL6VnWkQyxA5Zj06da3rhgsMhGMhSf09aoWEBZUAxkj0oAsIo2kfhVgRnGf/r4q/a2gRVGwbQcdcZJ6UtzauhG1Pl28+uc0AZsqDPIHqK53xPpou7QOiH7Sh+U/wB4dxXUuMrzkVRulyFwDgZPNAHllJWt4gsfst0ZEH7qQ5+h7ismgAooooAKKKKACiiigAooooAKKKKACiiigDd8IEnUzGP4kzn6GvU9MQBQAOVHB615p4KjUXskzYyBtU+ma9O0wbhkH5f50AbEA+XJ4Hr610+gyqlrGoAB3sTkdd3Fc3agykBcgdOegrpfD65YxZJO8jp1yM/0oA6S2jWOSIQ+Ym12Cx56AggnPpkVJICbohcZmYFw+AygLgfrViKLZ9pnJJ/ckKT2GeM/iKLteZpsEySBcso6KO/tQBmeXO1xcswZo3YfvW4yAeAAParogaO5G5V2l1kZtnXPAH0PFSPbrLLAVfbliVyckjuf51bEXziVTtDusQyewHGPx5oAzC7yR+Yzgpv2Z2Y24xkisfWJntbeS4LLvcYhxyQefy4yfwrffe9tK/J3ShEUfqT+PWuR10ifVzAmPJtx5ahe7cbiaAOemXBKn9ay76MFSowTnGDzmtaVwzMxAbnkdqzr1cRrgZywIBPvQBpWyAHOPujjPY1cTA9ATzgd6rRKdgB5J9B1PpVyMZzkEYxigC/oOU1JQ3LFCOB3rp3gYSRFMBpNoPzduuSK53QlB1W0x0fI+mB/9YV3U1qCUkIXAADH1HU0AYkyeXHujAw0hKA8bSOn60wbYA5YLuLBix444GT+tafltKkHloS3GE6EEjoa53xZdbJRYwtwygy7e+OKAOc1GX7Te3Nz1MrkqT1C9B+lU5ztUkE9OM1PMSflI5H6VWuyP3aL8u7kKP8AGgCpHGduFxktwMdTXSaVYRwHzUhSafcF8xs5XjkqP61jIm7y1GSxIUAe5rr7a3nt4gYrx0YcbXQOh9fwoAyJrdWhPmoTuWT5mUnO7qT2Has++0LyLeNYyR8nnzBCAG3jCqD2IwTXaLIoUjUrNlj2kCa1BZDn1Xt61XvJ9HliZTcwuMbCGyhGDxyOeBmgDyrWpHt1jXYBISyrg5C4rBsRskm+YnHGTXa+MdMEnkpaTR3Z5lZo2yydgvvXDW7gyyg5DA8jHIoAnvCTEyjqxA/WrllGNq4XHHUVnsfMlVSOnzEmti0jd1XZ/FwCeKANezjDOHXaXbhdxx075q1NDutmJO7Ddu/cmoYlxHGAC0aDZz3P09K07SEytsVQ4l4zjGTjkCgDnbmFC25QNvf61mXUA57nHrWy7Ax/d244APGPaqNz930+tAHGeIbP7RayoASwG9fqPT+VcHXqWoLkZGOK8zvI/Ku5owMBXIA9s0AQ0UUUAFFFFABRRRQAUUUUAFFFFABRRRQB2HgZAUlOOXcDPsBz/OvSdNjLkdo16471wPgSFhZiQ8iSQqo/KvStPhxGirjGMbjxQBfjG4KFXjHbtW/ooIucBgW+Vhg88/5FZ1pEIxuXLEjArb8PRZ1uxj37vlcnHYY4/WgDtZ0KSwxICBKM/ex/DnmqcE4LMku4+bx0xztOfwrTvjtZBGilkJU5+mB9Ko258pxJsRucZx7UAQwPve23qihYeQowRn0NX4dhhi2oDucZyegqpEwDmUhDgEdO1TROY7TLL84Bc45A9MUAOvlS2tb2Rl6Bn5I6V5nA5aSSY8MSWy3c9TXoXitki8LXjqRlolQtjuSB/WvPG/d2aKCMMQCuOMHOf5CgDPmk5Y7SuPQcVnX5fzIVb7xkX5iPetCVyHUJtz3xz16Vm3vMlrvztEoP6GgDXGNq43Hkjpir8AJXcxw34AkVQgDMoU9Oq+9aNqSWC+h4B9KANPQk365p6ouAZPY4G08ivQr3lEjz0HTFcX4Ot/P8TQIORFC0hz2zx/U12F3KWV2U4BYhfXGf60AJbqsUckrdUXBPavLr28+23dxdEDDuVVunyDoP8+teheKZfsfhW4ZTseUeWu087mOP5fyrzJl8tQi42rwM0ARSMwkAJA29SB361XZi02WUMEGAKWRiXY5IOecd6ghcbmyCQW/LHegC6oKpvJwRhhnt713hhRZYy7hSOcjPze1cNGuThueOR0PWu/tEM6QSOQpIGeMkrnH8+9AFJGnEcbhowHPzDlTjJGR+lMlMrD940ZdRlvlGM4z36U+5WMtcqyBkB2CQ9xnPSpjCslwomVx5pAYMBwADnj6UAcnrECxTo0axJvBf92AMduce+a5XWdMjuJjMYh5wHJUgEiumu7gXV3PMAAjMQp9FHSqF2oy3T5V9KAOFawuIZGdf30fAJHVfwrX0kxuQjNjbyDnt3GfrWnbQYU5AJz+VTR6dFIJJomEMowN46Hr2/rQBLZeV9ojMk6eV1IZeSB2xWhcsIookinSUbiyhTjAI6g9+1QRSy20Cx3B++SI36gAd/wA80yS5i3O/lpI5AA2oOmPwNAGbdBN7CUPuPIbvn+orIunxuGeR1PStXUplFnmOKOJ0ZVyPvEHP4dq5+6mKqWOPQDrQBR1BgV+p7155qqNJqdx5Sl+R90Z7V6X9iWRA1wMt/d7D2NZUtmBfzYAHTgCgDgHt50Us8MigdSVIqGvT4rMkBuB6+1R3WjW92hElupJ43dGH0NAHmlFaet6TLpcwDHfC/wBxx/I+9ZlABRRRQAUUUUAFFFFABRRRQB6t4IhU6baqnCpHk+7Nyce9d5a4LBVzjA4xiuV8OQ/Z9JsoVGXeJGY9TyB/Su2sIMYUgnkDI60AX4E2kfNhvoePet3wbb7tfLqQfJg5yc9T/wDWrHjIVSz5yTjJOST0rqPCcZjgurogkyOsSe/b+pNAG1cMuGk5bIZxwefSq5TZIYmK8Yx7cVNcYMpVtypGMbs8EAcgfjUcKOHQMrEMAuD1JPT8aAIbcSeU7MVJ3AE/jViWM7NoXaseHJHU85p1pasDhmVljU59WP8AnNOki/cNlhhkBwp6g0AZnjFivg+UqQT5kaE9zyK4G4OVVZicAj73fivQfGikeD5JFQqqzx5xz/EAa4FpCzNvYAAE4IJHTjigDNl8rceydcgcVmXitIPkxlXDfhWnOQXYLk7sDJqDYoD9yeh9/SgC1ZsHQFvQDk9RWvpdtPd4SziBBYZkc7V+me/0rP8ADtgLp5Gmcx28YAdj3z2z2+tdzbfLAq2xijiQbNkfYdyfwoA2PDOnw6Lb3MwlNxeXBCSSHoijPApl3I8p2pu3nIGBjFWLeLbGsSAZQqCQMDJ5/wDrfjT4Imhu0whVnbqSeMUAY/xKwkOgQAbrdi7sf9ocD+Zrz9nYu4bnceeK9P8AEax38TWl22VSLYGB+43qK8xmhaOSVJl+eNjGxzjJHU/lg0AZzqChyp5Y8+tRRhRGSB826rFwOHPQHkgjpTLbGWYnkNn60AWx8kLMR0HORzmvTre3MGnadAVKu+GfHOABnGfrXn1lbPd3VraxA7p5lHPJIzk5/AGvVNRxECykfKpA44oA54WbTGMKOZGJZew61z+tag3myw25wR8jMD29j710eu3LabpBlxtnm/dx5964ViNg/wBnk5OTQAzaEQYG3HcYqjcZZggOcjv6Vdk6HHB681VVfNdm468E8flQAsSAAhwoI5xnFa9raEWrZJLS/NjOMcYAqjBE0rlRjcBjJGBgVv2wSCCKK4jZFAGZMllyBxn0oAytX09J4BGqZdiQeT8h46D1965IpLbJCjYUn7rAcuen1HavTEs3jXLBWU9wMhsg5wf61Q1PTIDp5E0MZ8tcg4xtwcnBHOCT+QoA8zvp82EodgJMqqKR3DHP9azbQGa7LNjEfoOpP+c1f8QW6RXXmB3VXHAxlQR1FN0q1ZbRX3oS/wA57GgCZlBXB6/nWWyb7ybaNp3DnHbFbDxMMAFemeDVK2jzvHJLSEfrQARR7XGFBYjGR3qz9mfyt2AcdhVmK1YHJZDjkbe4qZEIwy8sR07UAc3rWmrdWskTxna47/wnsa8qmiaGZ43xuQkHFe33fBbLdRzgZz7GvLvG9ukOsCSNAqTIH+UYGec0Ac7RRRQAUUUUAFFFFABVrTrf7VdpEThTyT7VVrX8MI0uppDGMtJ8v0Hc0Aew+HY99nHOQTmMKi46AYH9K6u2BbG1iWAAxWDo0YitolRm2IoRQemBXSWpAUkkYPIzjigC5GjylEjIJJADY/MnHbrXdWUItba0t4goAXjPHA7/AI81zfhqye6aV1ICswTd0G3qxH8q6e2kaWadwqj5coT/AA8EAD8MfnQAsULHzFz35GePU9aH8qYpPnzGx5hYcgjOMfUVcEZRRtTILLlVHXjkn2p0AkeNCzRLg/KgH8PXGPyoAgWPyI9o2oodggcHkcnr6+9Pt0V4VDkfdUZXkIP84qx5YGdrrt5OBnr36/j+dNAjt1T53KryylcHPYH2oAoeIbd5vC17ARuIAPTPIOQcflXl2TJDuxywzuzjOf5V7CZo2iYbULE7dvJBHevM9a05NM1S4hRcW8o82EO3QfxL9Qf6UAYUkTEkOMY5JzyajkxjlRycj0FXJ3DOmDgEDJIwfpUbqTwoGD3A5zQBo+GY8WTqhQGSU53HggAetdLp0I3Im/CFgxP48/WuV0qVo7hFVXYMMqB2rrrC3LEbQq8cjJOT+HFAGzbxIs2GcrIxLHcT0zkVYPnQltsiS46eoAPAqhBayqVZLiJgD8pwR+v41Gy3ENw++JxGMEMhDKMDnmgCLV5v9NuMEbMAMp4G7HP1FcRrzCO7AVMB41Jx0JBI/oK6fUJBJ5kzMogUs5J6kg9B9a5TV7j7RdSSyYVAQijHQDmgDLmzyCf8PxoiC7xt5Qdcc4rX07T0RBNcRLLKQTsYcKD0JHc1r2UO1kd7UMBz5cabe/UnoRyaAL3gbTGikk1u6Xy1CNHahupzwWx+g/GunUefKNx+VfU+2ayjcvcTqSrNGmAigbQOeceo961ZJI7Dwzf6i/ztbh5dnByeABxQBxfi68a61d4Y8tHaLgjPAY9fyFc7MdhPB4zkGpBI8oEr8ySMZHfsSetV55RkMoQnpweOlAEF06hQEJy1SQhUCq2AQODnHNVxlpVDKMqNx9Oasx/MVIwf7vagDY0BVlvmBG9REWx64I4rXZyj5QdV2HkgZ9M9/wD9VZvh3aovZTghgkS47HOf8K0olL4LFSoyEY93fPGPoKAHw7o3ZYG8p14JQ5BOAfu9DVbUp7lbZ2MFvOsgzz8jc+vUVJCWE8scLlhFGEy3GWJyW/TFQ69I0EDJHjMqgKQeRgcnH+etAHn2vZ1O4Z5Qv70hQueFHtVHy/s0nkjhFGEJPUfWt7yBJKXfonbtUdxEjRkFAV/OgDCkcLG5IG0DPFLpyEgtj+EnjselF/blFCxY5P3RxgVb0q2LMv8ABtTJdhx/+vtQBoWsQVx90Bjge/FRC3G0jJVkJ49a0rS2LFV3rwpctnA4Gakns3SOKQtjzRn5jjj/AOv6UAYN3bkjaWbHUhR29a4Pxzp7SaeJFBLQMTnHUGvTLtMnEjHjgduK5nX7R5bWaBiAJEbB649KAPF6KluImgnkikGGRiDUVABRRRQAUUUUAFdV8PIg2uxyN90BlH1IP+FcrXd/DyEhBL28wnge2KAPTtOVVVApz74610emwvczQxR7suckhRkDGetYNjnILEnHTmul0adbPU7GeU4j8wCTI4CtwT+RBoA7NI/s+npFboAvC57Y9vb+ZrS0tNi4wdhbDAnlugGPas4FvtMqOmQGyHDYBAI4weOnNa2nwqWCu21ZACD1HXtQA65EYgKyyEKCGwi8A54Gas2TAAExH5hxjkn3PpSrZOAjTbVO8sSxyuTjtVgm3tlOXLt1bAxntQBWgaZ2bzlBU4GO+PQ06YzSBvlURMeGxyB6YpTqCrnZbRkbu5JOPWmtqMYYmW2UMOhDHrQBnzrIgYAruADLtHc1y/jdGP8AZ8hxldyswHJyO35V2kt1Y3ChBII3K7gJB0/EfjXKePYtum2YWVWCTL0bluDzQBxVyoaVZBjAPI7U6faQSRwCTnrnjr7cU9huIUq/HBOe/wCNSJbiW4W2BUK/LY7KOv5880AaNjaJDZRO+A0qiWVwQMAj5QCf85NbllL9nLM6sSAOnzZz0P6Gs7JnkLxorByAVPy5UHGM44xWjBHiOTykZdqqQC2edx/l0oA0EmQIEXkKv4k8du/UUhnjG9hJzzyM579qSRFD9wS4XG30IOPqcfkOapK+2G5O5SpDbc8lue31oAwtSljMi+VGGCA4Cj5c9c/WsJhvlAwSM7iOOTmr945aMFXO5257dP8AIqirgTnaB0wMjoe38qAN2YxrcyK7jzEbpjce33R7Hmr1lcHO5omkZQhLbsE5Pb8e1ZsU81wyTIplP+x/CfQ1q21w1vjzImjVcYMiHt6+ueKANOIiUt5juBkqI5CDnHf86XU7kRWMNq8ZVZJS5x/Eq8DIHqTUSzRtHgrk85Y4ye4/PisnUrjdfRKIVGX8v73Izk5/T+VAHK3ebaeeE7mCswyOmCeOPpisyVgOFyOeh7Vd1Nmlu7mTGB5hCgnnAOM/oKzG3CTcQASKALEThpZDjPQZzxjrVqMrksqjkfKPeqFkhM0rM4GCOPbFakcQ4GAOc9KANbSpTbaTfXbW9xcQ22HlS1j3yY4yQpIzgZPHNeefEH4paS91osfhrzbuOxvLfUWuGBjDlQ6tEUIz0Yc5OefrXsvhO1Nt4eSbJM1xceamewB45+gzXBfFT4Wx+Lp7jVvDsaW+vsSXtEUJHekclgeAsh59mPockgHZRvH9kS4t5BcWkqCaKQj/AFqsAy8+4I/I1g6hcGafzADiNNg56461y3w4125vvBVvot2ssN3ocz288UuVbDMSgYHkEHeuD/dremKqMudox/dyKAIHwDlO/p6e9QXAU4Ax6cHvU07EgBDu3enGfrVG9ka3tvkKiQ8AYzQBnXGdzFnAAHJPOB71oWNwqW7W5EYQ4dHdsDPpUNpbefJvRC0jjbjHX2xWva2YijKLJEzq+1wMEL+YoA0LOFXIKGN9zAbYplwMjHbrWlJpp8l42WVVTJ+ZDtUkdjWGtnDLIivDF5jq0gyu3gcjGPxqbyY/s7S2ss8JBwAk5dScZ6dR0oAoajbvGyh+GGQF4PHofSsS+i8y2dBneDlff6Gtl5IpRkMRu7t1J6msuYiNyuSoz07fUCgDxbxdCYNeuARjfh/zFYtdT8QMf2nA2MOY+T+PFctQAUUUUAFFFFABXpfw/i/4k0UmR/rG6j3rzSvV/AKAeHLIH+NpG/8AHiP6UAd5YLtGRj04/wAK2rYBlw+cHg+nSseyUttXGMjHWtmJgsTORkKBjAx/+ugDqfDUqyCKKUk+SuA2NxAzwD+fQ12tpeeRbeXbxgYbapb5mPvWDoOjm3ijEso3kB5EiOcEgHDGuvtrdYkJjVVHXIPU0AZc8Nxd+YzRlOnJYjP4VWNh85SS6YspztjGOPxrfdODkE+w/Oqk0JLGVEII+8COTwecUAZv2G16kTszL13nt7VHLpkJOYnnRsltpYMAfSrSBiUByvba5HHHP8xU8PzGQnLYbHT8/wCVAGO+gyDe7XQclcAEbTj3Nczq+j3ZJi815SpyFdQA/HQEf1r0MbSzqMht2cj06jP5Vl64rIoCHazHzMDsvY/nmgDzAAmQfKFkUncp4Ibpg1PbxlZJ5iMdEyD0z/8Aqq/4mtxBrKXCn93doWYgY/eDg/mMGq9sN1kG3Zy7E+4wBzQBqQwldKikcMSzE4Uckdsfj3q6qrFaXDlWCpCGZlJJZt3T0qG1lzY26g7dudnORjHU/rWpZhnthE4A+Q/IpIGCxw2PXk0AJeKBcq+/AMrSE8g7ioGP0rMvFYS/OqjbECcnjnls/jkYrauYQzlgOX29OwU4xnv1zWRqJV5nwBuYbiSvPOOKAOOvoyl40ajEZwY/oef61FCgZftDbiiHAB74PWr+rRg7fm/iC5VehPBpRCNqIuWKJxnvjrmgDTtLllIaQlgFZlYjhQAfSthLkiFy5YjcRnOVJHYisi3AFrMSxAVGHBzliRxntx/Or9wnlbAj53uN2OgchTgHuOM0AQ3UsfmLIjIuW3YC4BI46dunaucvr8mQxx8Sg/PIPfsD171rXaSNCpB43NjB4zzgD8q54kvuZiTu43P+n8qAKUkY3ECP3JAxVZ4wGxGDlj1I4q/Md5faAffPX2xTYLdJpUjPCffYjrj0HuTQBWsoxvdI0eQ99qls/jWxp9jcX86wwIy7jskkZcbR0PXv1q6ihCEUiJc5wq42ehwP5d62Yg+IjvkfaDt3AjLepPf6UAbt20UUMVvaHCRIkakcAVWvZY9K0m5vgV35MUfPO7p/M0sMCfdkG7CZYE9T9fb0rF8aS/aG02FJFWG2ZridMY5xwR68ZoA5R7WM6s2qPn+0JoTDPLn/AF4yCN47lcDB6446Ypki/Iy5JDHPX9an82O4QzQShl5OG4brUNwQUfbluo6YJHegCkpJtyACTuO05yOKhkLyMpHG4cZ7H3qvE8lvHPHggKcjPUZqS0RnYyuzFOmOozQBPbsbd/tKpM8Q4Ozv61uwxIYlkR1ljcZjkB+VmPb/AHh6GmxEWohjU+U5YFvL7Z4AP9almgW3aSa0VY1ziW3Y4jdsfeRv4WzQA5FnlugzNMJGBReOD8p4qDUoUgMckaBkZA7bTgLjr/SpLfULKBhHeTzW0qkg+dFk8nqCOD9ag1y4tp9zWciyK4IOGPHPoR7CgDmBcsG8t8r3BJ7VDdzrsJZsknGfepLlCyO6g707jsKyrmUNC+044yKAOB+IcgfUbYDHEWcj3NcnW54unE2qAKThYwMZzg/5xWHQAUUUUAFFFFABXr/glAPD+nrgnCFuR0+Yn+teQV7D4MJbQNOxjAj/AKmgDtrLG5cbRyPoK3rDAmTcMgKX5HQ9v1rBssllf5h3zjpXT+GD/wATePcok2wuVB6ZyP8AGgD0HRCRaQiY7XZBuyccj/OK6COQEDfgDHQfSuas99ukkRkMrxSMDn5vvdvYc1vWrhgwDFgV+THcY/TvQBcwdsbkkN29fxqDgvtyoY/e56A0CfIDAhSNw5GMHoKjVm8xztymwt1x0470AU7iJVmJKAZY9/Uck/lTrViocnaqMA44yeQP65pDIu9cAuSN5x0Ixz/PpSQKphQkHlfLZB1I/wAgUAWoxmQff3BtuW7gd6ratCGnV8ZG0pg+lWLckyEsM4IPt6H9abeg+WpYjO7jvj/OaAOO8Qaa15YiOKXy7mBi6A9GyOV9R2rlopC1u0LLtIYEBx6DDL9Qea77UG/1g6Mo64OM1xd8n/E0mkAwkipIAOPnI5P5CgDT0iUTwmKVTujRip9B0wB+VbNrEUaLdtcqnAJwP0965HTZ1S8Xa3zqxKN/MfjXZKxEURQj5wevfuBzQATM0aZKjcpzzkcg4HT61j3kf7x1+9gBAVPUZ61oXDFEVkIIOHJJyQRwciq2xmmlBClY2HAGQQ3OKAOcvzsmjjX7uSzY5OT0H5ZpbaHzJAh27Cv0wP8AHioJG826uGlwqmRgMc4A4rU0yNs3KKIjJ5YZQV4Ydx7dulAFu0UCz35B824CKOTyMDn1HOKnnOb0oSAY3djnjHVRn06VbtFjCqkaeUEjLIrccsQcfhUdzBlZ2BwXBRj0Jx39T1zQBhXgVYohGGbEZHTodvB/OueKlYUC8AcdMf56V02ouoLxR4DjOCeenbNc/cgI+BkAcjHBAPJoAz2BLvjjOTkd+altQiSjftKk5x3PFM4VyQeACM1csoRvBdVwWHHT8zQBdiijkuQZG2oTgj2A4Bx3ratXiWdlWVlZSigH5QADyB/OodNhimRE8mHGccqOPT9KnlhhMm+KMR45BByD6cHvQBau5ixLyyR4b+Lo2M5wPXoOa5vUtS8+R43G2aY4TKcD2/LNaU0rNbSI21Zecegz2H4Vy7FZru5V5GeSFGCY43seNxoAydIb5lxwBndkdquTFHhEjbguOg70G1litUQ4jQLycfMxp6hZGZtvysMEEdD2NAGcxDTeTNhFJ5OfbirmmrbyX9tbg742zIWC5xgd6qX0fnLJsGGVM9Oai8Pna028MJFXccDGE6df1oA6K0VQwmaRUZZAhckHOev07Yqe3lRJzBhFWRmbBPfnHH5VWtI1hjtoplJIILNjKqG5P6Y/OnxReXh2dSzsGAY/MATxz9M0AbcUss0Dl1ifagLxso25x1571zGoIqTyiKNdox8qjvjkDFdUREk8UbHPV2IX5SAAQD6VzbrI4eSXHXn1LHr/AFoAxJYvKUgjO7gg9q5S4zDcvC2TsOB9Oo/Su8uiChBjYMvBYDjFcH43uzYqbnGC0JUEjqwPA+vIoA8p1OTzdQuHyTlz1qrTmYsxZjkk5JptABRRRQAUUUUAFeteBWxolnnO4DHTsSSK8lr1DwPPv0y0Ix0KEfQnH+fegD0WwdQgxkkYyvrzXQeH5xba5pcxGIRcKjjqMP8AKf5g1zOnnAwTlc5BB/Ktcjzbd13bWI+VugB9v8fagD0Wa5EF/cNAC7s7RMGONxyfywRXRaTc+ZCjgMOASWzlc54+lc1PcrqWj22pKMzuo8xUIA3YwT+YP51NHcXEMJuI9sdx5SsUmbg4bpn35xQB0khZrcmU55UZAPY8mnSv9mNyyA+YCQMjPBIzWU2prBauGiLgSMEKnkg4P6DrTNWu3m1iBQskcM0eY8jPmYxxj2yfyoAus+y6uosfPENxj77PbFJDIYjMztvkt5CCynlkOOapXT+Xcw3aghiqrxznBxwfQir90fKvC4UNbvuiYEdAwBH8qALNvuVYQE28bmCnH3u+PepJiBa52klHA571HC26O3ZVw0RWNxux0/8ArGoNXufs+n3flhnfKAbO2aAMHV7m3KTZlJUjO7PGM9Pzrj3uHnR52P7yRiV56AcAflVnWLgTwokaCNQ28qDnc3v+Z4qoFIiRcY+Qnj1J4oAqksIwQ3zKcj+Y/WvQrJ/tVhZThsiSP5gPUjrXBqOfmGPXHb0Ndl4RlMnhuFW5dHdM57AnFACTrujwoxt4NSxRh4LgqMptHI7gVM0YjJHYfKwHfNTwKFtZRtAG7GQOvFAHnUeJN2c/eJGT781raVcFLqORhux+Z9R+QrLA2SS7c/LIw5+tTwymKWMyYAyMnpj0/KgDuhCEw4YMSucsOu3kVmag3yFTho+is3XPP/6q0XzE0gbIjxkYPUGsi6ZvMaLBIyVB6EZGRzQBkX6t5zEOWVvmAyOe/wDWsK4Ie5d8Daec+oFbOps8SYTOdoHJyckgHP4Csk8Jll5wOo/z0oArKgLkSK2M4xgnPt9at22JCOcldpypyR6U5VwEjBI47HvVi1gIVJSVCnoy8k578fjx70AaVoqqBvBZY42bgdSQQOPXtU0nEO5m+8doAHRVHP0PWpltgJjFmVSZRhPZRuyD3HSoLtFijUsucxs4BGByP8TigDPmuWjiyQpkxnC9c+nv2rn8SQJ+6RWuZ5A2QOQO4P68Vr3DFmKhcEZx/gKrSYEY3FQc4+Ycfn/WgCldoBvU5VWOcNUaL8oVUZiMde4pjMwdY8pweg71M6gKoZtq9yOv1FAFWdtguI8AvIB07jPrVzwrpciadPqN9+7SRisag5LKpHH41QlV5bmK3RGeV8KAo5PYf4130whsrS2tWcRi1h29QBu/H8frQBj6xbQ/aWnZfOIYAxnO054/HtSaaGeCe7uDH5St5gbb1wMfkKlXa84WTEkjKVYJ33d/aoNVlgS2/s+z+eKPiR1/jb+79B/OgCgL6a5nZsGOJvm3HO4571NIFEZTkLwB0yeeuex61ViQJkhPmPB4xxTSQNuzoc45IoAguC6FxnkZ4PT6c1wnxRiMvhgspJ8qdSQPcc/0rub3G4Pg7mTkH9a5Hx2ok8P3yhQQUMgAPHtigDxOiiigAooooAKKKKACu9+G85a3uoOSY3Dj8R/9auCrs/hw22e9H8WEIPp97/GgD1azOAuMHgdPX61tQyEhSAOOeh4rAtn5TcMA9vetu2DNECOg7UAdj4YuVbTLi1YgmF9yfNtDK3OD+Na7RtFFKiIhbeMqCCNp/TrXJaLKkV4glPlxTr5LHsG7H8/512Vkd0ccTLiUOEwRwG9M/gfzoAllRUEiuSqG6yhPIG9SOCKnkUeXaSTK7tDh1foR1BA/IVHgFJsgsrJuwOAOcDHpTiRHBCcMcKOvvQBJvcwKWJypIYNjcMHIx+FWBI8riMEmOZBx1wccGqdtJE2xmPyzfdk9CPWrEMhjhhkfJNvceXJj+72NAE1rI0sGoKSCUjE6H1GQD+VLrMQj0iRk+YlUk4+vWls7cW2qogYeUUeInPVWORU/iEFNAvjwNsDY/AUAeX3TC5umWIlgGwCxzk5/+vSTsEAHfd0zzgdKit1w0RwSSATg8/Wpr3bHIuQFIAzz0oARF6j73Pc11ngYb9MmgfgLKwU9+RkVy0HzcA8g9SOBXTeCTtFyB0EobBPtQBtTR/O5HUEZGKWHChwAMHlT+NTXTESyFQOO3rUFs2HKt2OQDQBwerRGLUL5SCuXEikHjn2qjMcQSbvu45rb8TIY9VGMgSx/mQawZ8iBz0YKevQ8UAd2js+kW0isARHsJ6kDsap3ieYG3AHEgYhjjdjH5c1a0cedpFuGwoMa1HKjPvLAZZsdOMZNAGH4mjxPbkDbuXI/PmseJB5jAAY/iGOeDXSeI49thbTcgJJtDD/a4Fc6g2SMGVNhzls8nJ9KAJIwu9SeDkZX1rTso8xLsA5XbkDkHpWYSAwOTjcCBmtrR2wzEMQqNvJ+nNAGrDamZ5HhjaUjzMY7BiB09gK5PxN4l8P6PiPWdfsYZgmxoo5DO+d3dI9xXgd8Vw3x28M3tr4T/tePxTrF1bJcLFLYXs4MZ35IMYUKM8cgr05zxisv4XfCsRJFrPi61bdgSWunScFsch5R2Hoh69+OCAehabfQ6zZG9tYLuG2c/uGuYhGZV671UHO09s4z1xUhwc/NkDn6VevJWlfzHcbm+YnsPTH6VSYnIVgSDwcD+dAGbPaRkoyyFMAZyuRj1pkqErJCg3NuAXuST3+laDgbUVY0ZD8n3qSJGt4JZoQpfG3cx+6PWgCsZv7NhVoNgvVG2WXHKnP3FPTp1NZt9dTXh23UvIlByBngdq0hZzX0j5mjEYV3ZmIGfU/yqOHRZoI1ePyrmPYSF83IJzwexoA29E3W9hNd2oVZJeIN+CHY8A/TgmsWCJkU5AWVSSW6Hf3FbFtY3bLbLMQkFkS209NxOP0zRrWxlSeKKPzImAlxkAZ5z9elAGL520kvgHPK5/lTZ2aSdt+TtGAc8mmXMoiuWbjYO56n61E838Aw2c8/3c9aAEn3DADAqBjNcr4jXdY3e8nYqHcSOQM89OldI5cKQhGBgkjisjV1Z7GdH2hDG4JPoV70AeC0UUUAFFFFABRRRQAV1PgCUpqk0YPDxZ/Ij/GuWrf8FSmPXFA/jjZf0z/SgD1+3JaFOTnjtW3ZuQyIuMZ7nP51z1g2UUAgehIyK2LSRvMwOVODx3NAG3GGeF1GzY3pya7jRLkXUCuxYSng89XXoa4SFtoJCjOcDAPT8PWun8J3GzUhbfKRN8ygnnIHI/lQB1qp91XAKH5GB9MH+pp2wT2MqoAWjCnB/ug84qVw4SJlX5gxVie4HT9DSxAF70qQu6EYx7mgChbLGiGHZ+7UhuvT3/lU6SbgwbJDjliOCelNhIKgKcbxzx0x2pxjQI6kkkDdxQBpQxiSENGDmNlJx6A1c8Qx+ZpF+pHDQvn8qq2Lsbo9gY8EA8EjmtTUIw1tKOu4FfzoA8WtFDxxKFI+TOenbvUt2N0vP3sDPvTbMFSEJztUqcEcYOKddMVnYc5B79uMYoAWEkAccAHoK3/ChIkvA2QSVIH4Vz6k/wB5SWB78LW54WYi5uhj+FffOM0AdTeAFc9N2MfWq0RHnDbjPTGe1XZMtAp5OP1qioWOZDxx05oA5/xnCMW0+G2hiDj3rmZhlZOeo4yM12/iuAyaZc4ALqu4EjPSuL+8O/K9c5oA6/w0fM0W37/u+OeMjv8ApUiD9ypbB6kg/nVfwe2dMgXHQsP/AB41oyxkLGoxleMAe9AGfrMH2jwtMqjJUiQA+xzXIsuWRsAArnP9K7+3jE1hLGVxuU9ffrXAQ7kQxNnIyuOoyP8AGgBobDAkFgMHB6VvaaV8xzksrDIB6HOeP0/WsA/3cY5JA6VueFHaS5nQdY08xAcc84NAEur6baahd6XLqEXnfY5ftEcUmDGZdnDMvcoAcZ4yxp1xIzys5YtIwySecknJ/Q1bkVPLwOZMsCzH+IDOcVVKpvdgTtKFzx0wM/5+lAGFOW83CgfKNoOOgzUBU7shdx9Scc+9Sqcg5IOfmP8A9eho1d+SdzHk9OKAGtneWO3jP0HvTmbfE0YZVVgQBUUrLHKQ+Q3XBwfoKlIXZIw2kABlORxQBLpkVvEWM0jFFBG0Rjge4+talomnJtLuo+TaPNj2Dk5IJ5HpWUGjiDM8Qkj+8PnIY/lUVzqFiW2zCeAv8vzruGev+TQB1VzshWQpGXgfq4IKnjse/WsLU/ISwnjZS0UiFJHXqvB/XmqdvqEcEmGZnsyAGCtxkHrWJqF4twJ1VnZJJN7tgLvA+6MfmaAMwGP7PEwRskYwTngU7cyovHzAZOR79aimdUhJQLlMgMRz+NRjDIWGcdMnt/jQBZmcOQNo5/Uiub8eTSL4WvhGQjfKCAP4c81uhyWOS2emOgrB8YlW8O36gkqUOGPPT39aAPGKKKKACiiigAooooAK0NCm8jV7V/8Aa29fXj+tZ9ORijqw6qcigD3DTmBVN2CWHIHatqzPCjkkDt657VzuizLNBFImD5qAgenHet+zYBQS2dvSgDailbGV4bpg960YJ5oPLuUP76Ah1OAc46/pWZa7guR1JypzWnC2EAYZI+U7R1oA9ZhIuYPNTBR4gwI7/wCRUSx/LceWMsAIypODxzxWZ4EujPoYhkzvtmMBz1wOh/Iitm4GCycBnbzF9TgUAZsO0sduchtu30p7ZyxVfmII9KcwDFeAGbqf6044ZEDBd574/rQBasm23EUvPysEbtkdK3nX91jBz93H0rm4jh3wQOB7966SM77dW6ZFAHjlwvk6jfRcAJOynK9t2aqNJ87/AHcFia0vEsRh8UatHnhnSQDGM5ArMkjCSnK4xwBQA5AVGSPlFbPhcn+0Jh6xjPHXmsdRkjbknsByPxrT8Ptt1SMAZ3RkcfnQB3UY3RN9M9KoSriPtwenXvWlbYKlfUdD3qldDYWA78/SgBupJ5sBX+8mM/hXm9vnaNzAkEqT7g4r0779oh/iXIOfzrzu+i8nU7uMLj95uA9iAaANrwa5+xFRyY5WBB/OuinQ+Yhx14HX/PeuZ8JHabpGIyzBuPp/9ausmX/RicgMMEUAU7A7ZyvQEbcjtXE6tCbbWdQhdgoEvmoPQHn/ABrukXZKAMbs5z/jXNeNoPL1e2nxhZ4ipIA5KnI+vBoA5/h+rkt1C56+1bPgkbtXuAWyfsrY49WH+FYwJSQBi20jH4+tb3gwEa1dsAm3y1Ax65PP40AaF1hXLbl6gsAO/T+VVxEw0jUW5GICvPp/nNaF7+7Zued2RkZ46H+dIIGbTdRViD/o7hTjGQFyKAOOAwgXPBxx6mh1wrEnBx3Of1pqOohUt90rnJ7VNb5u28qwilunxwtsjSn8lBoApXSBrYcDC/MS3amW8avAFKlXVtwHUEf5Nbl/4e1S00t7zUbQWVvjan2qVVaUn+BUBLE98EDofSsWOHy+YuQBgnuv/wBagDU8pXWJmlAjbJZiPQfdH41Q1aMTWsBlU+UXZhEhHB6DGORgVYtCzQKZSHxlQQcZU/5FZCQXkl8DFCY44z1JOHB9O/rQBHNpzrZC4WQqSMyLIenp074rJaM20jxupw3zA56jrxXZaXELuKO4lZmDo0U2SFHB449RmsbVNMYTASMwOzEcgOQR2H/1qAOZmcqHUOjr124JKnPekin8wspxg8Lhsf5NWrmznWUuTgjgvjhqzLWAqswbgiQ9+cUAW2bDoWYHnAwOM+lZWuJFNp9yrqFRY2JHYY/+tWoq+SWHygL/ABE9KwtZLz2k0anbHtCkdnz14oA8corp/h/4K1Xx3rsuj6EbUXyW8lwEuJRGHCY+Vc9WJIAH4nABI9A8b/BG80rQJNe0eaSLSbPSra6vRq7CCYXLg+ZAi7cFl+X5SeC23LMDQB4xRRRQAUUUUAFLSUUAeveF336ZZMD1jXAzXUWrDYcDLA5y1cV4Im83RrcZPyAqB9DXY2/zHaCfugnHYetAG1bncpyTj6+taVs48sKCMt3zn/PSsq1RiAu7AXvt65rVtcKDtIA9Ohx7UAdX8Prgx6rfW7DaJollHuVOD+mK7vUE3JFIPvKdvHbNeY+H7gWuu6dKeC0jQsevDD/9VepygPaNjqpyCKAMpjmdm25JHBpDnZ0Ktxjt+FO25ORkAZOfQd6HUbgVY8ZOCaAHRsm4M/A6Zx0NdBpxzbFTzsOM+ua50EKcPH8vfd2I+lbmkyZWROhUDNAHAfEGDyfFMLkfLc2+3Occqev6iublH71yxIkkUEdweP8A61dx8VrbFnp14AcxT7CQOzD/ABArirsZRHUggcjHPFADEC5xvBOO3FX9KzHf2pBwC2CQenFUUbftOCVIPbFXLU7Lm3cYyJAv4ZoA9Cs8lQef8KhvlO9uw54/WpLM5Vc5ovl/eHPG4ZxQBHZgtbSqcEqQ2e/IriPE8Ij11uCfNhRh9ckda7ixJMrf7S9Melcx41twLqynzgENETj8RQBR8Nnbqkowyq0YIB+vNdrz9mcnnAz9a4bQzs1ePn7ylf8ACu6jUtCQRyV6E8UAVIgRMoIwcY/DFZvjaHdo8c4A3QyoST6H5T/OtVk/2c89R607V7Zb3SLqAjPmwsB6ZA/xoA82C/OvAHH8XT2rc8Fg/wBoXPIPyIRjuMn8qxIjmJHAJ4Gcf4VteEWSPV7oFgB5S89Oh/8Ar0Ab+orm4c4+QsSPb3qa0CF5o3wFaF069PlrSGi3N0pnmaOzs0PM9wdoKn0Hfr3wPerGn3Wm2FyiabbNc3G4Kby5HTp91e36fjQByvgjTZ7OxW+8Q6Jo8WjxjMl3qqlZcf7CsDkemQuexNej+J/Eum+FbCMMgM7qfs9nEApf3P8AdX1J/U8V43qN3fSeIGuNVnkv7izui6LcH92CrZUBRgAdOmM1Vu7me+uZLu+mkuLmbl5G6+wA7KOwHAoAs6zqF5rWoPeanL5k54VFzshX+6g7D9T3rPMfzYUcjnnoamcDIAO5VGMU3DNg52g5znigBBlMlcq5wTtGatWUMyPLKvzLIAyYOOnBBPrUafMhwpJ64q/pqO9lIRgZcoq4zx3/ABoAqKRFGrKiLbuzFkA75/n/AIVk6inmWZKs5ChnTnkMB/I10N9atDEEgbCbi3I4x9az3+TILbo2UqV/2SOaAObs7gXBhiQb2GGfJ/z61HeRK6mQxJvzgsoxWw0AyqhVXgYZAB69f8KpSq53MpUEdyOPwoAwLuBZFO4k+nOcH0rEvbGacMkbbtw+XPc11NxGMbmJ2AcA9DWNekxoz4GVGQehHpQB5f4M8SWXhPxLf3954e03XVMM0MFtqCh4YpCRtkK4O7bjpxkE4IOCPS/ih8WdF1rSF0xLC18SPc6NbxnU7uDybiwvefOMZ2Z2nCnapC7s4yvFeH6g/mX1w/HMjHgYHWq9ABRRRQAUUUUAFFFFAHonw7kA0yVeM+ZjJ9D/APqr0KyXEacnJG2vMfhrLuupYSAQF3H2Gf8A69eoWrfwjoGIIxQBr2oVFO4ZyP1q7aMoy2DkenWs+3wX3ZyGXjjoa0bbj5Xxx0z7/wD6qALZzDFHKvBjdJAR1yCDXsMD+bC2DkOuR+VeP7WeOQYHzD6D616b4SuftOi2UzEbjEFYA5AI4P8AKgCS4wiNu54ByBTJNm/e3yqwAAz/ACqxKMmRFA3rz05Oe1Qqf3EmQCM8ED7uaAEjXYR91l35z6dav6Q3l6n5Yb5ZUJOTnnNUFAcblyMNt68ZqW1/d3IdW+dOgP60AS+PLT7X4T1BMEtComXHqpzmvLrZ90LBVyEw42+h6jNe4TRrcQMhwyyoVPvxivEbaI28zxOvzRO8LD2BxmgBUUx5VskjgHtipAQUXAwVK9PrmnFMbTwx6ZJ70/b8jZ54wKAO8sjlMZwT+tWbxdwifqNuOvpVLR5PMtIXOTuQcEdeK0Zhut1x13YJFAFCA7J1PfPT2rO8awA6UznjypFkP0FaRG2QMAf51JrMAuNPliJyGXn8qAPP9PkKXtq55+bHT14rv7LI2H164rzpC6QozcsjDkdQQf8A61egafIGhRs8deaAEkTbIy88fdBqeJwsG5sAK3XsKtppdxeM0oCwWv3jPMcKB7ev8veprW4sLHcLBDezgZNxMMID/sr/AJ+poA4C28Japdy3jv5GmaXDKxN9eHahXPBVcgkc9Tge9avhq90HSL9otCt5tSvvLy2pXY2pwRxGnXGSecD6ms3x011c+IFku7qWaKSEPFGzHZGwODtXoO3PWqHh1vL1u2w2N0br1z2oA7bVpJrs+ZdSvK4GQG6D6DtUFsSJY2HU4b6HOCKsz7hDGQArEd/Y1Gg2TAH7u8EZ9DQByPi6Ex+IrnaCBKiSg/UYP8qylXlSx7ew4rpPHsW28s5vWNozz6HNc4RmMEAEKevegBud43Hr0x70igg8jPHOaXqwxyw5IApy4xknHfr+dADlTKA8rkcZroNPhb+xLJlGGLM5Y8/54zXPsC6hUxuf5QAe5rtlhSDT0tx90KFz9B/+ugDHu12IVOAinjn2rJjtw/mnO5o0bLYyPWtacs7XI6x4JQY4zgc0xI1XTboHI227Fu3r/I0AcpH1HDYGQuef89aivhwSc+mF6f8A1qnjO+1iyOdoPXv/AJFVpBkFiAZsDdg/59qAMS8zGX2MWA+bGc4rkvEtyVs3iXKtgEkDqM8D8a7K4AYHg7TkHJ5rk9TtvPkY8mPrg+mKAPFrjPny54O4/wA6ZVzWYDb6pcxnGN5YY9DyKpUAFFFFABRRRQAUUUUAdT8Ojt18sfumJlOPfH+Feu2IGGBwCeTzyK8a8DOF8QRBjwVP516/YY37QeoGSe9AG5bn5VGANvf+laNqVZCDnOeQOhHt+VZloxZSQvzckZzgDNadqPkDKfmzk8d8daAL0OGIzt64wO1d14ClzpTxHOYZiMZ6A8/1rgoMkkZ5PcH+ddZ4Fl23d5A2PmVZP5g/0oA6+7OZd3OSNu4DBz2/SoYl/eyq3DMDjjoc1alw5CNghkJJ9CKqtkSJwcnHTtxQAxdxbg5QtjPv709MtcN2DZIPbpihwFbCnABHy54pw+SRowSNoPbIHFAG5pDtJYRkkMyHbmvL/FVoLLxfqcW0BJWWdTjsw/xBr0bQWAIVTuV0PGOp/wAiuc+JdoFudOvx1IMDn9V/qPxoA5YxkocYG4bvl9en4UijjnuOOO1LBwCAAP4gR3pyAb25BI7elAHSeGyfsahiMqSuD9a39uYJAOwz1rmvDhIWVMDCv9cZFdPFg544I7GgDOuAN2T97ircuDbYIwBkenFQyDAAY56g5FX9OnghgYvbeddBjtMh+QDHBx3/AM8igDhIPDGo6jcXhiVbPTlkZmvrk7IwvXIB5b+XuK63RLjTLG2iTT2/tSVVAF3INsRI7ovf/PNcr42mvL3VYmvriSWIruSHpGhB6hemeepyferfhJ8adGg/5ZsydPegDoNVnmvCrXMhkPZTwoPsKhtfldc46Y6VNKMwryOOOaqx4yCOKAMXxxCBbWs4HzRzGMnHRWH+IFc5pr+Xq1kcceaAOPUY613PiS3+06HeoBkiPeAB3HNcEGKiCVcYSRGJHXqKAPRnBaFf9ljgCoAMxkEg7WBI9vWrfLQt12ggnFVUySOgBBH5UAZ/jmMNptpcrz5cwHH+0DzXG8mNhzjpkDH4V3fiWH7T4Uu1UnMYWQe+xv8ACuEU/KGz3zz2oAYRuYZAIA+tPByDyR1GCuCf8801flY7cFRzjHBNORiMBiBng0AX9HXzdVtVJJxlzxjGBx+tdbqSbrNEA2lRuGPXOK57wrFuvnkx84GATk4FdJck7yw+5gAD8aAMq5ULHcbAVAAIXqf89agVmGg6wzIQGhKjP8QxVi/I8yRiuUYr068motUD2/he6ZowrsNjDPUZ/wDr0AcaqhIUGVzgDntVS6wr/L36c/z/AEq0wYfKFDOOSB16dAarXQBCg71zzz6+9AGdcfMQWLAj+9nkVg3xSJJHznahZs8YUVs3LMI2LMH29cc8/wCFcd4uuHh8P3km5lPl49CcnpQB5Fqd19tvpZ8bQ54HoKqUUUAFFFFABRRRQAUUUUAaPh+drfWrN17yBfzOK9u08KjgZbaRhm+teFaW23U7RsZxMhx/wIV7rpfzkKck96AOgtcFUDL6gjPJHWtGxblsFcEZA649azoGx90AHg8dK0I1EbEAn5GAH4mgC6pA+Vfw4xmtnwxL5Ot2zrkCVWQjPPqP5VksoDAnkZxjAq7ZSCO6s5EypWZenfJwaAPSJSqkFs4UgH054qMp+7dGUknKgnr7VITlSCMhk5/Ol+8SSOHB79COhFAEMiDYd5PQ9RnmnyBhKW+9uC5HT2pygq8h6jG6mO+C+AOHx/KgCewcwSxyMGBSQjrxjOKseM7L7boEiA8owZT/AC/pVUfNJOD02hvz/wD1VtRKLrSZUYfwY/KgDyOAkBS4CkEZz0/GngAMcEZ569RU+pQG3vpUDZBO8fjUbk7yWAOeDQBq+HWxdXCpjZwRXWwEkr35+lcbojldRAB4aMnp3zXY2/Kj1BAoAqzkhyAO/FS23ylQGJpl6u1pB23UQn5v94jigDn/ABjB8sUy8GOQAsPQ8VW8KMN9zFk4DBvwNbXiiIS6bPzj5M8DuDmuc8NyFdUCDpJGfzH/AOugDtDxCQDyOMVQjGWfnBBrQHKMD6dBVDhZSRkZ9KALwAkiIP3XXaa8wuIikU8RBDQuy5x1wf8A9VemWrfumAJ471w/iOAJrd4qn7yCT8SMf0oA7e1+a1HQEpx+VQbBgjAGDnBp+iMX0u1Y8kxAn3OKlID9RQA54ftGm3ERx+8idcD3FeXwZEEYYNuAAbdXq9r057kfhmvMr2JLbU9QgTOEnYde2c0AVmBJGQcH0HU55pQvODyp/hxxSOrAkEjJY9KewK5IxhfzzQB1HhKHbarJz+8JYD0GcVrzKZFJJPHRQO1V/DyeXpVpwP8AVbsjvVraRKoDEH19yM0AUTGcSg4ztGO+eaoeKCI/D8iKN20AYHHUitZUH2sqcbGGBxzWZ40X/QJIo/lYbCcdCN3T9KAOKJJAx8wKluD+n61QkKo3yYweDu7etW4uVyvQDOO3TNV7lTgMMbSCSvrQBjXpB3g4OQRnB4+teX/Ea7b+zYYQdqO5XA/iwc16be5SJtp3KOoYevvXlHxMjKPAm75Y2Ix2oA4SiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph of the foot demonstrates air in the soft tissues about the 5th toe (black arrowheads). Cortical destruction of the 5th metatarsal head is also seen (white arrow). Irregular contour of the overlying skin represents associated soft tissue ulceration (asterisk).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Perry Horwich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14833=[""].join("\n");
var outline_f14_31_14833=null;
var title_f14_31_14834="Radiofrequency catheter ablation for the heart";
var content_f14_31_14834=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/31/14834/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14834/contributors\" id=\"au4322\">",
"       Leonard I Ganz, MD, FHRS, FACC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/31/14834/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14834/contributors\" id=\"se5282\">",
"       Brian Olshansky, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/31/14834/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14834/contributors\" id=\"de1101\">",
"       Gordon M Saperia, MD, FACC",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14834/contributors\" id=\"de7537\">",
"       Brian C Downey, MD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?14/31/14834?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      RADIOFREQUENCY CATHETER ABLATION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Radiofrequency catheter ablation is a procedure that is performed to correct a disturbance in heart rhythm. A brief review of how a normal heart rhythm occurs and a description of some of the rhythm problems that are treated with this procedure will help in the understanding of radiofrequency catheter ablation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2\">",
"     <span class=\"h2\">",
"      How does the heart normally work?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heart muscle cells are stimulated by electrical impulses that cause them to contract in a uniform way and with a regular rate. This contraction produces the heartbeat, which causes blood to be pumped out of the heart into arteries and then to all parts of the body. The flow of blood into arteries can be measured by feeling the pulse, which corresponds to the heartbeat.",
"    </p>",
"    <p>",
"     In the normal heart, electrical impulses arise from an area of specialized cells called the sinus node, which is the heart's normal pacemaker. The sinus node is located in the right atrium, the upper right chamber of the heart (",
"     <a class=\"graphic graphic_figure graphicRef77576 \" href=\"UTD.htm?11/14/11495\">",
"      figure 1",
"     </a>",
"     ). After leaving the sinus node, an impulse spreads across the upper heart chambers (right and left atria) and reaches the atrioventricular (AV) node located near the center of the heart between the atria and the lower chambers, or ventricles, and then to conduction fibers that spread across the ventricles, which are the heart's main pumping chambers. As the impulse moves along the conduction fibers, cardiac muscle cells are stimulated and contract, producing a heartbeat (",
"     <a class=\"graphic graphic_figure graphicRef71235 \" href=\"UTD.htm?4/20/4420\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Sometimes, the electrical impulses \"short circuit\" the normal pathway and travel across the heart in an abnormal way. Abnormal pathways, or routes, for the impulses can develop, causing irregularities in the heartbeat, or arrhythmias. In other cases, arrhythmias arise when areas other than the sinus node become active and begin to send out impulses that either compete with or take over the pacemaker function of the sinus node. Typically, the result of these abnormalities is a heartbeat that is too fast. This may develop in any location within the atria, AV node, or ventricles. When the fast rhythm requires tissue from the upper part of the heart, it is known as supraventricular tachycardia. When it requires tissue from the lower chambers only, it is known as ventricular tachycardia.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      WHAT IS RADIOFREQUENCY CATHETER ABLATION?",
"     </span>",
"    </p>",
"    <p>",
"     Radiofrequency ablation is a procedure that can cure many types of fast heart beats. Using a special wires or catheters that are threaded into the heart, radiofrequency energy (low-voltage, high-frequency electricity) is targeted toward the area(s) causing the abnormal heart rhythm, permanently damaging small areas of tissue with heat. In some cases, cryoablation, which damages tissue by freezing rather than heating, may be used rather than radiofrequency energy.",
"    </p>",
"    <p>",
"     The damaged tissue is no longer capable of generating or conducting electrical impulses. If the procedure is successful, this prevents the arrhythmia from being generated, curing the patient.",
"    </p>",
"    <p>",
"     A pacemaker is a small electrical device that stays in the body and is connected to the heart with wires that stimulate the heart to contract in a regular way. In some patients, insertion of a pacemaker is a planned part of the procedure. In other cases, the need for a pacemaker is a complication of the ablation procedure. A doctor can tell whether a patient will need a pacemaker after the ablation. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"      \"Patient information: Pacemakers (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      WHICH RHYTHM PROBLEMS CAN BE TREATED?",
"     </span>",
"    </p>",
"    <p>",
"     Radiofrequency ablation can be used to treat many arrhythmias that cause a fast heartbeat.",
"    </p>",
"    <p>",
"     Radiofrequency ablation may be recommended for:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Paroxysmal supraventricular tachycardia (PSVT), which includes:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Wolff-Parkinson-White syndrome (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?8/50/8995?source=see_link\">",
"        \"Patient information: Wolff-Parkinson-White syndrome (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       AV nodal reentrant tachycardia",
"      </li>",
"      <li>",
"       Atrial tachycardia",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Atrial flutter",
"      </li>",
"      <li>",
"       Ventricular tachycardia and premature ventricular contractions",
"      </li>",
"      <li>",
"       Atrial fibrillation (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"        \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      RADIOFREQUENCY CATHETER ABLATION",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Preparation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients may be asked to discontinue certain medications in the days before the procedure. Most patients are advised to stop eating and drinking at midnight the night before the procedure. A pregnancy test is usually done immediately before the procedure in women of child bearing capacity because of the radiation exposure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Procedure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Before the procedure begins, you may be given a sedative medication through an intravenous (IV) line; many patients are not aware of what is happening during the procedure.",
"    </p>",
"    <p>",
"     Small catheters (special wires) will be threaded into the heart. The catheters are usually inserted into the vein or artery in the right and left groin (inner thigh) and are then positioned within the chambers of the heart using fluoroscopy (low energy x-rays). Occasionally, catheters are inserted via veins into the side of the neck, upper chest, or arm. The doctor will test various parts of the heart and usually will try to provoke the arrhythmia.",
"    </p>",
"    <p>",
"     The sections of the heart that are causing your arrhythmia can be identified. The doctor will then use the radiofrequency energy (heat or electrocautery) or cryoablation (freezing) to treat the problem area. During the procedure, your heart rate and rhythm, oxygen level, and blood pressure will be monitored.",
"    </p>",
"    <p>",
"     When the procedure is completed, the doctor will again try to provoke the arrhythmia. If it cannot be initiated, the procedure is considered to be a success. However, if the arrhythmia can still be initiated, additional radiofrequency energy is delivered.",
"    </p>",
"    <p>",
"     The length of the procedure varies from patient to patient, depending upon the type of arrhythmia being treated and other factors. Typically, the procedure lasts two hours or more.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Post-ablation care",
"     </span>",
"     &nbsp;&mdash;&nbsp;You will be taken to a recovery area while the effects of the sedative medication wear off. The catheter site will be monitored for bleeding and the heart rhythm is observed closely during this period. You must stay in bed for several hours to reduce the risk of bleeding from the catheter site. You usually feel tired but well. Pain medication is usually needed for only a short time, if at all.",
"    </p>",
"    <p>",
"     Some patients are admitted to the hospital after the procedure while others go home later the same day. Certain activities are not recommended for a brief period to avoid straining the catheter site.",
"    </p>",
"    <p>",
"     You may be asked to take aspirin every day for several weeks after the procedure to prevent blood clots. The doctor will give more detailed information about medications needed after the procedure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      RADIOFREQUENCY ABLATION COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Like any invasive procedure, radiofrequency ablation carries some risk. However, the risk of these complications is small in most cases.",
"    </p>",
"    <p>",
"     Possible complications include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Problems related to threading the catheters through the blood vessels such as bleeding, infection, blood clots, bruising, and injury to the vessel(s)",
"      </li>",
"      <li>",
"       Injury to the heart as a result of the catheters; this includes a perforation through the muscle or damage to one of the valves within the heart",
"      </li>",
"      <li>",
"       Blood clots that travel to the lungs (pulmonary embolism) or brain (stroke)",
"      </li>",
"      <li>",
"       Heart block, or failure of any electrical impulse to travel from the top parts of the heart to the bottom. This complication, if permanent, requires implantation of a pacemaker.",
"      </li>",
"      <li>",
"       New arrhythmias",
"      </li>",
"      <li>",
"       Exposure to radiation during the procedure, which can take several hours. This can produce a very small increase in the risk of cancer or genetic defects.",
"      </li>",
"      <li>",
"       Death (occurs in approximately 0.1 percent of cases)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      OTHER ARRHYTHMIA TREATMENTS",
"     </span>",
"    </p>",
"    <p>",
"     Other arrhythmia treatments may be available, depending in part on what type of arrhythmia is present. Medication, pacemakers, cardioversion (delivering an electrical current to the chest to restore a normal rhythm), and surgery are examples of treatments that may be used for particular arrhythmias. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"      \"Patient information: Pacemakers (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/10/24738?source=see_link\">",
"      \"Patient information: Cardioversion (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Some types of arrhythmias are temporary and non-life threatening; patients can be taught certain maneuvers (such as coughing or increasing pressure in the abdomen) that may stop the arrhythmia. Detailed information about available alternative therapies is available from a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1785038963\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H374970743\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/54/13154?source=see_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/56/23427?source=see_link\">",
"      Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=see_link\">",
"      Patient information: Heart failure and atrial fibrillation (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/16/8451?source=see_link\">",
"      Patient information: Atrial flutter (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/12/25795?source=see_link\">",
"      Patient information: Ventricular fibrillation (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H374970760\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/50/8995?source=see_link\">",
"      Patient information: Wolff-Parkinson-White syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/10/24738?source=see_link\">",
"      Patient information: Cardioversion (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link\">",
"      Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33431?source=see_link\">",
"      Catheter ablation of atrial tachycardia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/9/22681?source=see_link\">",
"      Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Heart Rhythm Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hrsonline.org/\">",
"      www.hrsonline.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?14/31/14834/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 27, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?14/31/14834?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14834/abstract/1\">",
"      Calkins H, Yong P, Miller JM, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation 1999; 99:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14834/abstract/2\">",
"      Morady F. Radio-frequency ablation as treatment for cardiac arrhythmias. N Engl J Med 1999; 340:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14834/abstract/3\">",
"      Calkins H. Catheter ablation for cardiac arrhythmias. Med Clin North Am 2001; 85:473.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f14_31_14834=[""].join("\n");
var outline_f14_31_14834=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           RADIOFREQUENCY CATHETER ABLATION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           WHAT IS RADIOFREQUENCY CATHETER ABLATION?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           WHICH RHYTHM PROBLEMS CAN BE TREATED?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           RADIOFREQUENCY CATHETER ABLATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           RADIOFREQUENCY ABLATION COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           OTHER ARRHYTHMIA TREATMENTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/14/11495\" title=\"figure 1\">",
"           Cardiac anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/20/4420\" title=\"figure 2\">",
"           Heart conduction system PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f14_31_14835="Patient information: Weight loss surgery (The Basics)";
var content_f14_31_14835=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16640\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/3/3125\">",
"         Your body mass index (BMI)",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/2/39\">",
"          Gastric banding",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/19/26929\">",
"           Roux-en-Y gastric bypass (RYGB)",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/55/33648\">",
"            Sleeve gastrectomy",
"           </a>",
"           <li>",
"            <a class=\"graphic graphic_table\" href=\"UTD.htm?5/27/5565\">",
"             Comparison of weight loss surgeries",
"            </a>",
"           </li>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/55/3954\">",
"         Patient information: Care after weight loss surgery (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/53/3923\">",
"         Patient information: Health risks of obesity (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/22/25954\">",
"         Patient information: Minimally invasive surgery (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/52/31554\">",
"         Patient information: Weight loss treatments (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/37/9811\">",
"         Patient information: Weight loss surgery (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33876\">",
"         Patient information: Weight loss treatments (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Weight loss surgery (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/weight-loss-surgery-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2356801\">",
"      <span class=\"h1\">",
"       What is weight loss surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Weight loss surgery, sometimes called &ldquo;bariatric surgery,&rdquo; is surgery to help you lose weight. It works by making your stomach smaller. Some types of surgery also change the path food takes through your gut so that you take in fewer calories and nutrients.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356816\">",
"      <span class=\"h1\">",
"       Who can have weight loss surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors use a measure called &ldquo;body mass index,&rdquo; or BMI, to decide who can have weight loss surgery. Your BMI will tell you whether your weight is normal for your height (",
"      <a class=\"graphic graphic_figure graphicRef62886 \" href=\"UTD.htm?3/3/3125\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Weight loss surgery is appropriate only for people who have not been able to lose weight through other means and who:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Have a BMI greater than 40; or",
"       </li>",
"       <li>",
"        Have a BMI between 35 and 40 and also have medical problems, such as diabetes, heart disease, or high blood pressure",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356831\">",
"      <span class=\"h1\">",
"       Are there different types of weight loss surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are many different types. The 3 most common are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Gastric banding",
"        </strong>",
"        (gastric is another word for &ldquo;stomach&rdquo;) &mdash; For this surgery, the doctor wraps a plastic band around the top of your stomach, making a small pouch. The band is adjustable. It gets tighter or looser depending on how much fluid it has in it. The doctor can add or remove fluid through a button under your skin that is connected to the band with tubing (",
"        <a class=\"graphic graphic_figure graphicRef66685 \" href=\"UTD.htm?0/2/39\">",
"         figure 2",
"        </a>",
"        ). That way, the doctor can adjust the size of your stomach.",
"       </li>",
"       <li>",
"        <strong>",
"         Gastric bypass",
"        </strong>",
"        &mdash;Gastric bypass is short for &ldquo;Roux-en-Y gastric bypass.&rdquo; For this surgery, the doctor closes off part of the stomach, leaving only a small pouch for food. Then he or she connects the new stomach pouch to the small intestine (",
"        <a class=\"graphic graphic_figure graphicRef68926 \" href=\"UTD.htm?26/19/26929\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        <strong>",
"         Gastric sleeve",
"        </strong>",
"        &mdash; Gastric sleeve, also known as &ldquo;sleeve gastrectomy,&rdquo; is a surgery that turns the stomach into a narrow tube (",
"        <a class=\"graphic graphic_figure graphicRef68282 \" href=\"UTD.htm?32/55/33648\">",
"         figure 4",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356846\">",
"      <span class=\"h1\">",
"       How is the surgery done?",
"      </span>",
"      &nbsp;&mdash;&nbsp;All the different types of weight loss surgery can be done as &ldquo;open&rdquo; surgery or as &ldquo;laparoscopic&rdquo; surgery. For open surgery, the surgeon cuts open the belly and works on the organs directly. For laparoscopic surgery, the surgeon inserts a narrow tool that has a tiny camera on the end into the belly. This tool is called a &ldquo;laparoscope.&rdquo; It allows the surgeon to see inside the belly without opening it up all the way. Then the surgeon can do the surgery using other tools that fit through small openings in the belly and that can be controlled from the outside.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356861\">",
"      <span class=\"h1\">",
"       How do the different types of surgery compare?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See the table to learn how the different types of surgery compare (",
"      <a class=\"graphic graphic_table graphicRef73045 \" href=\"UTD.htm?5/27/5565\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Gastric banding is probably the simplest form of weight loss surgery. It involves the least amount of cutting and it can be adjusted or even undone. Gastric banding also leads to the least amount of overall weight loss. Plus, people who have gastric banding need to see the doctor often for adjustments, and some end up needing the band taken out.",
"     </p>",
"     <p>",
"      Gastric bypass leads to the most weight loss and works the fastest, but it involves more serious surgery. It can also cause problems in how your body absorbs nutrients. As a result it can lead to &ldquo;nutritional deficiencies,&rdquo; meaning that your body is missing important nutrients. This can make you sick. &nbsp;",
"     </p>",
"     <p>",
"      Sleeve gastrectomy is safer than gastric bypass because it does not involve cutting and reattaching the intestines, and because it is less likely to cause problems with how you absorb nutrients. It might also be safer than the gastric banding because it does not involve any plastic materials that stay in your body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356876\">",
"      <span class=\"h1\">",
"       How do I know which surgery is best for me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The decision about which type of surgery to have is important. Discuss your choices with your doctor.",
"     </p>",
"     <p>",
"      If you have different options, ask the following questions:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        About how much weight can I expect to lose with each option?",
"       </li>",
"       <li>",
"        How long will it take me to lose the weight?",
"       </li>",
"       <li>",
"        What are the risks of each option for someone like me?",
"       </li>",
"       <li>",
"        What changes will I need to make to my diet and lifestyle with each option?",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Whatever you decide, make sure your surgeon is very experienced with weight loss surgery. Also, check with the staff at your treatment center or make sure it is a certified &ldquo;Center of Excellence.&rdquo; If you are at all unsure about your decision, you can ask for an opinion from another doctor. Most hospitals offer sessions where you can learn more about weight loss surgery and the options you have.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356891\">",
"      <span class=\"h1\">",
"       What are the benefits of surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In addition to helping you lose weight, surgery can help improve or even get rid of certain health problems, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Diabetes",
"       </li>",
"       <li>",
"        High blood pressure",
"       </li>",
"       <li>",
"        High cholesterol",
"       </li>",
"       <li>",
"        Sleep apnea, a disorder that causes you to stop breathing for short amounts of time while you sleep",
"       </li>",
"       <li>",
"        Gastroesophageal reflux disease, a condition that causes heartburn",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356908\">",
"      <span class=\"h1\">",
"       What are the risks of surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The risks of surgery are different depending on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What type of weight loss surgery you have",
"       </li>",
"       <li>",
"        Whether your surgery is open or laparoscopic",
"       </li>",
"       <li>",
"        Your age and overall health",
"       </li>",
"       <li>",
"        How experienced your surgeon is",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In general the risks could include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bleeding",
"       </li>",
"       <li>",
"        Infection",
"       </li>",
"       <li>",
"        A blockage or tear in the intestines",
"       </li>",
"       <li>",
"        Problems with the heart or lungs",
"       </li>",
"       <li>",
"        The need for more surgery",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356925\">",
"      <span class=\"h1\">",
"       Will I need to change the way I eat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Work with a nutritionist (a food expert) to learn how your diet should change. &nbsp;",
"     </p>",
"     <p>",
"      You will need to eat healthy foods that \"work with\" your surgery. For example, you should choose foods high in protein and low in fat and calories. You should also avoid liquid foods that are high in calories, such as ice cream. If you eat the wrong things, you could hurt your chances of losing weight.",
"     </p>",
"     <p>",
"      If you have gastric bypass, you will need to avoid certain foods that could make you sick. Plus you will probably need to take special multivitamins with minerals. That's because gastric bypass surgery can make it hard for your body to get all the nutrition it needs. You must keep taking the vitamins for the rest of your life. Your body will always need them to stay healthy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356940\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=see_link\">",
"       Patient information: Weight loss treatments (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/22/25954?source=see_link\">",
"       Patient information: Minimally invasive surgery (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/53/3923?source=see_link\">",
"       Patient information: Health risks of obesity (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/55/3954?source=see_link\">",
"       Patient information: Care after weight loss surgery (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"       Patient information: Weight loss treatments (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=see_link\">",
"       Patient information: Weight loss surgery (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?14/31/14835?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16640 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-124.240.187.79-C6995B1F2D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14835=[""].join("\n");
var outline_f14_31_14835=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356801\">",
"      What is weight loss surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356816\">",
"      Who can have weight loss surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356831\">",
"      Are there different types of weight loss surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356846\">",
"      How is the surgery done?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356861\">",
"      How do the different types of surgery compare?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356876\">",
"      How do I know which surgery is best for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356891\">",
"      What are the benefits of surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356908\">",
"      What are the risks of surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356925\">",
"      Will I need to change the way I eat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356940\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16640\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/3/3125\">",
"      Your body mass index (BMI)",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/2/39\">",
"       Gastric banding",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/19/26929\">",
"        Roux-en-Y gastric bypass (RYGB)",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/55/33648\">",
"         Sleeve gastrectomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"UTD.htm?5/27/5565\">",
"          Comparison of weight loss surgeries",
"         </a>",
"        </li>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/55/3954?source=related_link\">",
"      Patient information: Care after weight loss surgery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/53/3923?source=related_link\">",
"      Patient information: Health risks of obesity (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/22/25954?source=related_link\">",
"      Patient information: Minimally invasive surgery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=related_link\">",
"      Patient information: Weight loss surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_31_14836="Mastoid bowl";
var content_f14_31_14836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous debris in the ear canal after a canal wall down mastoidectomy with creation of a mastoid bowl",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When it is necessary to sacrifice the ear canal during mastoidectomy (canal wall down mastoidectomy), a common cavity (mastoid bowl) is created between the ear canal and the mastoid. Squamous debris must be periodically cleared from the mastoid bowl by an otolaryngologist throughout the patient's life.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14836=[""].join("\n");
var outline_f14_31_14836=null;
var title_f14_31_14837="Chronic thromboembolic pulmonary hypertension: Medical treatment";
var content_f14_31_14837=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic thromboembolic pulmonary hypertension: Medical treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/31/14837/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14837/contributors\">",
"     Peter F Fedullo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/31/14837/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14837/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/31/14837/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14837/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/31/14837/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1662726\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy other than anticoagulation for chronic thromboembolic pulmonary hypertension (CTEPH) refers to the use of pulmonary vasodilators and remodeling agents to lower the pulmonary vascular resistance and pulmonary artery pressure, thereby improving symptoms and signs such as exercise capacity and oxygenation. Medical therapy is not curative and its effects are relatively modest; therefore, it is indicated in only a few situations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The indications, initiation, and outcomes of medical therapy are reviewed here. The general approach to the treatment of CTEPH is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34293?source=see_link\">",
"     \"Overview of the treatment of chronic thromboembolic pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1663229\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR PULMONARY HYPERTENSION-SPECIFIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the only potentially curative therapy for CTEPH; thus, there are only a few clinical situations in which medical therapy may be indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As therapy for patients who are not operative candidates due to a personal choice, the anatomic distribution of their disease, the extent of their disease, or their comorbidities. The decision that a patient&rsquo;s disease is inoperable should only be made after a comprehensive evaluation at a center with experience in the management of CTEPH.",
"     </li>",
"     <li>",
"      As a bridge to definitive surgical intervention in patients with severe pulmonary hypertension and right heart failure. In contrast, routine administration of medical therapy prior to surgery is not indicated because there is no evidence that medical therapy improves hemodynamic or mortality outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As therapy for patients who have a suboptimal hemodynamic and functional outcome following pulmonary thromboendarterectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3757438\">",
"    <span class=\"h1\">",
"     MEDICATION SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medications used to treat CTEPH were developed to treat patients with idiopathic pulmonary arterial hypertension (IPAH). They include prostanoids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"     treprostinil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    ), endothelin receptor antagonists (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/60/29637?source=see_link\">",
"     ambrisentan",
"    </a>",
"    ), and phosphodiesterase 5 inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    ). There is no evidence that supports the use of one medication over another in patients with CTEPH.",
"   </p>",
"   <p>",
"    Selection of the agent is usually based upon factors like the experience of the treating clinician, the cost, the availability of the agent, and drug-specific properties such as route of administration (ie, intravenous, oral, or inhaled). An exception is that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    is generally preferred for patients who are most severely ill (ie, New York Heart Association [NYHA] functional Class IV) because epoprostenol is the agent that has been best studied and with which there is the most clinical experience (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The selection of an agent to treat CTEPH is similar to the selection of an agent to treat IPAH, which is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H31#H31\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Selection of an agent'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3757446\">",
"    <span class=\"h1\">",
"     INITIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy for pulmonary hypertension should only be administered at specialized centers that have experience treating patients with pulmonary hypertension. Patients with CTEPH who are selected for medical therapy should undergo an invasive hemodynamic assessment prior to the initiation of therapy. The purpose is to confirm the presence of pulmonary hypertension, determine the baseline severity of the pulmonary hypertension, and monitor the early response to titration of the medication. Vasoreactivity testing prior to the initiation of therapy is not necessary because patients with CTEPH are rarely vasoreactive [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/8\">",
"     8",
"    </a>",
"    ]. The initiation of medical therapy to treat CTEPH is similar to the initiation of a medication to treat IPAH, which is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Advanced therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16600338\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy for inoperable CTEPH has been empirically studied and the evidence indicates that medical therapy has hemodynamic and symptomatic benefits, but these benefits are modest compared to those that can be achieved with pulmonary thromboendarterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endothelin receptor antagonists &ndash; The endothelin receptor antagonists are the most extensively studied medications in CTEPH, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      . In a systematic review of 10 observational studies and one randomized trial (269 patients) that included several meta-analyses, the initiation of bosentan for inoperable CTEPH was associated with improved exercise capacity as measured by a six-minute walk test (weighted mean difference [WMD] 35.9 meters, 95% CI 33.6-38.2 meters), a decreased pulmonary artery pressure (WMD 2.62 mmHg, 95% CI 2.44-2.80), and an increased cardiac index (MWD 0.23",
"      <span class=\"nowrap\">",
"       L/min/m2,",
"      </span>",
"      95% CI 0.22-0.25",
"      <span class=\"nowrap\">",
"       L/min/m2)",
"      </span>",
"      when compared to baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/9\">",
"       9",
"      </a>",
"      ]. These findings are consistent with the only randomized trial, in which 157 patients with either inoperable CTEPH or persistent CTEPH after thromboendarterectomy were randomly assigned to receive placebo or bosentan for 16 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/10\">",
"       10",
"      </a>",
"      ]. Bosentan improved the pulmonary vascular resistance and cardiac index compared to placebo, although exercise capacity did not improve in this trial.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"       Epoprostenol",
"      </a>",
"      &ndash; A retrospective cohort study evaluated the effects of epoprostenol in 27 patients with inoperable CTEPH [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/11\">",
"       11",
"      </a>",
"      ]. After three months of therapy, epoprostenol use was associated with a decrease in the pulmonary vascular resistance and pulmonary artery pressure, as well as an improvement in exercise capacity, compared to baseline. Almost half of the patients had an improvement in their NYHA functional class.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"       Treprostinil",
"      </a>",
"      &ndash; In an uncontrolled trial of 28 patients with severe inoperable CTEPH who were treated with subcutaneous treprostinil, right heart catheterization of 19 patients after 20 months of therapy revealed improved pulmonary vascular resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/12\">",
"       12",
"      </a>",
"      ]. The five-year survival rate was 53 percent, compared to 16 percent among historical controls.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"       Iloprost",
"      </a>",
"      &ndash; A trial randomly assigned 203 patients with pulmonary hypertension (57 patients had inoperable CTEPH) to receive inhaled iloprost or placebo for 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/13\">",
"       13",
"      </a>",
"      ]. Inhaled iloprost improved exercise capacity, NYHA functional class, hemodynamics, symptoms, and quality of life. The beneficial effect of inhaled iloprost in CTEPH is supported by other studies [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/14-16\">",
"       14-16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Phosphodiesterase 5 inhibitors &ndash; In a double-blind, placebo-controlled trial, 19 patients with inoperable CTEPH were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/17\">",
"       17",
"      </a>",
"      ]. At 12 weeks, the sildenafil group had a better World Health Organization functional class and lower pulmonary vascular resistance (",
"      <a class=\"graphic graphic_table graphicRef62080 \" href=\"UTD.htm?24/47/25339\">",
"       table 2",
"      </a>",
"      ), but there was no difference in exercise capacity. The control patients were then provided open-label sildenafil and follow-up was obtained at 12 months. At that time, the patients were noted to have an improved exercise capacity, symptom score, and pulmonary vascular resistance compared to baseline. Other nonrandomized trials support these results [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/14,17-19\">",
"       14,17-19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional agents (eg, Riociguat, a soluble guanylate cyclase stimulant) are being studied [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical therapy has also been studied as a therapeutic bridge to pulmonary thromboendarterectomy; the data support the notion that routine preoperative medical therapy is not indicated. In a case series of 12 patients with severe CTEPH (defined as a pulmonary vascular resistance &gt;1200",
"    <span class=\"nowrap\">",
"     dyne-seconds/cm5),",
"    </span>",
"    a continuous intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    infusion (mean dose of 6",
"    <span class=\"nowrap\">",
"     ng/kg/min,",
"    </span>",
"    range of 2 to 11",
"    <span class=\"nowrap\">",
"     ng/kg/min)",
"    </span>",
"    was administered for a mean of 46 days prior to pulmonary thromboendarterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/4\">",
"     4",
"    </a>",
"    ]. There was a substantial preoperative decrease in the pulmonary vascular resistance, but no evidence of postoperative benefit. Postoperative pulmonary vascular resistance was similar and postoperative mortality was higher among the patients with severe CTEPH who received epoprostenol than among patients with less severe CTEPH who did not receive medical therapy. In addition, concerns have been expressed that the initiation of medical therapy may delay appropriate referral for the definitive treatment, pulmonary thromboendarterectomy.",
"   </p>",
"   <p>",
"    There is a paucity of evidence regarding the effects of medical therapy in patients with persistent pulmonary hypertension following pulmonary thromboendarterectomy, although limited the data that exist suggest that medical therapy is beneficial in this setting. In the randomized trial described above, which included patients with either persistent CTEPH after thromboendarterectomy or inoperable CTEPH,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    improved the pulmonary vascular resistance and cardiac index, but not the exercise capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/10\">",
"     10",
"    </a>",
"    ]. A retrospective cohort study that similarly included patients with either persistent CTEPH after thromboendarterectomy or inoperable CTEPH found that the one- and three-year survival among patients who received medical therapy for persistent CTEPH after thromboendarterectomy were similar to that among patients who did not have persistent CTEPH after thromboendarterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14837/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16600277\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medical therapy for chronic thromboembolic pulmonary hypertension (CTEPH) refers to the use of pulmonary vasodilators and remodeling agents to lower the pulmonary vascular resistance and pulmonary artery pressure, thereby improving symptoms and signs such as exercise capacity and oxygenation. (See",
"      <a class=\"local\" href=\"#H1662726\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery is the only potentially curative therapy for CTEPH; thus, medical therapy is indicated in few clinical situations: as therapy for patients who are not operative candidates due to a personal choice, the anatomic distribution of their disease, the extent of their disease, or their comorbidities; as a bridge to definitive surgical intervention in patients with severe pulmonary hypertension and right heart failure; as therapy for patients who have a suboptimal hemodynamic and functional outcome following pulmonary thromboendarterectomy. (See",
"      <a class=\"local\" href=\"#H1663229\">",
"       'Indications for pulmonary hypertension-specific therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe CTEPH (ie, NYHA or WHO functional Class IV) in whom the decision has been made to use medical therapy, we suggest initiating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      rather than an alternative agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients who are not as severely ill, a preferred agent has not been established. Thus, the selection may be based upon clinical preference, availability, and drug-related factors. (See",
"      <a class=\"local\" href=\"#H3757438\">",
"       'Medication selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with CTEPH who are selected for medical therapy should undergo an invasive hemodynamic assessment prior to the initiation of therapy. (See",
"      <a class=\"local\" href=\"#H3757446\">",
"       'Initiation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medical therapy has hemodynamic and symptomatic benefits, but these benefits are modest compared to those that can be achieved with pulmonary thromboendarterectomy. (See",
"      <a class=\"local\" href=\"#H16600338\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/1\">",
"      Fedullo P, Kerr KM, Kim NH, Auger WR. Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2011; 183:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/2\">",
"      Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2011; 364:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/3\">",
"      Bresser P, Fedullo PF, Auger WR, et al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/4\">",
"      Nagaya N, Sasaki N, Ando M, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003; 123:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/5\">",
"      McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/6\">",
"      Hughes RJ, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006; 28:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/7\">",
"      Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation 2009; 120:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/8\">",
"      Ulrich S, Fischler M, Speich R, et al. Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest 2006; 130:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/9\">",
"      Becattini C, Manina G, Busti C, et al. Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis. Thromb Res 2010; 126:e51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/10\">",
"      Ja&iuml;s X, D'Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/11\">",
"      Cabrol S, Souza R, Jais X, et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2007; 26:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/12\">",
"      Skoro-Sajer N, Bonderman D, Wiesbauer F, et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2007; 5:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/13\">",
"      Olschewski H, Simonneau G, Gali&egrave; N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/14\">",
"      Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/15\">",
"      Kramm T, Eberle B, Krummenauer F, et al. Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. Ann Thorac Surg 2003; 76:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/16\">",
"      Krug S, Hammerschmidt S, Pankau H, et al. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension. Respiration 2008; 76:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/17\">",
"      Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008; 134:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/18\">",
"      Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/19\">",
"      Reichenberger F, Voswinckel R, Enke B, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007; 30:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/20\">",
"      Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010; 36:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14837/abstract/21\">",
"      Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008; 177:1122.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16628 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-EB31556FB1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14837=[""].join("\n");
var outline_f14_31_14837=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16600277\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1662726\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1663229\">",
"      INDICATIONS FOR PULMONARY HYPERTENSION-SPECIFIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3757438\">",
"      MEDICATION SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3757446\">",
"      INITIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16600338\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16600277\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/16628\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/16628|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/47/25339\" title=\"table 2\">",
"      Classification PH function",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34293?source=related_link\">",
"      Overview of the treatment of chronic thromboembolic pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_31_14838="Travoprost and timolol: Drug information";
var content_f14_31_14838=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Travoprost and timolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/60/23492?source=see_link\">",
"    see \"Travoprost and timolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5094947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      DuoTrav&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5094951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker, Nonselective;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma;",
"     </li>",
"     <li>",
"      Prostaglandin, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5095019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Control of intraocular pressure:",
"     </b>",
"     Ophthalmic: Instill 1 drop into affected eye(s) once daily in the morning",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5095020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5951006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     DuoTrav&trade;: Travoprost 0.004% and timolol 0.5%: (2.5 mL, 5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5095021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Remove contact lenses prior to administration; wait 15 minutes before reinserting if using products containing benzalkonium chloride. Separate administration of other ophthalmic agents by 5 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5094952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers, prostaglandin analogues, or other IOP-reducing agents and in whom combination therapy is appropriate",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5094943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       DuoTrav&trade; may be confused with DuoNeb&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5095001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents. Based on long-term studies:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Ocular: Hyperemia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%: Ocular: Eye irritant (6%), eye pruritus (5%), dry eyes (3%), eyelash growth (2%), iris pigmentation changes (up to 2%), blurred vision (1%), eye pain (1%), photophobia (1%), punctuate keratitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic conjunctivitis, anterior chamber flare, arrhythmia, asthenopia, blepharitis, bradycardia, bronchospasm, chromaturia, conjunctival hemorrhage, contact dermatitis, cough, corneal staining, distichiasis, dizziness, dyspnea, extremity pain, eye allergy, eyelid dermatitis, eyelid edema, eyelid erythema, eyelid irritation, eyelid pain, eye swelling, headache, hyper-/hypotension, hypertrichosis, lacrimation increased, nervousness, ocular discomfort, periorbital disorder, postnasal drip, skin hyperpigmentation, thirst, throat irritation, urticaria, visual disturbance, xerophthalmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5094956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to travoprost, timolol, or any other component of the formulation; current or history of bronchial asthma, severe chronic obstructive pulmonary disease (COPD); sinus bradycardia, second- or third-degree atrioventricular block, overt cardiac failure, cardiogenic shock. Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5094957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular effects: Use of agents that reduce/suppress aqueous humor production has been associated with choroidal detachment after filtration procedures. Discontinue use in patients with chronic or recurrent choroidal detachment. Macular edema, mainly in aphakic or pseudophakic patients with a torn posterior lens capsule, has been associated with use of prostaglandin analogues such as travoprost. May permanently change/increase brown pigmentation of the iris, the eyelid skin, and eyelashes. In addition, may increase the length and/or number of eyelashes (may vary between eyes); changes occur slowly and may not be noticeable for months or years. Long-term consequences and potential injury to eye are not known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angle-closure glaucoma: Not for use alone to treat acute angle-closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Conduction abnormalities: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in patients with compensated heart failure and monitor for a worsening of the condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iritis/uveitis: Use caution in patients with active intraocular inflammation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may worsen disease or other myasthenic symptoms (diplopia, ptosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: Use with caution in patients with orthostatic hypotension; signs and symptoms of hypotension may be enhanced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal Impairment: Safety and efficacy have not been established in renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Beta-blockers: Concomitant use with other topical beta-blockers should be avoided; monitor for increased effects (systemic or intraocular) with concomitant use of a systemic beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Product contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Absorption: Systemic absorption of timolol and adverse effects may occur with ophthalmic use, including bradycardia and/or hypotension. Beta-blocker therapy should not be withdrawn abruptly in order to avoid acute tachycardia, hypertension, and/or ischemia. Patients undergoing major surgery should be gradually tapered off therapy prior to procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Initial therapy: DuoTrav&trade; should not be used for initial therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5095008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5095007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5094953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproductive studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5094954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk (timolol)/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5094955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Timolol has been detected in human breast milk following ophthalmic administration. It is not known if travoprost is excreted in human milk. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5095023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     IOP, iris color changes, eyelash changes; systemic effects of beta blockade with ophthalmic administration",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5097191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      DuoTrav (AR, AT, AU, BE, BG, CH, CN, CO, CR, CZ, DE, DK, EE, FI, FR, GB, GR, GT, HK, HN, IE, IL, IT, KP, MT, MY, NI, NL, NO, NZ, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5095013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Travoprost: Selective FP prostanoid receptor agonist which lowers intraocular pressure by increasing trabecular meshwork and outflow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Timolol: Blocks both beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors, reduces intraocular pressure by reducing aqueous humor production or possibly outflow; reduces blood pressure by blocking adrenergic receptors and decreasing sympathetic outflow, produces a negative chronotropic and inotropic activity through an unknown mechanism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5095015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barnebey HS, Orengo-Nania S, Flowers BE, et al, &ldquo;The Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Fixed Combination Ophthalmic Solution,&rdquo;",
"      <i>",
"       Am J of Ophthalmol",
"      </i>",
"      , 2005, 140(1):1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/31/14838/abstract-text/15990081/pubmed\" id=\"15990081\" target=\"_blank\">",
"        15990081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/31/14838/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuman JS, Katz GJ, Lewis RA, et al, &ldquo;Efficacy and Safety of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Once Daily for Open-Angle Glaucoma or Ocular Hypertension,&rdquo;",
"      <i>",
"       Am J of Ophthalmol",
"      </i>",
"      , 2005, 140(2): 242-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/31/14838/abstract-text/16086946/pubmed\" id=\"16086946\" target=\"_blank\">",
"        16086946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10345 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14838=[""].join("\n");
var outline_f14_31_14838=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5094947\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5094951\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095019\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095020\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951006\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234363\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095021\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5094952\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5094943\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095001\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5094956\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5094957\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095008\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095007\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5094953\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5094954\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5094955\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095023\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5097191\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095013\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095015\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10345\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10345|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/60/23492?source=related_link\">",
"      Travoprost and timolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_31_14839="VSD gradient CW Doppler";
var content_f14_31_14839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    VSD gradient CW Doppler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 431px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGvAjwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oieviqgD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqigD7V/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6viqu6+DFhPe+PdNI0yO/0xJUGoGezS4higJ+Zn3qVQYB+bgjnmsMTXWHoyqv7KuOKu7H03/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1eJEaBZ+HfD1tqMejs99pNu0VomnD7U9y1yw85pxGPk2qQVLnOMbec1peItDtU8dNb3+lyw2a3F4LCC78OW+mWk0yxyGCIXCMDKhYKBuxuGD3ry/wC2oqTUoNfF315e2n+S8y/Znrf/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fOPxE0y8tvCmlXmr2UdhqMlzJFJbvocWmyjCKcr5ZxJHliAxQHINXrvTdTh0DTm8NeHNNv8AQJdKWW5vpLGOXE5jzNvuGG6N0fcFUMvRcA556FmUHCM1bVtb2Wnm0r+WmvoLk1PoD/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6vFPivY6W+k63Bo1lZyXOnXdu0qQadDaPYwmLlt0fzTI7MoLN90gcfMCeU8EaLNqnw/8aSQ+H/tksFvC8F+lvJJJGwuId6KclR+73scDdtzk7aVHNIVKCruNk3Ff+BW11t3/wArqzBws7H0t/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV4Prdro8/wwuNQbSpdLUWtpHp6XGmRQma43IJXjuQ3mTqVEjHcu1cjGMAGLwr4WSL4neINDtvDlzfWtva3aBb6MTzWrC3kMZPlEx7y+1QfmGSMYbBqVm1P2c6klblvpp0tf8A9KS0ur3Sb0u/Zu6R9G+Hv2lfB+va/pmkWem+IEudQuorSJpYIQivI4UFiJScZIzgGvb6/Nn4WxSQ/FnwhFMjRyprdmro4wykToCCD0NfpNXrbmZ4B+2t/wAks0r/ALDUX/oievKPAuvf8I7+zNdXvna1DnxOY92kal9hm5t0ODJsfK8crjnjnivV/wBtb/klmlf9hqL/ANET18meGvB2r+JRENHOmSSzS+RFBNqlrBNI5xgLHJIrnORjA57UAfS3wu1JZvBfw0Nx4h1HTmvdU1FxA8hdNSfzWIhuJMj7xOMlGySeASK8Ag0zxFL8YZLDS7CPSvEcmpyCG1IUJbSFicDcMbVB4OOgBHauY0zRNQ1TW00jT7fz793ZBGrrjKgliWJ2hQASWJwACc4p3iDQtQ8P3cVtqkKI8sSzxPFMk0csZyA6SIWVhkEZBPII6igD6l1fSrTT/Hnwy8P+N0v9XFhNML3xBqsDiG4uHRnit1lkH7xQ4GASew9QK+gadef8LS+HOr61fa9Bqtze36NomsXYmNsqxuPMhAVNkTbQANuDgYJAzXydRQB9F2cNlqvwj8QWnhrQ7ueaXxXBEbK+vPPFzIeMbo0iKqfrkddwri/jt4Zs/C8+l2Fj4Tk0qWKPbe6ki3Ytru4IBKQGd2yif3gcscngYryiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvafjEnwxXwPo58DmE6sZEz5RYyeVsO7zgejZ2++c44zXi1FcWJwft6tOrzyjyNuydk79+5SlZNW3O/1L4VeINO1XxBY3D2OdFsjfzzrIxilTBO2M7clvlcYIHKNzxXN3HhTxFbfZ/tGgatF9oBaHfZyL5oC7iVyOcDk47c12esfF2/1S61UTWEQsLxLxY4BJ88fnqVG58fOqF5CBgf6x+eeHX3xM0yW2sLew8MfYILTUE1JI7e6jiAdEZVUNHAjlckElmZ8DG7nI8+jWzWKXtKabtrZrt67t/LpctqHRnnR0+6Sa0jnglgN0FaEyoVDqxwGGRyuc8j0rsr34YatBey29vqGlXi21zLaXk0UkiR2bxoXfzTIi/KFVjuXIOCBzxWL4p8S/2/4lj1uS1MNywjadBKWRnUAEoCPkUgDC847cYA6C/+KOo33iW9vbmztm0e7kuTLpaKkSsk42sGkjVS74xiRstkfUV015Y+ShKkktHdO2+lku/Xql37Erl6nKa3o8Omw201trOl6pFMWGbNpQyFcfeSREYZzwcYPPPBqWDwh4luNPW/g8PaxLYsnmi5SylaMpjO7cFxj3rQ8XeLY9b0LSNItYNRjs9NaRojf3/2uQB1RQikIgVFEYwoHGTWfB4ov4NPWyS30cwqnlhn0i0eTH/XQxFyffOfetYPFuktEpXd+bXS7t8Ol7WE+W5L4J8KXvi/Urmy02SKOS3tmunMkcshKhlUhViR3Y5YcBfWrVh4Ma/1i60q31rTBqULtHHbyx3UbTlV3HbuhAXGCP3hTkHtzWPoV1pVtLP/AG1ptxfQugCfZ7v7PJE2QdwYo4PAIwVPXsa7O0+I9vFrmoaxNo9y99dO2UTUWWCaHYEWG4jKHzlG3J5Ukk57YyxUsYpy9im1bT4d9O7u1vfby3unHltqcd4W0K68S69Z6TYS2sVzdSLGjXM6xJkkAcnqeegyx7AmqS2VxJqAsbeJ57ppfJSOJSzSOTgBQOSSeAK3/Dev6Vo2t+HtSOizPLpbLPL5V7sN1MspdGO5GCqBtUqBztzkE1W0/XLfTfHFlr1lZy/Z7W/jvUtZZwzHY4faZAgHJGM7eM9DXQ6lfnnaOltNt7vz66f8OKysJc+DvE1rBNPdeHNZhghj82WSSxlVY05+ZiVwBweT6GnQ+CvFM8cMkPhrW5I5gDGyWEpDgjcCpC88c8dq2LDx9JajTg1m8gtF1EEG4I8z7XGyZ+7xt3Z759qL/wAfS3S6kq2bxreJpyYFwSEFpGF/u87iN3bGe/Wuf2uYXtyL1/7ettft734bjtHuZNv4R1GUaDloIn1m8exhSQsrRyI6IfMG3gZkHTJ4PFQS+FdcW3vLqLSb+ewtHkjmvIbaRoFKHDHfjAA967GX4t6omq2d1povbC3j1e51S4toL9lW6WaZZPKfAAIABXJBzuPA6VeTxhol34YurvUZEj1gadd6da20M8pIWaV2BZDCI8/OcsJeQB8uemDxOYU7OdLd9Nbave3lbXXv5D5YPqch8J/+Sp+Df+w1Zf8Ao9K/SmvzW+E//JU/Bv8A2GrL/wBHpX6U17ZmeAftrf8AJLNK/wCw1F/6Inr5V8HapY6BpusaoZg2umH7Jp0IVsxGQESXGcbcqmVXnO5wcfLX1V+2r/ySzSv+wzF/6Inr4rwaAO38DXWh6Nc2s93q+G1Swv8AT7wfZXP9neZE0ccmRnzAdwJCjIXI5NdZpvijRdM0230TS/EsdnqFpo5tbfxBHBOscczXjTyIhEfnIpRtu8JnO7gA5rxzBowaAPddM+JkOmXvh23bxVNd2y6jfS6vOttJGl0jpGEZ02/OCQ/BBPcgGvO/G3iY+JPDvhl7+/mv9btkuI7uWfc0gUy7o1LkfMACcAE4HHHSuOwaMGgBKKXFGDQAlFLijFFgEopcUYp2ASilxRg0gEopcGjBoASilwaMGgBKKXBowaAEopcGjBoASilwaMGgBKKXFGKAEopcGjBoASilxRg0AJRS4NGDQAlFLijBoASilwaMGgBKKXBowaAEopcGjBoASilwaMGgBKKXBowaAEopcGjBoASilxRg0AJRS4NGDQAlFLijBoASilwaMGgBKKXBoxQB9F+KtG8IReIPGrWNlpgv30+8t009YlC2TwRsTOq4whYeRtYY5830rndW+E9hp9vpDz22rLPPfrZXMUVx5gCtEzmZHe3iQquwkkFkIB+cda8WxRivCo5RXopKFd6Lqn0Vl12/HzNXUT3R1Xi/Sbfwn4mtIrENewRRxXCXFwFeG9z829FHHlHpgkng5wcgdB8QdK0vQdEnuLG3t2XxFdLeaeSAzW1kED7V4ypLybD3/csO9ea4oxXf9Tm3Tcp35d/73VddLNX+9bEcy1O08Laf4OuNISTXtQ8i+LMGT7dNFxnj5VsZh/4+foKyfC1ne3XiZI9CtlvJkLukRto7stGAclYpQFkbbkhcAk9AD0wcUYrT6s1ztSb5u+qXy008g5j3pNA07+3dYaPSidYTT7DybWDRYrmZDIG86Z7HcsaOCqZX5ggfOD1FDRPDfhi0t/F1lcatomo64LW+MrvayhLMRnCPEqRmME/eJU5UYVR1NeJ0V5qyirZxdZ202S6JddXbS9tNfxv2i7HeeB/D2vQatBJHpT3FvPbR3DiLTLfU5fIcnY6QyepXBPBUdfQrd6BYal8Yr3RWMFlYSX8yqllIGVQNzCKNiANxICDjAJ6dq4Kiu54Wo6kqnOk3FrRWt5vV3t/XUjmVrHrGk+B9DmuLOPWtG8UaRLe6rbaXFbXF0iyR+aD+9bdbruHHCgDPPNQ2fh7RdOn07xLp8V4NOsVurq4gvpUl3SW8ipEMqiDDySRAqQcAnk15bU0dxPHBLDHNIkM2PMjViFfByMjvg+tYPAVm3+9dn01tazT3b9U+6HzrsepaX4Dsdc0PSdWvJNRtpNQuYlvNQvHaGJWll2kxq0G2XIPVZs9SVAFXdS+GWkWt/Ilvb6/dTx2ck66TGsqXFwyyog8qSW1j3Da5YhY2I2HnnI8aoqXl+I5rqu0tdLd+m/5W8ra3fOux23w+t/svxn8MQfZLqy8vXrRPs10cyxYuE+VztX5h3+UfQV+j1fmt8J/+Sp+Df+w1Zf8Ao9K/SmvWirJIzPAP21f+SWaV/wBhqL/0RPXxXk19qftq/wDJLNK/7DMX/oievm/4P+FtF8aa7aaFeWevXGoXU5DTWM0ccNpAFGZXDRsWwc5GVHTBJOKYHndHNevz+BfCWh+AH8Q61PrGpAeIZtFEmn3MUKGJAxEyq0TliQudu4ZyORXG/FPwe3gXxtf6Ebn7VFDskhmxgvG6hlyOxwcH3FMDksmjNLRQAmaM0tJQAUlFFIApaSigBc0ZpKKAFzRmkooAXNGaSigBc0ZpKKAFzRmkooAXNGaSigBc0ZpKKAFzRmkooAXNGaSigBc0ZpKKAFzRmkooAXNGaSigBcmjNJRQAuTRmkooAXNGaSigBc0ZpKKAFzRmkooAXNGaSigBc0ZpKKAFzRmkooAXNGaSigBc0ZpKKAFzSUUUAFFdt8JvB9r4y8QX1vqVzNbadp+nT6lcvDjzCkYHC5yM5Zex4zW38P8Awv4O8d+JV0bT01/T72exuWt4p7uGYG5Rd8fziJNykB8rtBGBhjngA8uor6N034BaVLbeELi81DUI4p4JJfEIDoGsm+zCdFT5DtOCAd27r2r53uPK8+X7OHEG4+WJCCwXPGccZxQBFRRRQAUUUUAfQ9n4k0Wzh8BjVEzrekWFnLo4ERYTNOSjBz0AiYLKuepyO9SeF4tBi8T+L47fWdLTW9RGtrerdQXBltoljuAqxlYmTBwJHYNuwAoGchvCfC+iXPiTxBYaPYvDHc3kgijaYkICfUgE4/Ctb4f+DLvxhd3ywfahbWMHnzm0tGup2BYKqRxKQXYk+oAAJJAFAG78E9UPh/xJruoxJDdiz0i5kKMD5cygplSCM4YZHIzg16JpF5oM2n+HdM8KvDLoOn+J4nilvocfaJHhlkbcrEfN9yJckDKKe9eUaL4U0q+8WP4fvLzxFaX73S2tvCdFjMpJ4zKjXC+UR3GWwOc1nWHhuLVfHi+HtH1KO5tpLtreK/eMorRgnMpUEkDaC2MnigD1/UzeyeOPhNJqyavDff26A8Gutv1BV+0wlSz4BaLkhMqvIkxwRj7Rr8+vB/h+y07x/wDDrVdF1KbUNLvtdhgV7i1FvIksU8O9WQO4xiRCDu5z0GK/QWgDwD9tb/klmlf9hqL/ANET181+Bfinqng3wtqWg6fpekT2uouWuZplmSd1KgbPNilRgoweP9pvWvpT9tb/AJJZpX/Yai/9ET1478JbMXHgiwg0aLX0ur7VJYNW1HRbxLeSyh2xeW05KMfJAMjfeRSQ2W4GADi7L4mTWvhtNAbwz4euNJi1A6nBbzrcsIZiu0Y/fZZQCflfdnPOa5XxPr2o+J9evNY1mfz7+7ffI+AB0AAAHQAAAD0Fev8Ag+08PWngbxVpmj+IdImuJtFlm1CeW3uRMHWeMIoxEVESj+6zFmcEjCjE/hnxYvinT9H+02iacumXVpaWM91ciW3jvWjWCMwxlB5UagNcONzZaNc4zQB4JRXYfE3wk/hHWra3lvLq5ku4DdML22+zXEZ8x0Ikj3vgnZuB3HKsD3rj6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiloASrFnZ3N7OsNnBLcTMCRHEhdjgZPA56VNpWnzalew2tqm+4lbCr0H1J7Aete2eC/hQt59nudE8V3OlavCpWWaOIspLAhgpUgqMEjnqKAPB2UjrTa9k+IXwhXw/pds2i3rarcopNwEXHm+pjUdMdNvJPWvHXGDjr70ANpcUlaOh2C6jqUMDv5cZOXbuF7496cVzOyAobT6UmK+lLPwbpOtaHMNEgtbC2t2aFZGiLNIVTcWd88A9O9eG+LtI/s6aORU8tZCQVHTPtW86HLG99iFO7sc5RSkcUlc5YUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAG74M8U6l4P1tdU0d4hN5bwyRzJvjljYYZHXuDWnY+O59K8SaPrWg6Lo2kz6ZMZ44rWOUrKx6+YzyM5BHG0MAATgAkkw/DuHQW1ia48S3tpbxW0JltobyOZobibICpIYkdggyWPHO3bkZyPYfFS6ofFXjafwjfPeeLLiy0qWM6QkiXCQ+WgmCDYrckQsdmRtbnHzAAHBy/GzxTJH4wQpp4XxOAt3iNx5I8vy8RfP8vyYHzbugrzCvfv8AhJzb+OfEXhWxsY5ZNSnc3VxFcrFbK7Wmy5a5jVSJY4282UAFdrBjzmuc+JPheK78K2/iyxvbhdLiggt7C2e02wrb75EWNZt/zzDYZJF2jBkJyaAPJKKKKACiiigDq/h3441XwRrttfafdX32NZVluLKC7eCO5xnAfGQep6g1Ppnjm6lOrReLn1LX7XU7eO3mMmoMtwvluHjKSuHxg54KkYY9DzWb8PdPtdX8feGtN1CLzrK81O2t549xXfG8qqwyCCMgnkHNfaUfwH+GTOB/wjQwTj/j/uf/AI5QB8j3nj9pdb1fVrfTvJvbnT00yykM5drSJY1hLFiuZJDEpXfkfeY46Yy/C3iS28OyaXeW2kpLq1nfNcPcyTttngKKv2cxjgD753jn58dhXsXwr8A+ENa8AaTqGr6SLi/mEvmy/aZk3YmdRwrgDgAcCus/4Vb4B/6AQ/8AAy4/+OV81X4pwtCrKlKE7xbWy6O38x2wwFScVJW1PG/B/iGy1Lx/8OtJ0bTZtO0uw12GZEnuhcSvLLPFvZnCIMYjQAbeAOpzX6CV+d3hi0t7D9oHSbOxj8u0t/FEMMKbi21FuwFGTkngDrX6I19FTmqkFNddTjas7M8A/bW/5JZpX/Yai/8ARE9fJ+ieE5NQ0f8Ata/1XTdG01pjbQz35lxPIACyosUbsdoZcsQFG4c5r6w/bW/5JZpX/Yai/wDRE9fLum6zoOpeEbHQ/Er6nZvp1zNNa3dhbpcbkl2b43jeSPGCmQwbuQR0qxGXpfhi51Txna+GrK7sJbq5uVtYrhJS0DMxwG3KCdvPp+FXLXwfHfakLXTPEei3kKW8t1c3aC5jitY0GSz+ZCrHOQAEViScVS0270qx8Xw3VtcazaaVDNuint3QXkQA+VlIwu4HB4I9MjrXdXvxD0u7lhstQvNd1S0k0u40671e7hjN6/mSLIh2GRgyoyLgNJkgtyOBQB594m0Kfw/fxW81xbXUU8CXMFzbMxjmicZDLuCsO4IYAgggisiuk8c6zZateabFpK3P9n6bYRWMMlyqpJKF3MzsqlguWduAxwMc1zdABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABT4lLOAoyT0plWoJtg2R4Ut95jQB6H4A1dfDxkhtIrea6uwI5DJGHL5PAHoM+nXPNe7aJq+nQ6nLpdrcBLu0jb7VFbWH7s7B+8bKnJVeRk+leE/DO4t9P1a81e4USWui2xvmPB3yghYYifeRlPr8tZNjrCC7kcSvh2ySxId2Y/MT7E0rjt1PozxZr1lFZW+qaZezRh2KxyJCMJIOxA6cEEYr5z8dw29/fTahbLClzLmS4iiXapPUsB2PqK9GtrqW88G67YCeJZYoRqMCFfmHl8SjB6/I2f8AgNeR319HI5CCMAkn0P40xGARg1a068eyvI5o+SDgrnG4HgimSLG3+pJA7g+tVzkU07O6A+g/hdregXmneT4k1uxsNCtrlZDDM22aWVxgKAATs45fBArifiRYatr3xGl0Kz0pbS4EjG3tjMoR1IyGV2IUoR9055B968yz0zXd6HqcHijSU8O66JDc2kTHSdQUbngAyxgkH8UJ+YjujdOCRWk60pXuRyxjr2F+I/w+1XwhPbCWx1BrJ7K3ne5eA7EkdAXQuuV+Vsr17VwbDBxXo3j7VNWtfDmiaMl9N/ZVtbG1KLIyrNiRpBvTO04LcH2rzpjliaxTUldDhNTXNEbRRRTKCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDR0PTU1S9MEuo2OnRqjSNcXrsqKB2wqszH0CqSfSrHivw/ceG9TSzubi2uRLBHcxTWxbZJHIoZWAdVYcHoyg+1J4Wl0y31UTavd6pZLGu+C501FeWGYEFH2sy5AwejKc4INdB4w17QPEWp315OdYluY9PhgtbuQRiW7uEKhprkZOMruHysx4XJPJoAiXwBcz2CXOn61ot9/pNvaTx28kpNu8+dm5jGEboc7GbGDVu7+FfiC01DxPazvYqPD9qLu4n8xvLnQrvUQnb8xZQzAEDhWzjFaNt4x8P6To1rp2n3XiHUbSPULW7httRijCaeI3LyGEiQ7nckj7sYIJyCcYJvilNeLqdjeo50trbUIbTy4gJibgsY/NO7kJuIGPuhiBmgDmZPBOpJr93pBns/tNtph1V2DtsMQtRc7Qdud2w4xjG7vjmqOqeE/Eek6et/qugavZWLFQtzc2ckcZJ6YZlA57V3tx8V7iXV9QT+0ddPh2fQG0uPTjOfKWY2Ag3eVv2BfNBbI5wc4zxWH4u1rw3ceEtN0jwzdavBDbBZJbS4sI0W4uCMPNJMszFiOirswq8dSxIBwdFFFAHVfCo7fih4PPprNmf8AyOlff8N1+9Tn+IV+fnwyOPiT4TPpq1of/IyV9zw3H71P94UgPn34Vaqtv8PtIhJ5US/+jnNdYdbX1rxvwZqHkeGbKPONof8A9Datk6t/tV8Ji8uU8RUlbeT/ADPs8Lhr0YPyX5HLeGJPN/aC0mTs/iiFvzuxX6I1+cngR/M+N/h1/wC94itz+dytfo3X3FFctOK8kfIVVapJebPAP21v+SWaV/2Gov8A0RPXg/w38O+H7vwVp2pa7p2jSQza1PaX17qGpvayQWyQwNmFBKodx5jnASQ5wCMV7x+2t/ySzSv+w1F/6Inr5L0a08S+ItJGiaJp+oapZ2k73n2eztDMY3kVEZyUUtgiNBycccd60MzQ8B6TpV/qWvXeoQy3un6Rp81+trvMRudroiKzLyB+8DNjnCnBHWu3+H+ieGvEM+h67PpEelrHdXlvcWcCvdW07RWrTo4SaQtxjDKXYH5egY48u06+1nwjrvnWxuNN1S33RukkeGAYYZXRhggg4KsMEGtCfx14hlvLK4F7FCbKOaK2it7SGGGFZVKybYkQICwY5O3PfOQKAOt+KM2jReDPDI0h43uNThe+mkOgWlm0o8+aPdvjdjHjy1URJ8hA3E5OK8rq9qGq3moWun215N5kOnwm3tl2qPLjLtIRkDJ+Z2OTk8+mKo0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUuKWNC7hV5YnArUtoktZB9pGYWPEyjIjb3H9KAMsrjuKAOma6G/06O3xKtzFIjDPmZyufb2/UVX8M217qWt2em6eoMl5MsAGwMBuOCefQc57YoA7K3tH0r4c6baKqi61uc6hLnAxDHujhB9iTK35Vzsel3upX81paw4urWJ7iVJJFiZI0XLHLEc47Dk9q9O8QaBqGt+JL7/hFbeG+WBBb2towBRrZAEXaeAOFznjkmvMPHthd6dqyQ6lGYrtY1Eivy2QOMnucYGfauCliKdas4qSue5XjLDYaNNLW138/6sM8G60uj+NdN1GVzNapMEuBKfvwONkin6ozCqXivRX8P+JdV0uXLCxungDNwXUMdrfiMH8azlkjx80S46Eg12HxAU6lpXhzxGBlr6zFpct3Nxb4Qk+5Tyj+ddyfQ8eUb+8jlLWSOS5UzsI4QMEKvP0H+NE0STs7W6kEHhD1I9RVWMMW+X604Haytkjr8wzTMyI9asWF5PYXcdzayGOZDkMP89KdKFnOYwFcDlQMBvcCqpGKAavuekeH9R0fxnYvoHiaW307VmkMmmayw2RLIQB5FwOgjbAw4GVPXIJxxetaHqOj6zeaZqdpJa31o5SeFxzGfX/d5BB6EEEdaoW7KHO/HTvXoviP4iPL4G0vw9pMkpkWyW31DULhF+0zpuLC1Vx8wt0PQEkn2AxQlbYSSirI82kQo209abTnYu2WOTTaBhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB1Pw+0qz1zU9R026h8y5n025axO5htuI0Mq9CMkiNkwcj5/XFeg+LvAWgaLpN/qcVszW+naQbG4VpXOdYWVInIw3GBJv29Bt6V5JoerX2haxaappM5t7+0kEsMoUNtYdDggg/QjFXrvxZrl5o17pNzqEkmn3t8dTuIiq/vLkggyE4z0PTOOnHAoA7L4p6d4e0SN7DSLbw7HcrHbErE+otfJuiR2LGQ/Z8Ek/dzwRjnOMfwnLoB0Sb+2/DaSWsMcqz6r9pmEwmZW8lIlDCPOQMqytkBjwAccrrGqXms6hJfalN511IqKz7QuQqhV4AA4CgVs6f421qx0S20iM6ZNp9szvDHd6Va3JjLnLENLGzDOB37D0oA0YJdBfwbdPe+G0tJPs4is9SS5mae4uwylvlLeWY9pO4BMrlfmyRnpb7RfDeqWNpN4XsvD9zp8LafHfSJLfrfwtIEWQssjCIqZd65QHAK9OtcTc+NtautGg0u6OmT2tvbfY4TLpVq8scXPyrKY/MHUnIbOTnOadqPjvxDqEEcVxeQBUljnZobOCF5Xj+40rIgaUjtvLUAdfrPgvw3YQeOZl1ayuk0+7jjhiskummsYzdBGyJVjSQhMrjeckdR96uW8e+GNN8NJpa2Wq3l1e3cP2iezu7FbaW1Q48veFlkG5h823IIGCetZtr4q1m1vdQu4btRPfzpc3JaGNhJIsolUlSpH3xnAGD0IxxS+KPFOqeJ5/P1j7A9wXaV5oNPt7Z5GbqXaJFLn/eJ/WgCX4cnHxC8Ln01S1P/AJFWvtOG5/ep/vCvijwAdvjvw4fTUrY/+RVr68iuf3ic/wAQoA+UNFmZNLgUEgDd/wChGrv2hv7xrG02TbYxD6/zNWfN5rzKlO8mz7jCYlRoQXkvyLXw1OfjD4VJ769a/wDpQtfpFX5t/DE5+LvhM+uu2n/pQlfpJXpR2R8XWd6kn5s8A/bW/wCSWaV/2Gov/RE9fOmgCy1zwDpWkxXdtG1jqE9xqOny6nDpzXausYjkSaYeWSu1lwckdQPmJr6L/bW/5JZpX/Yai/8ARE9fK2ieCLnUfCz+I73U9N0jRhdfYluL4zHzJtobaqxRux4JOcY4PNMzPWNNPg6yutU+yPY+Ir5L+FZJNa1iyBa0+zxfKJriB1dVk81CYdr4C4zxjDXUPDP2TTNJW28NJYz6HqclxL5cLzJcq90bcfaCokDjbCFGQWDDIIIFcrB8NLg+GbvxBd+IvD9ppFvqB037Q0k8yyS7A4KeTE+VKt1OOhBANcNcxrDcSxxzRzojlVljDBZAD94bgDg9eQD6gUARUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAC0oUnoCaQDJA/nWlYAIC0RBmGVaPP319qAK1pHvZVEe/OcjOM/T3q3JLLbQMElEkEo2knnOOxHY+9W7fTnuX82why4AYxE8g+qmqmspGdsiIEkPDjoc+4oAzc54XOPTNemfBeyS2k1nxJdGVItNgMMDoOVmlBXep9VQMfYkGvMgBxXs8aL4f8ABum6MVVbn7Ob+77hZJ8FVI9ogn4mufFTcKTa32+87Mvoe3xEY9N36Ib4R8QfY/EsUn2y4giniaF7lQDJHnowHQnOOO/NdJ45uIta8S32oQ3GmmCzshIZLyYIXIxzFwecn7n1ryOaYIxwc46EVag8P6/qNhLqUYhmjG4wxvMrS3GwZkMKHmTYOWx0rjo0Zc0Wto3ey3em++3TY9vNJUItyfxSXL+v5lzxdosusxf2lYWsCGMKj+SflcY6jAwTUfhm1l1bwH4g0SWNvtFoY9XtFYbT8v7uYfTYyt/wCm+GPFV9bQzW7y7oZHy0Rxtb3HHH4V6V8NotLvvEdrPdsqvJvjZGAUGN1KurDHIINemfMnn9vo3hvQ7JkvwdX1tlwY1kMdtat6ccyN+QrjJEieSSUyLBkkGJVwB7CvTvip8OX0O9jGkpMYslAV6HHvXnyeHtUvEVLfSrtnXrheB75piMq1P+mIVDDB4CjPH1/rVrUbaKRJLi3XYQcNGQfzyepo1KyvNJdYLkGJzyOcn2BqzY2klxIqzucyH51z19PoKAOfPXjpRV/VrR7a6k3DALHaPUetUKAEooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDb8EsE8ZaC5IAW/tyT6fvFr6bj1e0Ei5u4ODz84r5g8IYHizRc9PtsH/oxa+ikMJdQYojz02Ck79CZc32T5xtJQtsgLAHnjPvUvnLn7w/Oo7SMG2QlQevb3qXylx9xfyrsjlbmlK++p3RzGUEo22NX4WnPxZ8IH11uz/wDR6V+k1fmz8LRj4s+EQO2t2f8A6PSv0mrlceV2ORvmdzwD9tb/AJJZpX/Yai/9ET182aR4s0a++Ga+DvE39o2qWt+dQs72wgScgsu1o5I3dAR1IYNnPb1+k/21v+SWaV/2Gov/AERPXz54G8J6VceErC9u20SfWdZvpbGxttWmuo4x5Yj+79nA+dmlAzIyqBjrnhCJLb4k2ug/C298MeELvxBpt++tm+iu0lERNv5KoVZ42B3FlztAI6cnFeWTSyTTPLM7SSyMWd3OSxPJJPc17FpHg/Ql8L21rqGmWza5NpV7dyxyXUy3/mxmXy2gQN5LR/uxkMC5CyED7uV03w/4H1620r+w7Y3M1qIZbuCFrlZrjMaJ5Epf92JJLllRPJ4CMxPIoA8ZorZ8U+H9S8PX6Q6raw27ToZovIuEniZNzL8rozAgMrL94kFSDzWNQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUtFACVr6TZmSWGSJgW54JHB+lZsKeYSM4bGQPX2qaGRoJndAFZRx7f/XoA3/t/wBjDBo3gkycgjgn1U1j6o4uHS4Qbg3Bb39KZdajLcgCdY3AGM45qssh5BGR2yaAN/wBoa694s061uR/oAcz3bE4CW8Y3yEnt8oPPuK6DxXqralrd7fTb1a4kLlfQdl/AAD8Ks/DbTbpvCXiC/0e3e+1OV47Ew24Dyw25/eSPs6kMVRMjPG6uP1LUZ1upo5onjmDEMJF2sD7qelc1aMqklFbI9nLa1PC05VZvV6L9R87o9wih9gzjpyvv9K6LQdfvtM8ParawappUUlkpeyM8btcoZTskW2fomVyWB4OT3qv4S1nQ7UhtQsg7qOXbklvXr0rpbe++GsjZuPCN9OznPmR38iZPc4J6VtCHKjgxWJdefNseU2YczBI1JLHaMDNes+AdNt4fKmvLp5JQwUonDAZ9O1a8TfCFgCfDGqQvn5R/aEjDP51q6bc+AbNjLpds1nMRyZZGcZ7Zy361ZynrNxf3N8LGa3eKe2a3O5Z9pjR1OCfm79OlcT4k8Tao8kun21hbSRdftEcOxAfQE9fwqNNRtZvDV9cS4u4dNK3yqoIjVchGUkcd1OM5ryHxf4zl1W4lnW5lhAPyIjH5R7UAV/F7LaXktzNF5t+33jL92PPoKxdFh8u4iYlZJZCHaRumKwri8e6nZ55Zpl/hEjnmuj8PyCb7PHsAaVwoDc/ixoAt+PrG1j8s2bGa52gyuo4UH39a4eaIryVCDsM5zXqvjGwtZIRZ2rTSy43TTHGC38q81u7JY59qSkxKDl2/p60AZtFTNCRGHBBBOFHc++KiIx1oASiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA1PC52+JdJPpdwn/AMfFe7pdfOvzd68E8Pnbr2mn0uYj/wCPivXhdHcPm4zQB5Zp65s4j9f5mrBSnaTEW06E+uf/AEI1b8g+lfe4PA82HpytvFfkcU5+8xPhh/yVzwl/2HLT/wBKEr9Ja/Nz4ZjHxf8ACg9NdtP/AEoSv0jr4asrVJLzZ2R2PAP21v8Aklmlf9hqL/0RPXyr4O8SeKNPQ2HhkvMVdrxIlso7p4HVfmmj3IxjYKuS6YICg54r6q/bW/5JZpX/AGGov/RE9eGfBjxB4X0mGO0udRvdM1C7iuxqE7WkTRSx+RII4llaZSgzhtu3532DIAGMxnHaJ4s8X3lvDoWkSy3s0kUltAsVlHPdiN8l445dhlVTlsqrAct6miCw8ceHFe0i0rW9Oa2dNYdWsHjePySQs7EruCISeT8oJ9an8GWsuj+ING1XStT8PzPci7EUGpXPkhFVWTbcAMPKLhvl+fGT94Dmu90bW9C8FXWq3+kjSbbUW0GL7bp9pffabWSb7fFvhikZ3L7oBlgHbGWweDgA8y16fxR4sewv9Qsrq5jkR4LNrewEULKhZ3WNY0CcFmZto7kmueNpcCzF4YJfshkMQm2HYXAyV3dM4IOPeve9M8ZeHrmPwutjJBaaNpepalFaWV9OqyJbGxjCtLhsjzJTISQeWZgDxXPeG9S0/XdA0OwsU8K+Gp/7bmaVblhNAkX2dcyvHeSSAngqucAsABg80AePUV2fxYuFufFZeGx0exthAiQR6ZLaSKyAkB5Takx+axBLAYxkYGMVxlABRRRQAUUUUAFFFFABRRRQAUopKKAL9tDbywEeYVm6Y9aqzQvEwDDryKYrFSCDgjoavxSC5VlmGHP3CBkZ70AMW1/cLKQ6q2NkmPlPsfSoZSy5SVcSf3vX6+tdRotrJHA8Mo8xGHzRseAf6Vd13QoRo7z2YwU+9C/JQ+xoA4M0UrAg4PWkoAkgnlgmSWCV45UOVdGIKn2I6V19v8RfEDRxxatdW+s26DiPVrZLvH0ZxuHrw3OOc1xdFAHbr4n8N3BZtR8Faaz9QbO8ntwc9crlh9AMAVo6dqPw8ubC9nu9L1zT7uJVa3srbUPMjnYtggM0ZKYHOTnPSvOKASDkHBoA75/Eng+MhYvC+o3QPVrvV2Vl9h5aAY+opD40isVDaR4Y8P2LknZO8DXci46HMrMAw9ccnqO1cFmnNIzKAxJAGAPSgDo9b8beIddRItV1S4ubdT8tuW2xD6IuFHtxWTd3LzLmSRVA6RKP1qhVtYC8RcPuHTA6mgCqOvpXoPgWxLWSz7DcOSQkYbaq+7GsHwj4U1LxLqcVpp0BbLcyEYCj1Jr2vxQ+neENFg0rT3iur1V+dlGVB7nI460Aefa+8trBJGZBg8FhwoHfFcT5MMtpJIfMlkd9seTyB6+1dDqFxPqBWKdCgb5nc9/pUyadb2tr5ieXFCvLSOf5+/tQBi6fpYQqrAtIfX/PArJ1cw/a2EAHB+Yj7pPsKv6nrC+W0Fhu8s8PMwwz+w9BWCTmgBKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigC5o526vZN6Tof/HhXoE94QBhiPmGa87sDtvrds4xIp/WumuLsEkF+mCOe9Ai54btmk0a2YLkHd/6Ea0jZN/drd+H2lNc+D9Pl25DCT/0YwroDojf3P0r9dy3EUlg6Ka+zH8kePVnabXmzyv4drt+M3hhT21+1H/kwtfo/X50eC4/K+O2hRn+DxJAv5XS1+i9flOJd602u7/M9eHwo8A/bW/5JZpX/Yai/wDRE9fMfg7wD/wksOgzR6otvBf3tzaXcjQ5FksMSzGQ/MNwMZY9vuGvpz9tb/klmlf9hqL/ANET18s+FvGsug+D/EmhLZrcf2sqCKcybTasAyOwGPm3xuyEZHY84xWBRt6L8LZbzV9N02+v5oLy8utSg8i3s/PkC2cRYsq713M7qyBeOVzntXK+NNBj8O6nHZrHrcTmISMmr6Z9glGSQMJ5j5Xjrkd+OK6rV/ilLqfi7T9bk0pYxaaXcaebdbjiSSeKZZZy23gs87ORg9MZ715rQB6V4g+EmtaHeeLvt0OoxaZocLywahNp7xw3xE0cYVWJ2jIkLDBbhT9RnSfDjX73XLy00zSfsix3n2GOC+1S2DmYgERLIxjWV/mHCDuOOaZqfjv7d4i8b6p/Z2z/AISWCSHyvPz9m3zxTZzt+fHlY6L1z2we+8O/ELw5rXiCDW/Fqw2I03W31iyt0uZzMC4iLLhLdkkGYUxl4uc5OKAOKuvhxqE3hHRdW0iLz57i3u5ruF7uFXBglkVvKjJDuAibm2hsdeBiuArvLL4gfZbvQZv7N3/2VbX1vjz8eb9pMx3fd+Xb53TnO3tnjg6ACiiigAooooAKKKKACiiigAooooAKcGxn3ptFAG9o+vy2rKl0pnh6Z/jUex7/AENereEp9M1yBoIZIZg42tGflce+DXhgqxY3k9jcRz2k0kM8Z3JJG21lPsaAPZPFHwtiIeXTw4H3tuDkV5jqnh24spdrFVA6785FekeC/jtrOnNHBr9pDqsI4M+BHNj3P3W/EZ969Ct/Evw28arsu5o7W4kOPLuT5Min0DdD+dAHy3JHsOMgnvg8VHXtvjj4WW1vK1xpMxe0lPyuef1Xg15jqfhm8sWbmKRV7hsfzoAwB1rXtrfSW0e7a4nu11QSILZERTCyc7y7ZyCOMYHNZ01vJCSJEKt6e1RqpYH+poAaepoHWpIovM7hR6k1pWVid5IcEnps/wDr0AV7bT5p2GyCaQHpsGc109noflyRNO62yKMsHPWtXR7a2IVNQv8A7PCAA3lAs/611NtrfhLSiJLbThe3K/8ALzqL7gPcIMCgDS8I6JrY0130WxuFgkwDO3yKw/3j2qPWdItbIm61q+F/cIcfZrclYY/YseWP0rH1r4wahJE8UF1L5KDZHHANqD+gryzVNevdRkdppXAYk4DHJ+poA7DWNe05ZWlnCuM5S0t8c+m5j0FcXrGr3OqTlpiEiB+SFOEUe3+NZ27r/OkoAGOTk0lFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAORijqw6g5FTTXDSNknHGOKiiQyypGpUM5CgswUc+pPAHua9F8HeDLG2k1u88V3WjNBptpHNGn9ofaLZ5JJfLXzXszI+BhiVXDZ25Kg5oA7f4YeM/B2k+BdLstY1dbe/iEvmxG2mfbmVyOVQjoQeveuo/wCFifD/AB/yH1/8A7j/AON15Xo2hQW/xBl0XVPDvhy4s5VTUJLsT3pt7ex8oSmWJhOrFfLO4b8tkgcHiud8MafpHij4nW1pFZyWeiXV47raJKS6wjLCMOxJ3FRtyc8mvSp5riKcVCNrI4Z4CnOTk29f67Gh4Uube8+PujXNjJ5tpN4mhkhfaV3IboFTggEZBHXmv0Tr4I8LWmmXHij4X6/pmlw6S974iW0ltYJZXjPkz27K6+azNyJsH5sZXjHSvvevOk3Jts7UrKx4B+2t/wAks0r/ALDUX/oievDPBmleF9T+FdhaeIWstMuLvVbuVdXdFEiLBHbM0O7qQ0cku1c8vs45r3P9tb/klmlf9hqL/wBET18Yvd3L2cVm9xM1pE7SRwlyUR2ADMF6AkKoJ77R6UhnufiTwn4U1jUr7xHfLBoejR2OkstjZl4FRrm28zJaO3nI5XHKfMTywPVvgzwloXhvxxoEkP8AbGpz3t9drZTr/o0cMUOVBlieIuz9SRlMAg968fsPE2vafeC70/W9UtboQrbiaC7kRxEoCqm4HO0AAAdAAK2fDOu60Ir3PjTUNHtppPNmC3c5M8p/iKIcseOWPoKTdldibUVdnHUV1A0TQc4/4Sq2/wDAKb/CmyeGrQtmHxJorRHlS7yoxHuuzg+1R7WK3/JmTrwW9/uf+RzNFdL/AMInMeV1XQyp6N9vQZHrg4I/GlPgnXjxFZxzZ+6IrmJy/wDugNk/lS9tT7h9YpdZI5qkroZfB3iOJGd9FvtoGTiIn9BVUeHNbPTRtS/8BX/wqlUhLZlRrU5axkn8zIoq3LYXcTBZbadG9GjIPXHpTBaT5x5Ev/fBquZdyuaPcr0VK8TxnEilD6MCKZj3FMobRTse4o/GgBtFPIptACUUUUAFFOAz7Uu0+ox9aAGgkdKMmnAc9al+yz4BEMvP+waHoJtLct6frepacpWyv7qBO6xykA/h0q9/wlmqMf8ASJkuR/02jB/lismKxuppUihtp3kc7VVYyST6AVcPhzW/+gPqX/gK/wDhS5l3Fzx7jjrEMh/0jTreQHrglfyp0OpaWkgaTR1ZcdBOR/Sov+Ed1v8A6A+pf+Ar/wCFH/CO63/0B9S/8BX/AMKXNHuHPHuXl1zSRy3h6B277p2H8ulSt4rVE222j2EQ997f1rMHhzW/+gPqX/gK/wDhWkng3VI1D6l9l0tD/wA/swjYjuQv3iB7Ck6kFuyXVhHdmRPq93J/y0CZ67FC5qi7u/3mLfU5rpDoug/9DVbf+AU3/wATSjRdC/6Gq2/8Apv8KXtY+f3P/IXto+f3P/I5nJ96Q10z+GIpGItPEGiTZ+4GnaIsPfcoAPsTTf8AhDdUcZtJNOuwOG8i9ibb9fmFHtodWL6xT6u34HNUV0jeCvEY6aRdOD0aNQ6keoIOCPpVR/DWuI5RtG1EMOCPsz/4U1Ug9mio1qctpJ/MxqWrlxpt7bSmO5s7mGUDJSSJlYDtwRUJtpwCTDKAOSdhquZF8y7kOKSp5IJIx86svAb5hjIPQ1ER7imMbRS49xSgc0ANopxGKTFACUUtFACUUuKcqknA60AMop+O2RUi20zKGEUhU9CFODQ9BNpbkFFW0srl2CJbzMzEAAISSfSrh8Oa2CR/Y+pcf9Or/wCFLmXcXPFdTIorW/4R3W/+gPqX/gK/+FH/AAjut/8AQH1L/wABX/wpc8e4c8e5k0tay+HNbJx/Y+pf+Ar/AOFXYvCOorEsupNa6VG4ypv5REzD1CcsfypOpFbsmVWEd2c5iiumOiaGPveKrXcODizmIz7HbzQNE0InA8VW2T0zZTD+lL2sfP7n/kL20fP7n/kcxRXSt4YRiVi1/QpJOiqLhlz+LIAPxIoHg/UZB/olxpl246pBfRMwHr1HFHtodxfWKfVnNUV0jeCvEQxt0qeUHo0JEi/99KSKqP4a1xHKNo+o7gcHFs5/pTVWEtpIqNanL4ZJ/MxqKstZ3KuVe3mVlOCChyD6Un2Wf/nlJ/3waq6L5l3K9FOIxTaYwrW8PeINS8Pz3EmlzRoLiIwzxTQRzxSpkHa8cisjDIBGQcEA1W0T7F/bNh/au7+zvtEf2nZnd5W4b8Y5zjNew3NzZ2Goatc6hH4Alt4bW9bSUtI7SUtjy/K3quQ3+yJcyE7s8UAeXXfivW7ubVpri+Z5dUjSG7fy0BeNCpVAQPkQbF+VcDCgYwBVmLUfEmh+HtDkhuHtdNN7JqOnshQN56bI3kBHzj7ijnj5TjvXod1e6R4ihudIgsPDSz3fh62ng+yWlvDK+ptJCCquoBDHLAxKQvX5etJpl3pT+O9SsGXSbrT9G09NJsHvbi2TBjdd80QugYHLv5rbXxxKSOQKAOa8EeJNT8Q/FXwKdTlhKW+sWiwxW9tFbxR7rhCxEcSqoJPJOMnvX6I1+euiJZx/tC6Iumz2dxaDxDaeXLZxCKFh56fcUEgDOehI9OMV+hVAHgH7a3/JLNK/7DUX/oieviqvtX9tb/klmlf9hqL/ANET18VUALToySwXJ5NMpR1oAsOiFY2RmG4nIPOOacYAWf5iAOm7qaesjlArJhSOD+NIcuPmyHY7sDtQAwJGAfldtv3iDx7UQpl1YhwT0I9utO3FFJxyfkz6inyHyiBkbcHHt60AOWaeC4R7eaeN0z86SEH8DUo1fVsru1K/wRnH2h+f1quqK0SoAdzMDnPbFP3c55GWCgY4UZpOKe6JcIvdGo3ijXoQFTW9U8sYIK3LYHA96cvirXyiEa5qmWLAj7Q3GB9axUOx5QPmG7nI64puTtV+Mtk49Kj2UP5V9xHsaf8AKvuOgt/GfiJMRtq1y5wW/ehZDn2LAmpU8aeIizA6k4wM/wCpi6f981zqDczODkA9Mc0g++SxIOdoGOoo9lD+VfcHsKf8q+5HQHxt4jXBOpNjPJ8mL/4miXxt4kicg6mTxniGP/4mufhjaU4XDBs8Z6YpVTajLyOdwA5zzij2UP5V9wewp/yr7kb58UC8GPEWlWWq8/68qYJgPQPHjP8AwIGmvd+EZ1BfSNXsyOMQXqSBvcl04P0rF58sAEkthQPfB5qEoQy5OXQjPp1o9lHpoJ0I9Lr0Z0C3fhG2UldH1e8J4InvUjC+42pyfrTn1Tw/GubfwmCCNzG5v5Xx6Y2bMfjmufK73bzGOSfnA7UOMHAdgGzgHngUvZK27+9h7CNrNv73/mb58S21uES28L6GkRG4CWOSZjnvuZ8/hUZ8X3yMGgs9JgA5jEenRfJ6YJUnj1JJrFZSWR0cgHHfpTEXDLt5IycGn7KD3V/xH7CHVX9dfzOg/wCE68SZBbUmwe4gj5/8dqGTxZ4jMhI1zUueSPPYf/WrI2hgpRm2IpPPYk9BQX+6Pmyc5Wj2UP5V9wewp/yr7jVPinxDIGQ61qZVhgg3DdOh71WGrakZJP8AiZX+wHA/0lsn9aoxuAT6Nx+FKNqwMvRgcLgdfrTVOC2SGqUFtFfcXBrOomQ/8THUSOg/0ls5/OiTWNTWUr/aeobQf+fh+/41XIxK4BUnGBjuc4pGDCSTcxYKwUE9xT5I9h+zh2RaXWNUVm36jqJx0/0hv8aqywu0S3LLcfZ3bYsrjILAZYZ/GkjC/afvbuTj06U3e3l+SXcwD5wpfhW7nFNRS2KjGMdkQxoJDgthsgYPpUpVRGzFTjGBk9DTkj8t2LA7SpIJ75FRhS6HBOCfu0xgVC8Hc/HFSC3Taj4ZkYdvWnRrnBc4Xf8ApTSHSFgr5TqP0oAaWZAoDTAdsNVoazqSqQNRvx6D7Q3A/Oq68naCDt+bmnIEaTLjConzHGTnpkUmk9xOKe6NOLxLrlvHGkWrarHEXPH2hsfz61MfFXiAzER61qZAbPzXBPH0zWMCThXOQBlR1HPf602MK90kW4qnc/rUeyh/KvuM/Y039lfcdAnjDxFGGA1a5ODnEoV+T9QcD0HQdqX/AITXxEJArak4G7GPIiz/AOg1zeD8+4/xY/OlbG5nJ3MDuOe4o9lD+VfcHsKf8q+43z448RD/AJiZPsII+P8Ax2l/4TbxMAxOoH5euIY+P/HawmYFBvUlfVR71HBjfIzORlTnHv2o9lD+VfcHsKf8q+5HRHxHb3qpJ4h0a01OUkg3EbNbTEe5T5SenJU/jUbS+EHbIs9fQddq3EJC+2SnNYeNhQ5Ifk4zx9Kd/wAtXI+UMpB446f/AFqTpLo2vmJ0I9G16Nm0G8Ik/wDHr4g9f9fD/wDEVINS8MKD5Xhe5kZOAZtSYqx/2gqD8gRXO7dzZBZWPP4elPAKHarnMgwR79c0Kkl1f3sFQS3b+9m8viKxt1P2PwtpCFj8xn86fj23PxUb+LboN+503RbeI9I006NgPxYE/rWRhvNZQxJA5Oe3So41811VQwODtBPBx2p+xhs1f11/MPYU7Wav66/mb/8AwnPiRjxqOeM4FvHx/wCO1E/izxHK+8a3fpkZIWUqv0AXgVjxFjhxjaQTwOnXikCBWXaR8qAsB70eyh/KvuK9jT/lX3Gv/wAJXr7LtOt6oxZcEfaG6dCOtUv7X1UAZ1DUfT/j4b/GqgHKEAbMnkelLK+4oM4AXJAGM01TgtkgVKmtor7iy+saosuP7T1AqD/z8N/jSnWNTKkrqmoDC5INw/r9arZzk/KSMEjFNZfM+bIGc5A70+SPYfs4dkXBrGo5IOp6hxnn7Q/P61VmSe5DXdwZ2VmKmeTLbm7jd3OKjaIcEMRuyRmlUTNAUEx8oNkKScZI649eKFFLZFRjGOqRGUBfAJA7HrmpWgCoSpLMeAPw60QhfLHynd13Z/pUi4kUtuJweg9MckflVDK6IMkyE8c49fanBYljfcGMmTgegx1oyrmLjncePbtUilXlBDBVIJJ9KAIhvEKNlgrEjg8VoQ6pqCqkY1DUFRRgBZ2Ax6AZrOVfnWM5zkk/T1qWIZl2j5CqknNJxT3QnFPdGoPFfiFFQDXNTC4wMXDHp+NSp4t8QoQ7a3qX3sDM5OfzrGjZUMJYDBz+tNcARlSSwUZ57Maj2UP5V9xn7Cn/ACr7kP1jULrU757m+lM05AUuQASAMDpxVi+8M67p+kwapf6Jqdtpk4Uw3c1pIkMgYZXa5G05HIweRWfdLscEdCoP6VoX3ibXdQ0mDS7/AFvU7nTIAohtJruR4Ywowu1CdowOBgcCtErKyNEklZGRRRRQMKKKKAOr+E//ACVPwb/2GrL/ANHpX6U1+a3wn/5Kn4N/7DVl/wCj0r9KaAPAP21v+SWaV/2Gov8A0RPXxVX2r+2t/wAks0r/ALDUX/oieviqgAp0Zw6k9M02nR/fXHXNAF+4EgHIHKk/SmNu2JGxCyA9fbGetOjLNG4fJIjzj15/+vTpykk21ecx557HGKAIFBbeD9z73FSRbxISVDbshcjoTSKBwWHyYwCD1xSuDhSTyBgHtQAxHby2JwMcHIoyVKM2BxkrmnMo2Ljlic47E9afMMKCFRty5IxyOlACR4LfP0APTvxxTCjMjsSoVBzjoD6UpAEyFcj5sgjtzwacWADAH5A3zZ9CeaAEVHfckfBHIzxmmozPEWGCVI4/GnRZ6oTlSACeoFOiG1n8oE7k6Y9xQAsKkNhE5Z2HoMe1RDO9QvTHOexFXCpN0xUBRnkjsDjNJKAk8xjwEVCUIHUHjNAFP5kYlsjYMcH2/wDr0SHZKqSZwMHHoKdjcMnDFjjn8qQxli7HDMo5Geo9qAHnPzK3DE/M3XAz/wDqqNXBRi6njgEdzQN+4FSPm5/xp2cgAAfMfX3oARkMaBGUgvgcHqO1GStwWOCR6dsVKxCMmeSpx/hUcmSJACR8pY/TNADWkBcsmNgwdp4wfanqdskYbDErvJz7HimFVUFyob2PpjGKkULtLDJIJbB9MdKABNnlBQq78Hr1x1pJCxTBTaeAp/nU9pE01xwQhRDKp646cU69xthZMn5iCemWJyaAK0jKF85BiRdpGOgPelV8Rkhhn7xz7f1pGCtKyAhkzke3tTBjIcgBc4Iz60AAKtEAQcEjp9KVsGSUZAzx+FA3KFUjaccD1FTNJFJYJD9niV1mZvtIzvcEfdxnGBj9aAIpNzNuDgkkDk8GmqDtCKQGwDz6U1hn92oG5Oh9c1MyMHyVBwAob9aAI5W2rIhOS2OfWlUP5YCHkjBOf8+lAwJCsi/dPelLOIwyhRgbiQOgJxQASFS8hBzwAPXAAJNNyEXg5PX8KcRyi9VcfjUgREm+dcjbnn3zQBFuZVAbH7tcgA8HNICVG9hwR8pqQIuIwSu5x+mP/rUkR2KQ4BIXqOTj2oAYwUyOJD1w3FNMmxV3AE4IwB27Zp7kiRpCQSAAcdKQbnUSlQM8A5xnmgByyAQoSOAMY98mkVVRSrKWPbHrT40EmVzhW5+o60MBG7BjneMcdvlBFADGzvYAA4GVJpWl2krxgAH68dKCMLJgNk8AfWjDMz4CnABPt2oAaCThuh5GPftUtqIzeMJSQpU7D/tYwKYy7V2xfMM5x3NSpayPJEI0Lbnyqk9fWgCIfeHqq7TSJKyNlB0B+b09amljVZHES8L0ye3eoSoWCMFOA2WUnn/9VAEwlCRP5BI4BPp8vaot7MwHy7mPb3omYBWIGEfgYpBtLfKMFDgGgBJQQcggBDgKP1p5IYhjjB79hQjKY0Pyhmzk4pijchUn5eSFA6UASI7O4IypddjccDjmmmPZLzksFOD60sbHLAkBck49aF4dgvUDIz0HFACOYzH8x+ZWAC+3emmSNSCgYEHJHvRIqsVKnkAAjv0/nUjPixWE2iCTfv8AOydzKR909scZ9aBoWFfPCCIqrBSSCeKjXCsGJAJG3ApyRvHgghsISR2FDIxaMbW3jnHtQIPLAUFSAykAn654/KkRvmK/3jnb/jT0Kl23khVOcD1xwKbEcP8AcBZRkk+nSgBNuJGK4yePoaRgTIcnGQACO9Om3ZcoMZbqPemoGWQK7ZVDxQAqhQhEi7mRSoA9fWmuoeEyLy2cEfXpTnDZjx153H8c0KmN244w3Cno1AEN2+9wB0UACq9SS43sQMDNej6T4v8Ah1baVZwah8Lvt17FCiT3X/CQXMXnyBQGfYFwu45OBwM4oA81ALEBQSTwAO9dPL4C8SQ66+j3OnC21CO1F7KlxcRRLDCQCHkdmCoPmA+YggkA88VPoHiXRtH8a3WtRaBKtl+8ays4r7D2TN9x1leN9zJ2LKecHqK7bXfFnhbXGvtPt72409NR8PWVk9/fu9yI7iF4ZPLfZCHI/dsrOqsC21gAKAODtfAXiO41S/09bGKK4sTGtwbi7hhjUyf6sCR3CMXHK4J3DkZFc7e2s9jeT2l5E8N1BI0UsTjDI6nBUjsQQRXq2t674b8RabeeHW1yLT7W2bS/s+pT20zJdLbWrW8nyojOpy+5MqOAQdpNcF8QdZg8Q+ONd1ezV1tr28lmiD8MULHBb3IwT70AW/hP/wAlT8G/9hqy/wDR6V+lNfmt8J/+Sp+Df+w1Zf8Ao9K/SmgDwD9tb/klmlf9hqL/ANET18VV9q/trf8AJLNK/wCw1F/6Inr4qoAKcgywHrxTalt13TxrnGWAoAvSqyiIJkMfk9sjtUSjy5fuhl24x65FaV6kuSQu2FhlR/d6gmqPzASttXYoKjPHbtQBCJCTsUDnBOO1SSNhF2YZCFyx9f8A9dRwx7D+8bAYZJ9KcVACoCCFO5vQd80AOjYghlAJR8gNyOT/APWppz5bISNobIOOv/1qUFiuVXa4yeRxmgMcOv3sr3HU9TQAp2lFC5YsBu/2TSQkKqNhTgYAbpSIf3WEIBGQT75prZXCqO/FACbHJBQ/M2Qee1XbcmEKAOXXDN17iqnmhGdUHzE9BWnokT3TXIiUErGzkP7elAE8Vh5trcSvlPlWIEnHzk8Z+oqhcxvG7wTgRPFGIyD3x0rqb+yjigjn3F1e4iITtgLt6VF4xsoYJY33AySgBhnoozj9aAOTy2ApUqxHJx0pUTDgg4ODz+FJMCrqSflJ5Pr2qQ7QrFifvkAA9fWgCEDdCgBHyk8eueKRY92I8BCrcsfpRCwRemTluvanHBTDAgMQxOenagAWQC5cDruyP7uPWnhRt5wQwOWzUI2guq4ctkFgcU9HygVBuwOntQA0FcIyAAEEY79KdEVjAaQ7lxyB9KiC7mTAIKjpjrUhACq6klhzgdxQBrafbySrClqu5yrEjucDj+VQ6jFIlpbmRNokZnKjoucV2Xh21Fvb208zAytGVyB0G2s7xVZtb+WZYmMY3pkdz2NAHHOuTKSOQoZSD+lJwIxGyk/Oeac8JbeN3zJjBJ68UQqTgnA6tn3NADBysbSE9CFPXA7UA5K7Two6DvT03SSMVwnXKk56CnSRRLYCZLpfOaUobfaQVUDhs9MdRigCFF2Fm/jUgrxxz61Kwb7L5rkbgQoX1GKhX/VrlsFnz05qa4yBtc7th6j9KAHSqwIZsGRhtI6c4quQAxUF1VgM59KndjujwN25Q59+elIyY2nIwexOeO2KAHxlUuGaVCV8zHHOMChEMkYjBO6MFmHtkj+tNiR7hGWHJZnB6ex4960bGzMcd+8u4OsJAH949SPyoAqOApicco4HPpVVeZdgxkBhkfSngsrFXTlgAqelEALy7fuMD1HTb3FADCpZAGGPb3pSvmuNh+VcbVPGB3ppIYr94gjknuc9vwoXa3C46YPHagB+VUK5+fenToRzUe4KjdWBf73tThtyJAcAjDD0ppVwhjA4zncfT1oAehLt5eABuHP0BoOBbbo2IOefcdv1pEbbO5RRgEY+o700dW2DcNo3AHjNADtpUx4JDAjgcmtrw/pl5qurNaWMLtes3yKeBGM/MST0FZVmM3lszDhWGee+a9C8JXV5pviG5vrIqPNu3hljI4aPAOPzwRWdZ1FTfsvi6X2uZV3VVOTopOVtL7X8zktd0qawvbqO9QwSxybXjbrgnI/Mc1i78MPrtPPSvQfE00mqa1JJeczXm5UwuAmANo/AA1wTROHk3hizkjPvmnTcnBc+/X1HS53CPtPisr22v1sQrvK7SPkyWo2jaCq8g8VLMgMZcHkYC8d+9A/hAI24JJz3qzQYAoQKwOAfl+uacCPNRjhVJxn0pMAjLdOopY2LMFIzxt/DNACSEwhAQSAoYE9eaUrjuC5/wpijzEUOeccmh8jk/wAPQ5oAVvmhZsbeQAOvbmpbZfNydwEgBKjPU1WkfnGCDtwQexq3Hbb9I8+Jw0kcrbkVTlV2/eJ6Y9qBpXJI4N8AyCpYsTjpn0/lVZ3JEcwGW2/OM9cHrWvbW8semwfKWUF9oA+9kgD9azJoVjcKzbkBYc/59aBDZG/0h3cHD4YDpimK2JsdAQc59KniG6aFnyRvG7Pbj+VV3w8zMxyGLYAPp0oAkjZEMcRGNxAIB6d6bIctyBgZOR7VGpDSPJ1YA9aeykD5+rEgjPTAoAeHzMrP1zn8KgX5EY4y+/HX2pzx4fYTuYD5qarbVUOB8p5BoAhmILDacgCo6cylcZGM8ius1zQvCtn4TsdQ0rxj/aOtzLEbjSv7Llh+zlly485jtba3y8deooA5GiiigAooooA6v4T/APJU/Bv/AGGrL/0elfpTX5rfCf8A5Kn4N/7DVl/6PSv0poA8A/bW/wCSWaV/2Gov/RE9fFVfav7a3/JLNK/7DUX/AKInr4qoAKmtFY3MW3Od4HH1qGr+jKx1Wy2LuYzLgevIoA6LV4MahJHCTuDJCN3QAgkn9MVhvEZWKLk4LDPYd677XLD5p5WCguoPHJDbiSB+BrkbyBV1BTbH9zgp15zz/jQBnbEMbB2JIIwT/EO1RMm11cElX6qO3PANXljXaJYx8oCjB9eRVMgB94wQxJHtQBHJl+qnJB+Wk83JyPuquF/PmnSpiONRnOCBk9O9BctPzgMwAbHTpQAtsoKIoPLEnn0pZ18tUXDAlAPm+ppqklBs4ZRgDuR1zUzMWCbWLKByG68jpQBCrhZE+ToP0xXR+Dy8T6kyQmTMH5HIP8q59yHLuMBl4+grqfh7KVu7hQrP5oxnHagDs7/So5FtyWwscgR/T1rm/Gdh/ocs8YJMjoqr9CxP869Mv7WOOONI496vECc/3uzVyXja1STQrj7KxMqzGVh6HFAHm9l5MlqkEi5uBLzx2OP/AK9RapavblYxj92cknuT1/pXS+F7WG5jW5ZN0iTEIR1Ixyfwqh4nAW5MMYG5o9xz2GcEfXigDnF+RmAySCSQOgoVlwxA7kYqQAR7mLAkZGB3qFTuwsQIIHGe57/pQBLabFVnkBIyAoHpnr+VRxAhsjJCgsFxjI+tNDKPlBJymF+vSpJWbzVDMMlSuMYxxQAokBUgrt3cikWINyT/AAZP54xTNxUxvx8h6N3qQKyyRP8ALsbGCT1ANAHrWjaUWtoUyVEWzaP7w64P51W8cWxj0hPOk4WdixHBVc4P612HhuzbJlLZQQhUGOdxXr/n0rI8SadLeaZMZV3LNLIgPpwOaAPHV2SybUO1pSPvdsmr1zZMtpEduyRtpK465JAH8zWhqmlGI2n2cAyvJ8snuBwK6S503GmlQuVgUsGbruXkH6daAPMvmjYkKScAD65ppARSrg88k+9S3B2sp3DdncePeh7O6+xJdvERaySmFZTgDcOSPyNAEYdXURqvyk9T2PtTg/mH7vzKBx64ojJcBQw5OMkcUEqApAIHA6fe560AMXDMAc4Tp/hSqREAxXJJ4+lLG584HaM4P/1qevzwKP4A3Q9c/wCFAHQ+EYVaS3DEFlvFUZHXKNWtqOnyJHbIuXMYfd9SvU/nUPgK2Elwyx/PtuEbP/ACf512jWSrceVKdny+ZkfxA9qAPJrqB1nM23JQAEdzkdqrqAxRV+QLGCW9D6GtnXIZbXUJePNXd5hKjtz/ACzWdLZOkTI8hD7MlO5HGP50AU4x5jqVO4lycdlFQmTZEoweM4/rU7RGEgLjMZ2nnuajYDJ3DJBwwA98mgBEQqhHO0r19TThn5mJOGXB56U2RgsrnJ2HkccjvSp80iOpG08YPf1oAFDCIbQTu569PemqNwRBlCAc/wC1zTVOy2JxnJx7VIgAMaqo3bexoAktVEl3CqsSrMBgepIFenaXZ/YLm7ljXepndMnJztXC/j1rzfSHX7fbZXgyBsH644r217B12rC4H+kZIA6nIGf50Actq0DtdPcRn5Y9pA6Fcgbj+GSa5G8s1XV5baP/AJbElB6bun4969Y1fT4kdlK4ZW2fUHn+Yrhn0hzqqzzyDzkbenbC9PzoAwJLKQ2K7owQ8wiTHoFPJrAMYRNh45YH8K9Wax8rS5pFdQVczAMM7eOn6V5vrCINS8mIg7gM49TyaAKJBZw6/c6AfzNJ5oRkyuCB1H14o2fd2MAApIz65pr4cgZyx6D0/GgB6RuYy2Aoz0745oTl1HBGd3PpTZZHYMd4JIA4/KnXEYiI+YcYBA9KAGghdrSAktnHvXWeFrE3OmvEQCu2V/8AebaODXKedgjb24welek/DKO3/sh2l5mEshz2GAMgfgaL2BK4+ytUSxhSVGyh4PYBmJrgNSgeEFCQ20uMeg3f41629lssdgkUiJGXd36Fhn6CvOdat/tM9zHAG+TMobs3GSB+NAFFIhNZTzklCHjUj0yDzWfKYh5ZjLbg5UgjgDNdbaWZhtIjgEOIlfP3eBnP/jx/KsjXrQR6gVVPkcEpxggAdaAMQKFkIxnPzU5wS7MWLDHSkTowLAnpn8KIwRKsTYyB6+1AApG5t3DM27n+VB4MoYH5sfzpkrKQuM7c9amkHlMpYhg2Rx6dqAKUjbjgZ2joKZUtxnzCD2AFejaT8DfiLq+lWepaf4e86yvIUuIJPttsu+N1DKcGQEZBHBGaAPNKK3o7L/hGvF0lj4n0yKd7KV4LmzlnZUDgFfmeIklVbBOw5IGARnNei6x4c8N2cN34gttJsbzT7fQYb2O3t7i5FldXD3Yt2dC7CcRpkgqzK29eykZAPHKK9d1vQfDvh3TbzxC2hRahBctpYt9MnuZlS1FzatPJ8yMrscptTJPBJIYiuC+IOjQeHvHGu6RZs7W1leSwxF+WCBjgN7gYB96ALfwn/wCSp+Df+w1Zf+j0r9Ka/Nb4T/8AJU/Bv/Yasv8A0elfpTQB4B+2t/ySzSv+w1F/6Inr4qr7V/bW/wCSWaV/2Gov/RE9fFVABWjoBca1p/l/e+0R4x67hWdWx4V3f8JJpG0ZP2uPA99woA9ZvtPdLokBnJ3Mgbsd3T9a4fXLAQ6jPBDF+9DAjsN3Ofx6V7brdkGmDoojVQcs3rjJNeeeIoFg1nzLsE/NFswOhc4/WgDh4VZbdhtA8ttzF+OWHp+dYgTAwHGFP511F7DJHLqcTw+au4BdvU5bA/LmsC6CtKQsflsFyFx14oAqKxILcfJ8oz3/AM4pJQxTcmQoGQO/oaic/IUXoeT71OCWTapwwwGzQAkeA8YkAAC7gfUY4oGEQKGO49M9zSAtIyknhVz7Y64+lMfcVDKPm9aAJYhzKDwXyPpXofwmhYQXrbFZ4mX3+UjmvN2eQ5LDjvz3r174LxAWlzMwBHmbTx1Cr0oA9M+yrM0IVNzoMZ9R1ArnNc0gS2txPHgCYkbfTIxn9DXaWESwhojnLuGQn1A61n6tFt094pRhBIAW789fwoA8j0u0OmSxKgHkIJMBuu7cP0xSa1aI832+VBiK3YE4xknJJrTudNlkguIhIN68qSecjn+WKztZu5IbCGKf/lkDv46L5Zxn60AeZqriRSwwuMA/1pkfJJYrgjgirN2oYoVJ+c5P+fxqOQh5EYIAqfLx/OgCLGxFkCjbnCnuakLBsksAzDnP6U08YY42qQceue1MbBWUH7xPAA6AUATxt+9jbGdhy2fSlsYxcXUMLEnLAL7DdyKhDZhO3+LCn1z9K0tBtxPr2noCAWmRDnpjNAH0xodoIYE2sCmwFCO/yj/Gs/WLQR2sdvGMBXdiPQle/wCJFbmmxCPyQcDyztwOn3T/APWqS6Q7JHWNZPUn0/yKAPFb6B4LndMoECKvlkc4fJGcfjVrWppXsGSA/MXWObj+EkhsVs6zaNFImQCqupyfY5Y/lWHeu0VrczKQvmIwUnkFeoP5GgDzPUkVbryYwCFUL9Tn/CqhAlZ9hOzPBPrVqdkadvKJJ6At3xVX7zYRSq9/rQAsI8sxqRnnDe2elNRm2sXwwU4pRnGI/uqT940/cAuZACS3TtQA1ARjAUbst6ECmrN5buFJZSxwD3py8KTkkfdDH0pGKY24OSRgg8+9AHp3witHuLd24XZcrlvbaf8A61dc8bfaYC3CRAq7Y6jrWZ8ErdE0O5cnO67ABPZdvP5cV1mrQLE8EUajaC24euBzQB5zdWhS+e2Zf3TRZ56nJOP0rMm01YbwTzAMBHyM8noF/QE13F3biJnnlXIiwoJ7Z6Vyl8UAmkdWyjA4x1ySBj24oA47V7SezvGQriPzCVJH3h1H86yg5fcyt95izA11/iQNdaTFO6+W6k598ng/p+VclMoVRNkAOMAD260ARHbhdxIKDDA9+aGLrIcMEzyMjinBNwLsVAVSVPrzQj5YFlHIwueoB/8A1UAMCFj5e5Sw6jsaMkhAOB93PfinNuXds6gZJp6oxkIfHyjcPXpmgDT8NW5utfs0xvVHBwB/ADnn9K+htLsjDcF5AGkEjkfn1/WvEvhtHE/idRtZW8ooo9CSM/pX0Np8LRlvNwymQhGPfigDC1iw86R3DDDyjae4wMivPfE0UOn30ssjOxhhChR0Zm5J/DFeu31nHKsGAQgm3MR1+v8AKuN8badB8k7IDgnd7+tAHMXMc91oreR8sxKE7z1Bxu/SuF8ZQC11l5BHtJRScDgHFekwbEyjkh1QPjs3XP8AKuD8aRzZhklG5pCxBHp2/SgDlj5RWIqQAWO7Pt/So4wJCGA+Zj8o/DgU9gVjLADdk9+/rSQEAMVHyqMqT1z60AIqsXGMYxShiqKSNwJDbcZyKSPcM7FxtUsTntnrSBnKsMgFOlADWhJ24x0B/rXtnwl0dG8MQTTriSR5FX3Bxn+VeNvKjynylABGSMYHTkivoT4UWrDwJpvGSxZsnsDQBXk0thGPKUbQGDIf948/lXH6tpUSsTDuEMYk6Hpxkn6dq9W1CWK3nSMp+8KbMgcbuf61yGvWDbykLDYHCy/7QZfu/wA6AOH0OKSSxtVyGi27HXPX5Tx+FZurWTXLXcsAHmQiPlmxgFTnH5VsWlm1lG8Me4ZkDj0A6H+VUvEe2FY0tgVSSXv/ABnHSgDiHbfIMgAEk4HsOlNEii4Z16/MQD6FadLG0TSpjlRx7eppkoSMpgbjt5A7GgBuEZoyRjoMf1pUBAcSHJUcD8RTlUswZ/ug8EUwncQSpDjp/OgCO6K+YAvQAfn3qCnyHLZzk0ygDQ0LWL3QtQW90yRI7gKyfvIklRlYYZWRwVYEEjBBrX/4TrxB/av9ofbIPN+y/YvJ+xwfZ/IznyvI2eVsz823bjPPXmuYooA6m18e+I7fVL/UFvopbi+MbXAuLSGaNjH/AKsiN0KKUHC4A2jgYFc7e3U99eT3d5K811PI0ssrnLO7HJYnuSSTUFFAHV/Cf/kqfg3/ALDVl/6PSv0pr81vhP8A8lT8G/8AYasv/R6V+lNAHgH7a3/JLNK/7DUX/oieviqvtX9tb/klmlf9hqL/ANET18VUAFbfg5lj8U6PI7bQLyLr/vCsStnwkqv4n0hXI2G7jB/FhQB9Q3EJkgEEi7lZySGPIyM81wHiu2Lyx7ipXzA+fUq/y/zr0ED5roSuxYMURvXPSuL8QRZvSs2PJSJs8dCCKAOMuIpY/nf5HLl23ddq9vz5/GuL1lka8lESl2dFb0xntXot0VnjVpv9YNzOV/hBO4D8sV59foqXTyRS7geen3cHgUAZSlUdXVeQRtU9/X+VRxgh23ZyOTmpZnDu5fBfOcdgaQA7A2DlkIX3OaAGxtukHlnG4hAp9O9G4ooQDC5xj3p9rHi9txwS0gz7c1G+DIp5wCS350AMD+WUIBJ5DA+te5fBq1jXQppH4zIXUHu2BXisLgIxI8xnH5NX0B8KbeNfD0fymNlXI3D1xk0AegQFCUkwMryPY9aztYRZllWTLRkBmxx16H9KtHMLnYAVVQx9eaZqcqPK2xtpiG2Rcfe44FAHn2qW+JCUjZt0zOGXsMDANc9rkCTQqtwBmQEN9Op/QYrrtVGLqeJG2lWUEe+M/wBa4vxdCHsJLqGTywqBkB75BBH45oA821BN/kyQ8pg47elUlZsFF6kHcT0rU1OBkuktlBjVERjn+9tycVnluWMa5CqN3fr1oAbKMrgjLEZJ96cqMS55VCSPoaN/7mRUAbfgZ74FJsDOEHGCMc+ozQAqgA7dpIU/e6cVteED9q8VaUs4UL569PY5FYpf5mcj5OUJ/DgV1XwrtVu/GdhHMM7R5wPXBXvQB9LWMAfT13ELKv3mqC7jMTeUpbD8n0GOgq7EEQ4K8E/KP5Ulzbu8e0sA+4EnuetAHBa7tjSSJhuBUk+2F5rAnsoU02BJWLiNCQvcoF/+vW/4kimLQrs5Z3Vh/e5HNc/csyx+Y37scJg9cZ+7+NAHlWoWSYVoD8ojVsD7xbNVL+Ura/ZRHAESQy+Zs/eksB8pbuBjpWrquYIpbeNvmjAbd3HJyPyIrHuxi7eOQ8g4980AQwjaQAAWLd/pnNNB3qwwAGAzilH8G/rG2PwpxizbvKpwVKoFHuOtADhHkoFAOR0qOJlUg4zliBSJw8ZGME7c+lLnlMcKH6mgD6A+Dls3/CIgsF2SEnPfpj+ldRewpcysHOJI4uSOzsOlUvhxC8PgKyYqPN8kMo9cj/69a8yKJ7gEH++cc5PWgDjNXiItY7eYENKS7DvwvT9DWNqKRS3ECPFslyg9vUf1rotReR2upJ4+Vb5cDOFwP6GsCVd0sbXB3HdJ04wAPl/nQBxGsjzALdSfkdlXnhkyf/r1yNxtKkqMoj7QD6DvXYeIrSRtQt3AZbZI2lP0HJ/E1ylyytMgCkRgHvjOcn+tAFRsFQFAwxwB/dqTYGDsZNjJgY/lQMAqF6E7gffFPcYZXY8jBb8KAIy25PlyTgjpTywknViSoKDJx6LSW7YmBdTnG5V7Z608DdEqnk45Hb/PNAHb/B2CWbxLJIpD7Idze/IH8ga+gpIwIIIZCd8chYFe/pXiXwKiRLvVZimSETDZ6DkkV7fEx3p5mS4JwAP1/lQBLIiyeYsWeMq/pk9a4/xPbJI0cTNuiKABe+B/+qu0YrErKW5IaTaO+TzXOeIYEhxJCmWiQjcT1HpQBwmtILqa8ZVaNHX5SOCmQFNcX4ltmu4rZP8AVgBnGeqIBj9T/Ou58QkSWYghbbM0RHH8XO4n8q4TxVJcttVVKyRHZvHG7v8Alg0AcnJ5e15IwRGh2kEe1VsBcAZ4H5Zp1zC9tdNbyDDIcMPw70Sook4yBnJGevrQAjJ8wOcKQQ1NQZ3FgQ2OalwJCxxgjnntTBt2swJC5DNnuDQBHKjMwx2GK+o/htp5tvDGm+cz+YLNcoG+XJHp69K+YzEzMrKcbiQnPevq7w3MX8L6ezxMjfYIz6Hdtxj880mrgnYNQgjmZ32lgjbePYdf51yev+ZErSxgSCV0k+pA/wAK7aRgLeJsErt6D+9/9euZ1uBkeKEjJEbNz9CMUwON1ZFaVIkwRKhkLAcDjj9c1x/jKK4Z1jY7YkVTAw/ibGTXb3jJb2qMoLRFVkPHO32rkvEdtLdR+XGymJB5sRPB6YKmgDirppJWDSKQxG3I4wP8kVXUEosh6MPm579jVq7LmNd330Q7gfqMfpVNhuVo8bcAHp1xQBPCVE0G7IQqW+vX+tR4Mj/KoCgkDn3pkoDKpA+XHUj1qeY7JCAOVOcKaAM6QYc/Wus1zxr/AGt4TsdC/wCEZ8MWX2VYl/tCysPLvJti7cySbjuLdW45PNcvcktKzE5yc1DQAUVa02wvNUvYrPTLS4vLuU4jgt4zI7n0CgEmr58L+IBrQ0c6Hqo1cruFj9kk88jGc+XjdjHPSgDGorYsvDOvX+pXOnWOiapc6hbZ8+2htJHliwcHcgGV59RWS6sjsjqVdTggjBBoA6n4T/8AJU/Bv/Yasv8A0elfpTX5rfCf/kqfg3/sNWX/AKPSv0poA8A/bW/5JZpX/Yai/wDRE9fFVfav7a3/ACSzSv8AsNRf+iJ6+KqACtfwtuHiPSmQAsLuLAPruFZFa3hdhH4h0qQngXUfT/eFAH03dXCSQ3BTPmRzj5fVh0xWD4vZDGxiGFkGZPbca3FjaWV9mFJcDcBxuU8fyrK8QOs0KSCPJI3OBzj0FAHDandQWsBmjDOJQFCqPujJGT9BXD606CXai7f3CNKrd8cfnXd38WyxuDIqsoj/AHi+iryBXB61eLcXreYpXIAkwOmR/jQBk3KN5UaYDbTnOO59ajJOwjnAPyj374qW5eR/3hYBCuOnccVC4LDnIwuc+tAFuzjJ1i2cNmMyrkn65xVcclpCcA/LwPrV7wzEtx4m0yDlg1yikH61VdlFxLGciLzHGMdPegB9ikj3KRxqWlY5VOuT1r6Q8ExNHoFk524ktkUqOx9/yrwLwnAZNWgYsVZZOAepGDz9K+jdDiEOhII1ztTP1bAoA0GcxNPMx/dMuzcfrx+dOmZbj7Q+3y5DyMj2HNOIQKsQwUIGNxzg4qO5JbYRgyEmNvQHtQBxGoxO0k06MfNySc926cfgK53VI96GB+UUAndzk46Cuw16H7PcRi2Bbyn24/vf5ya5jXMLKWYARhM5B77dxoA878UJIbiKREbzDF5h4+7g45rmuI2LbiwOMgfyrr9WuGktIHuNqXE0nl5HdeMVytzAEuPKUjZyefrQBCzDzCxXZk9O1LgeYWc5KqBnp+NNTLt83RwVXjpVi4ZI2dGQsCFC898UAQRoWjRQcISS3sfWvSvgnYLP4juJUOZYYiFPsRmvOItwjQ/KOpIr234L6R9ht0vl5a6Rt3+zzjH5UAeruVxGnIkwOfQ5qHzHuNjKSH3MvsM0XZcOGBCszZBPbrS+assvlJlGI6e+cf0oAwNeXzIHk+8CGRSo75/xridVha5tZIZBmaRRtJ47j/69dhr5lFwYo2GxG3EDsc1zF6MxPPtZth27e4+X/GgDynUrVt91LM/zNgccZO7r+VZV6IjAJo3nF20pVoyg2BMDaQ2evXjFbeqs3mG3uBtlkRCqnscknP6Vz94HG0qeXYEn+6e4NAFfcSgDYKscDPWrcSEabKRyBKgL+nBqsqHLCUbmBwPerhJj0m5hUcedE+f+AnH86AKcgRWAIPJyPrTgY/LdMkA56jkHFDneuFB2KQeevNTWcXnXVqAFIMqjnuc0AfU/hSNrPwrpabeDZRsT6HAqO8DQX0hJIScbVYf3hVy23f2HZQnJcRhMY+nH6VVeRUCg/MfmdQexJ/pQBn3CSCOaUlDzmQY+6CDx+grhJLJ/7SVjIzRklgo/2h0r0CXypmliVvlZPm9/881yepyCASrFGAyKxUntjv8AlQByniFImt2tlkJfY7jB527un4VwOpEs0ZUbQc4OOdxPSvQLpbOe4tLuxf5DuAb1DAcfgQa4nWY2s5BEWViCJV/XmgDJVAsvl5+YkAgjp60J/wAe8gLcqcc+9GNzE5wwOQRTD0kJYckEigC0AI5o/MGd6K6npgGq8bsjZIyQehrT19Qh0tT906fETx3OapRwvPcxRxjLNhVGOvagD2n4R6WkOlXMRAEtz5YLDj5iD/IGvWAqxyKyAkR/KPU5HNcl4Mt4Y7BWdQrRsqgjs2MV1by4b93kkodp/CgAADIN4+ZM7iB1Hp+dYusgmH7pUkEt6c5rWEpeSUqRt4O0/wAQ71T17L2MxXAZB5gX1oA4C8jIhhUAGVSEkJHO09a43xxdLbrb7o8P5qlsdwBzXfXYCu1ww3PtJfH8ORxXnnim3+0zoLliPITdkHhunX8aAOL1I79UvJt+VeRmXvu9KrMy+Ywx8h5BrU1pYbea3Fvjy9hmEg7g9PxrKVlY/PkEg4A9ewoAUsFUsecN93PUYpn+sUAEnI/rU7BX0+2c/wCsaZwfoAuBUmlRFru2zjy3l2bj2FADLG2nuryKGPJOc4zjvX1tAlxDbQQBEMKwx5fd83TkY+lfOXw109tQ18r/AAxFWJI7hq+lrg7Ufbwy4VvfH/1s0mrjTsULptkTMpzEV4AGCDjIrndVike1LSPucKGU9+R0rpJpCQVwC3Qfh3/Wuf1RTHGscpLODyw7fLgimI5i3t0ubQRKSXhVVw3uK5XWFlgjllYFghKY7hMnJrrJphFLJNGrZkKqEHsBk1zPiQ3DwMIQGuCmHzxhc8n64xQBwGoweUw/5aF8jOe3X+oqlneiHGCuRn1rX1ZAZJ0R1ZpH3Lz90dR+lYUpfy1BPHJwPWgB/sCfQDPWgq0Xm45YfKR6c8U5ihR+dpXBU+/erOrxrbavdRgkKCGz6/Ln+tAFDKM5MvX0r0PSf+FPf2VZ/wBr/wDCwP7S8lPtX2X7H5Pm7Rv2budu7OM84xmvOZ0KPgrjvUVAHV6HYWep+OZbTw7rD6NpcryrDeancxwSLb7TlXYMqF2XK7cgEnGQDmu0jluZIdc0O71HSbe4m0OPT9IkOsWsiCGO6SVoXnSQojOPMb5mAP3RgECvIKKAPb9eurbXdP1LRNJ13TItYhk0Y3F9NqEcEd39ntGikZZmYK/lyMp4OWxuXOK81+Jeo2erfELxHqGmMJLK5v5pYpAu0SAuTvx23dfxrmqKAOr+E/8AyVPwb/2GrL/0elfpTX5rfCf/AJKn4N/7DVl/6PSv0poA8A/bW/5JZpX/AGGov/RE9fFVfav7a3/JLNK/7DUX/oieviqgArW8Mf8AIw6VgqD9qj6/7wrJrT8Pxedremx5277mMbh1HzCgD6aie4Ek0ZjG0MHXB/iz1qrrkUccrJGAA7YYDpwMrV4vJK0pjTnaVVfUjHP4Ua1D5ltDsQl3XJI7nGB/WgDzrVLSW63wwsEMnyk9ioOT+nFcX4ttIYkgmtgrI0jB2XnPHf6c16RqKILqG2QMAwZC46qSvWuD8Swrb2zraIrhpCSvZWOAfz60Ack4dEUYAjU5xj9KqNjaAc7iOh4q7feawlV0OA24H0HT+lVXVtrDBOcEewoA1/BSGTxjou0qC10i8euaisrQ32r3se/mFZJAQOu3p/WtH4cQNd+PNGSJAf8ASkkB7hV5JrV8G6d5uoaiN6h7q1meIjnblyP6UAWfh1YyStbXDxb/ADyYwPRc17faGRdOtFxwAATjiuM8G6e2mafZLsLkfKHx1GOtd5pG9YYraX5nePKNjgnHNAEzgNdKiAMcFi3ZfT+tNu0WaFQpKEj5iPXNRvLN55SMbWB5HY9c1biQSoGfJYYOD0zjGDQByuq+Wl8ZWBbbjykHXJ4P865nWbVfM+TJSNSuOzA//rrsNcthcXcdzt+YFUXb/ePrXMaluSKbdzIG8tffrjH6UAeUeJo1hvRJKVO+aRNnZemCPTFYF2rIwk52sDtJHfPNdVq9gWDedh7oTR7wexYcgVg68scdvAI0+aN3TaDkAHn/ABoAyEJznoqdfxq3q9t9l1C4ts8x4cE9+Af61HDGJ7qGFcEyMsS4HcnFb3ju2MXjDUrdoyxQRp6YIjHJoAwbRXuruMMoYyMB+tfTnguyh0zwxsIP7tnwe/JFeF+GdJK+JtKt1Rx5kIkcsOFPU4/lX0bp1uILfydu+PG48e44oAllcNLKk+WJG5h2VR0/WnQqZJPNGOUIH1yTmpAqSSuzrznDD+8MVJaFJJlKYVWP3R7cUAc9r6ZiJRAD5W5n992TXNX8hWchFLbmJbjjB713utW8UdjgLu2AKV/vZYZrjNZYwxzyYG8uFC9+OcD8MUAeS+I1STVBjBnchA3qF6muUu4LhLdrl4c2rzNEJM8M46jH4113iWKKa5khgBDxhvLcHrJvxz+dclcJ5akSL+9ZySB6g9qAIYpHcgkqoLA59COK0bZAfCl7IcktdRKD26N3/GstPlG9hjceD1+orudL037T8KLiYRkudUQYHpt/+vQByy6dcTwKIUYl13kfiRj9K2/BOii+u9OmfJC3ZWQfQcV02n6BPHottb5SG58gkSDnaMnr+HP41r/DLQZYFsppB8n2mRz7daAPXL4eQ0YGNhwF/wBk4xWUArF+eC3lnPXGeg/OtaZWSSRXUHc2AT2wOazZUCMjyAAhVVwOx3cH88UARfYljtpjgByCoH93GcfzridcgMl44icHChCexOATXoz2x8+4Myh93IP4c/rXCeKF8rUCbaPy90oyCMYG3BoA5bUrZbeWBkiVYIImK46ZJ/8A11wmtoZtauJpEBgC/Lz044Fd9ewSXMEtuzP5UkJwc9CAcgfjiuHvUBMbMh+0eXjaTwSCBn8RQBzrHblQvThj7014Rt3r8xON3saWQgTyMQcbvu9+lJ80SnjhuDn6UAbmtQtLcaGkS5M1jCqj0OWH860NB06S01m5BT5Yl+Rm9QVJ/rWnrFgr+J/CKFW2y2dsQcYwxYk/yrvbTSIxqd0nlhmYB8AdSSQT9OKAOt8OW+2yPmJ945K/iCDW7cKUkwnzFBkrjrwQP51T0pVXzmkGZCRGyj+HFXkYNIAX+dWJ6dQeB+tAEQiWd49mECHJ9vX8M1HqELvayMwCtIdq56DmpY0mjjYADe5Kj/dzT9VL/wBmgJHuIAYAc9v8aAOCNkYIpTLIGRpD1645Fefa5IZLQuqqTLExBP8ADtOT+gzXpepxTPbhyePL3sAOc5GR9ea4PX41+y3AtI18wbgwP8IA/wADQB5vq/7yyikAO0BQTnjp0rNI27WOST6Vv6isL6AXgBU7kOz/AD9axWLZQsMcZJ96ANa6t3Twxa3hiwZrmYqf9kKAf1p2mWRGlQ3ar+8MxjQZ4YYyT9a6+80Ca5+FPhSeE7QZrxuf4huAFFhpyDwrpMiqRHFcE/iRz+VAGx8HdFmW9ilyCFLq57OMjke+a9fuL2A3DQo48xE3+X3YdM1znw2s1i0+1khC7GDMp7FS2c1u+V5cQVvmKsfMbv1pO/Qat1I/tKK64AAdiffnP8sVnXsBeLe4BlZScfTOfxwavwRcLuBYxgpk9ueo/Oku0ENmS7cRMyt+I4NMRxd7DHGiwswWR1LJx0PNcpqsMttNlmx5igSPjqpGePyrudVtxNfEy/L8gCn0J/8A1frXK+KI2lFxDGGICkoaAPJLqNoHuA2GU/KrevP/ANaqzgABQACctk+uOlamoJEpuoYwzLFKNp9MLg/rmsqZwHCtxz8wxmgCRkjHlsd3lMMHH06/pV3XG3eIJ5Ao2s6jJGcfKKTQrMajrun2asWhmuFjwO2e1b3irTxYePbuzMZSNbpUDHoFGM4oA5XUoGguFikI+4ACO1buufDrxToXhSx8S6rpfkaJerE1vc/aIm3iRd6fKrFhleeQMd6X4kWi2WvxxRjAa2jcD6g1yFABRRRQAUUUUAdX8J/+Sp+Df+w1Zf8Ao9K/SmvzW+E//JU/Bv8A2GrL/wBHpX6U0AeAftrf8ks0r/sNRf8AoieviqvtX9tb/klmlf8AYai/9ET18VUAFavhxtuuaZkZAuo+nX7wrKrb8GgN4s0ZTkhryIED/eAoA+n7RVjuPLjPmBgfnHQHHJ/SrtrYmKWNCSYVi2njp6flTrWBY/MdECxD5T7HNbJgKxSFW+8uFGPegDzTVbZLe4l8xQC4KnH96uD11Ft4VaSEKTIitH3yTgH+VeoeNtNf5ZAu1UkAyDyTx/8AX/KuA1u1MkEgnYtIp29OhLDB/SgDzfWUdLx1fnepcHoNu49P1rKDb8tgkFSK1NWLfammnYllzGF7bV4z/WstU2bsDIIz+Y5oA9G+AFi8/wAU9NRxysMjFfQbcV0/gPQ3j0l5poSJJoWVMjt5p6fqaX9lO1+0/EbULsjc0Gny7cc/MccV60dMFrplqpUYBZeP4ecgUAZFlbxRRxkqQyII/YcD/Gr+3ZtZCofovse4/nVuKGN5iDwxIcgdMjFRfY9xnCt/rAXDdcEcCgCFlMUswZSJd5IHqMDmtC0R3ixJjDsWYDqtQSLIjo0p3AHO4dcYFaVlEqJM7DBDBgM9cjmgDB1eCXY/2eMYwNvsa4jXrN7aOxab5nVvmx256/iK9av7dW+4CEQfMD36ZrgfEliZ7e63E5yNnYBFOcfrQB49qlhIJxvdhdeYZWfscf4AisO8tk/4RfKtulE3nMT1yxx+XFd5q1u7ygOoxISgb0zgf0rkpbaL+2LjT8kFy0KAnuVB/kDQBh+DLT7Z4w0W24Ie8QED1yK9N+I/h7Gta1fRxHzBclc9yAFHP61yXwgsRcfFrw/bRENsvMsev3c819LeM9Ciudd1tWTJuJic9hxigDyPT9Dk/tzR79SESO2O6IcgccfnXqlvE25nPyR7AreufUVn22ni3vdPXZwsZQ49O1bTRtI4QAhRjIHY4/xoAYYULHBODyfwH/16SwtgiyQt/Cfkbv7frU7YyImBAfncO4qeOPdNHEnG9iM+w6UAUb+2LR7SWIGCSPqK4/W7TdayShczZySe3Iyfyr0trdpLWRIhlnPJx2rj/FFjKsEqRKduSFHrwB/SgDwzxLYwy3QMSurR3C/Ov+0T/wDWridUXfezTIjBd7SbCfugdR+GRXqviJEVpXGY0jZUII6H1rzPXTLDa3Fi7Bo4bxyrFRlmIGcnrjHagDJj2mLKZyOVyelfQ3ww8PpqHwOtvNAVZ9b3Mx6soXA/9Br56t4v3iISVxk59a+wPhBpSf8ACg9GDLmSSYzD3OWxQBzF3ohE8zxDMCo6kHrzjAH0NbfhbTobXTNPCxYIZndfU5ropLWNW3spG5CMepx1qpCBFZoAp3hRg9wT/wDqoApX8ga8dQSIyN5Prk8GqlpCLh5Wdy4Yqfrj/wDVV/YqymPYHUYQH04zUdvCYXn3HbGiAbfxzn8qANG3CuSWX5+UGR15zXH+LLVGu5XVDJIxAYD+EZIz+Fd3aRLLHE65BZQAfT1rOv8ATd10ZmBKcrtx/DmgDya/Ahu44QpdGZ23DpwCDn8a871cNFBO7RfPH8isei/M2Aa9d1eyZdVu3VNqlc7T6knOK8612JrvTbiMJ5cYXewI5bAOP5GgDzoCOaFSR+8UfMSeuaekPnzxoxPzkKAD3yBn8qilbaA4XAZiT7e30rR8PwfaNdsF7PPGAOufmFAHu19oIh17QX8oukNjbuV7rjcP611mnaX5GpzzEhw64yegXccj+Vdd4m0yJfFkkUQ2MllDvJH3Vxj+lZ86LHPIi4xgdPpmgChYxiJXV+TI7Zb6nI/SrVycxiVRtVR6cmo7eOQGQYyGY4b39B9K0GjV3IfPyDDD0OAM/pQBVt1Qv+8++o4PovWtRLdmjk2LxJkLnoOKo2K5YI4JZm3DjoB61vRKFtE2jcM8+4xzQB53rFscv5I2sWJwOhXIA/UV5x4gZftjxRrsLSYbI6jpivYfEdkoZWjBwhzgf3R1H515z4itlWcymMNhtw9yp/rQB5Hd25t7iOFCN06YTI44Bz/T8q524jMeVYNgZ/Sux8Twtb/Y2kQKyytFuY9AT1+mDXL6uUa/uRCcoWLB/UetAH0jbaA5+CPg1oyCGt5piMdQWBqhb6CTpyI6D92pdY/9o9K9X0fTRD8H/BkRGSlhGMHvuQGseKzUSsnUDGM9hzigDO8NWy2OkWSKvJTke2DxU5ty0bliAFOGb3HarkMYS2wcBlBAPvmqqwQNLJcopO/IJLHGM5PH1pO41YZbRmeIArxg8+2elS3dugs5Y5B8rJhT6445qyqKiyKQRk54+matXFuzqwdcgYA9u9MRwesWkn2lsjByhfH8J9PyxXIa3FO0zeXy7xlSew5HP6V6bq9sSRPj5sBzx17f41x2uwSh0n8vDPCSE7ZI5H4f1oA8c120WAxlBw2QX7uf4j+lctKUM20KfmAHrzXoXie3WKwtokUuxMnOeUYYH5HNcCYys0XYjaT7HvQB0fwltvt/xM8M2x6SahGSR2Gef0r1r4geF/tXj+V4E3iDUXd+4dFIyP61wv7O9mt18Z/DqgZEU7y9P7qE19E6zpkP/CYaljhDOwCjooP+NAHzZ8dI1Txlaxx7RiwjHH+81easMEj0r1f9omKO1+INtGoGBYxMePUtVTTfjn8RNK06107TfEXk2NpElvBH9it22RoAqjJjJOAByTmgDzzTbeG7voYLm8gsYXbDXE6uyRj1IRWY/gDXY3PgOCw8VeLNO1LVpItM8ObvtN7Fa+Y8mJViQJEXA3MzjguAACc8VzV1q51jxJNq3iUT3z3UzT3fkSJbvKzckhtjKvP+wR7V1+r+P9M1LxV4k1GTQrwaZ4iiK39kdRUuJPOEoeKUQgJhkXAZH43ZJzwANuPh/Yab9uvda16W30KM2YtbyCw86S5+0xGaM+UZF2hUUl/mJB4G7Nch4n0afw94i1LR7tkeexuHt3dPuuVYjcPY4yPrXX3HxBsNSa+s9a0CW40KRrNrWzgvvJe2+zRGGMeYY23BkYh/lGTyNuK5DxPrM/iHxFqWsXaok99cPcOifdQsxO0ewzgfSgDX+E//ACVPwb/2GrL/ANHpX6U1+a3wn/5Kn4N/7DVl/wCj0r9KaAPAP21v+SWaV/2Gov8A0RPXxVX2r+2t/wAks0r/ALDUX/oieviqgArf8DRmXxjoKoQGa9i5PQfOKwK6HwCSPGughcg/bYuf+BCgD64kjbYyoD5chI/4F2rXiD+WzbAJAoCqfqP6Zois/Kt2RwSoPB75q3bR+ZKsmdpBAwf8/SgDA13TvME0cnJlPy9+QOK821yxCtJG8e15ieT125/pXvBtEuNOZgPnIVl9wT/9euZ13wwt7p8l4EzKymEj0bPNAHyl4jihkhshEoyiBGJ/iX1+tcqgkZsADBz1PQV6v8TfDk+kWssixHAG5OONo9K5uPwdcf23aWjZC3cHmlgv+rz2+tAHq/7IdhJHqGrX6kKvkBQPUZOf6V7BLA8dusdwuON5XuMjrUfwM8Mx+G9Cu/3e2QKkTkjnjP8Ajmug1FYp7mZ+g8tEwfTp/SgDk5wkbvtOCh2exHrSRBVtjs4ZyUx+NXr2DKl2QMrZzge9DRJzLtBzwgA60AUlSMyhGO7y0PBHXtWgsK+Q67czSLs47DGKhig8uGPzBufJBbua1prNrWMqpzPkg57dMfzoArTR5slVFJ2KRk9x0Oa5nXdP+0xSrF/GPl/EDI/Su5tBCY5rd8k7+B6cYNRXenqtv9pix8yIMDrkjp+lAHgXiSwktndRho1HmA/j1rgb/TPsWo3N3O7IiShonPUkgf8A6q998S6LG0Mvy7XGMccY/wD1mvNbzSJm8w3MZlSKUrk+p70AZn7O+nwv8ZNM3ZkdVnkkXHHpn6CvqPUrPfqV+JFAeUtKPoDgV5H+zfoAg8eXWpiIYS0aIOe2Wzj8cV7Pr0kkWsyBx8rIyBvYjOKAOOe2H2v5R0Vwp99uKrsjRsPKyfM++c9CP8mtl4GMcezLclveq9xFsSTy0OT04oAzorfzoEZXKnuPYc4q1FH/AKQo5ydoJHYY61P9nWAyMueV3n39qt2CLG7ybDJmMsDjvwMUAT2o5eGPAi2na/cnFc74gtJPJPd1kH4DIrp4rffbsJOCI1EQX2Pek+yx3MbsQAVKxgZ5LYzk0AeG+JdIPn3AIBClmzjglgcA15h4nsltbd7eaNTNM7uhI5Pydf0r6Z13QxNHclE/eSAnPrjODXjnxK8NTq8Btk8x40OGYdAw7fnQB4VKXMbyD5SAoIJ9uor7w8BWxsvgr4QjjX5hbwnafUgnP618fWnhDUJ7O2vJ7dldpPLaP7oAzgV91mzS08DaZakeWtvbQoM8YIQCgDh718vGCDiNFZh9RUJt2JkkPBwAq/hx/OryQSu7zBh5f3CD6g4FWJo43s18xjvPBI9aAMK3smWMknAf5vdT6U+aNGSZXA3OuxR6mrccJCsSTjsPerMMG/yJFTADDA7+9ADLS3CQwoBuEYJ47HFF5v8AssbDDEsFJ9gv/wBetKSExuWj4iYYVj3BOKabfzIhGmAEkP4H/wDVQB5n4wtmhT7XGMu4VQewBPIrgdWtEaOUTkRllKn2J6Y/OvctV0v7QrQtGrKrAnPfP/1q808caGbeCSdFOTGzBMZ+7yPxzQB84XihnaNsAqNgx9a6z4Q6X/afjvS7f76mZMADvkEH86wrbT3uriOBopVm2mRwBycnivoj4H/D7+xPGdnLK27YqXKsV/h25wfoaAPaPEsCjxLO064iljVWcehz/hXMxQQhix7d/U4x/Kuu8YsBfwupHmNErOvY4P8A9c1y29XyRwHBbp3oAzzGYSN5PyOSM+/NW2g3QyHd8zDgZ5OelPaETI3mLlgBlf6/ypY7RpVjIPcDP5igBNKi2yMzcg4GSOenNX7e5+zpMqhTjkE9FGeR/Kks49hWRAWDsSox6VYMSyFIniHms+WA6EE//WoAyr2zkkSR3UhA7bT/AHscmuA8SaaXknZFz5hOQP4Qe/6V7SjIz3Ebx8JE7huy56/pWNr/AIcthHKke7ahCsx75GaAPk/x7GftwjuOYInj8xj6kcAVxV7aI1vEUYk7WB4xk56fpXvHjvwz5LFXTdllJJHccg/nXmNh4evLnX9Pswnmh76EkYxuLPhuPSgD7OmtGtvCPhy34BS3hjRfTESjH86wXgj+2y8DBJGPTAGK7bxbau9lZQwDhJAv0wv/ANauMEBAhc5LfMcnqcUAYkkIRLhixIkcFvbipoYgY40Xoccjv3P9a1Lm3Yk5ChG5247Y/wDr1nwR3KXHljyTAuCV535B656YxihjWo6MLJtlbAOOV+h6Vbs0aWeWNsgMd5+vQU22t90cysvK4Cn26VNBG7XCAMR5a4Y+uBmgRVubJZI40bAGwDHqea5LxHp7/ZYniXMiMN3HQEc/yFeo/Z4XMjNtLRqnyj+IYz/M1z2p2xnhdETaFUbR6kZoA+fPFGlxtG77iGCl8e4OcV5brCO1/MyRkFcZXuTgE/zr6I8TWCeZA88JTbKEHuSDn9BXnWueEbqWMTwQFp5riVXUfw4Rdo/nQBc/ZWha4+MmnyEZ8m2nY+wCbf619OX+nRNq+qF+GlmLZPXPb+teR/sneEptO8Sarql4m2QW/kqD2yw4z+FexeKJZLfV5dgGWfqfcUAfJn7SgQePrby2z/oCAsf9968jNevftJxLH49sY+w06PJ+rvXH+IB4EXwtZDQf+En/AOElxF9q+2+R9kzt/eeXt+f733c9uvNAHIUUUUAFFFFAHV/Cf/kqfg3/ALDVl/6PSv0pr81vhP8A8lT8G/8AYasv/R6V+lNAHgH7a3/JLNK/7DUX/oieviqvtX9tb/klmlf9hqL/ANET18VUAFdV8MYln+IXhyJsgNfRdP8AerlhXW/DCN4vGekaiPLMNjeQyyqXAdl3ZO1TyxwDwKTairscYuTsj7cksniYGZSDJJtUdgMHJpZLF/JmKKfMTCA9sjrXMxfFC3MlutzY3jKHHmDyGyoGenqcYqzcfFLTAA8FleLHuZirQNhx3we1Z+2p9zT2NTsbdqLpGmR48GOQLtzxt/yavac/lmJJQzszZdR2BOM1w6fE6yka2lfTrxxkmZliPz88Afhir0XxO0m11ESNY3/lyJsbdAwKg85HrR7en3QexqdjR8V+F4tQ0K5tJIQwmby42I+6fT8xXLJ4JkuNQW9jT9zHbqqj1ZT0/Kush+Kmi3Mipb6bqc8MRUsY7VnMZzxkAdzV+28faJsaF9L1mCJWJOdNmOfyXij29PuHsanY6bQbT7LoMSyx7ZJMFx6Ht/SsW50y52TT7futwPUdaV/iNoiwlhbayUAzkaZPjHrnbioLv4haVJYutrZ6yZGAIU6XPjr3+Wj29PuHsanYFt3F1MBF8uzdg/w96bFpUjWp3AjaGcH+7WbdfELSku336XrG+TZtb7DKplwPmwCM1J/wsWzk1I40nWVsY4SuP7PlLOxHQjHAo9tT7i9jPsalppO6aJ2UNEwJBPTIFX7ix3spOTkqxbPJyK5d/iZosNx5T2Gqx28UOIwbNwS3oQR+tRR/FfS1cvLYaiofZtxat1H3lHrR7an3H7Gp2No2chZ5lUgGRsKPReuan06JmaOFwfLYls++04rmLf4n6a11cLLY6h9mWL90yWrkszHkHjj60kfxO0mN5DJp2pZVFCg2zYBBPX8CKPbU/wCYPY1Ox1l3p8GoafGkkY8xlCFsdQAefzrEs/ByPat5kCBi/KnnkgdfwqpZfFLRxbwo+n6pI4/dsI7ZjgckfjitK0+KGg4m+1Wup2yg5G6ykO4DvwOO1Ht6fcPY1Oxs+C/D0WjtJLHEsfnAcAfdx1qXWLQXGqTq5OWQOmfYYxVGP4laA6DyY9VkBGRs06Y5HqPlrPvviDp0t0uzStckjABDjTpgQe45X0o9vT7i9jPsX5NNmiW1S3Us7KU3D88/lQmnSSBflIGc59No/wAazb74iWcEEX2DS9ZmCBvv6fMpU44529KSP4h6bvjjXS9cMYcGQjT5eAV64x65o9tT7h7GfYtLY4iEuGLPbs+3+6wPNWorNrS2gWJCWlLZ/wB0n/GsOX4jWMTOLjSNU2jcFb7BKoKk85yPSnJ8TtCFtt+w6qJtn3Psj9c+uO9HtqfcfsanY6aewUXCGNtqxuA+ex64+nBqlLbR20zMobawOz3BOAfwFYdt8U9CeJzd2OpLI5wY1tXOMe/rVK++KOkTxWjW+nagWRywU27YPUAD16/pR7an3D2NTsdglqn2thInyNGEUntxx+dc74j8JbnjDfPEG+ce2en8qg/4Wlo5t0BstRMyxDzFNs2M5HP0AzVm6+KOi3FjNnTdXcK42D7I+GYc4Jxx9KPbU+4exqdiKDwxFNJbxtaKYmlDAY4BzmvRdStBc2E9p1DINo96423+J3hgrEu3UVbgqpsZCc+2BzVv/hZGiuG8u21qQDjKaZMeR2+7R7en3D2NTsVpNPWNwitjec8/yqGyBuyF8r5EYox9WFVr/wAc6ddQxCLS9ciIcsT/AGbKSPQjjv0rPj8fWtq0kS6DrBWViYwbKRTnOT254o9tT7i9jPsbv2NlhimKFN33x64NWYbU26RlkJLFnH0HWuYn+IlsbeW2bR9WFvCoR5TaSAqevPHyn61ft/idoLxostjqYfy9qsLNz1PTp3o9tT7j9jU7Gotu8lrD8jbfmZc9Mf5BohSMzyKM+bO3mAD+6AOf1NUofiToEEUMUtrqyR/NnfYyDYMnHbvmse6+J+jwiNrOwvmmEUkeWtmHB+7j60e2p9w9jU7HXvbRAwkqQjEFs9eMj/69ZHiLw5b6hpVrCYiXILM39axF+JVjtgaTTdSLxxqzx/Zm4bH06EnrV63+J2kyQQIdM1R7kj5ljtXPIIwBxznmj21Pug9jU7HA6T4FCeLoh5BBALBmHVc5Fe0+FNJEWoXF4VwoQQqO3bNc5H460u4vobhtJ1iJB8pcadK2VHI6LWzF8RNDRAsdrrIGT8o0ufrnn+Gj21PuL2M+xo6xpTajqsbxkiMW7I2R71jQaWsdxMgjzs2lMj8D+FTxfEnQnyY4dXcjsumTE8fRaqzfEPSFMkjadrZDIMsdNmGOehO2j29PuP2NTsS3miXKmSZR8rIW4+nSpF0traOOeQBUIUAe/AqrH8S9ILYfT9bXzTgD+z5TxjjAx39qkf4laGAqSWGtCMf39Nl4P5Ue3p9w9jU7E1tp09tL5jqdkWVyP73OPwqSKxcXm8c4YgEe44/U1RX4l6EUeI2mrlWLBcafL84z0HH1qH/hZugK0oFlqyggBW+wScj1xjtR7en3D2NTsaqWzRwFJGO9z5ch7YHSrCnzLXyJ4/3kr7UB9jj/ABrlbf4k6S8DJc6fqwYlCqiyc7yOp6fjUdx8UtJN1G8Wm6k6xuWybZuSR9OO9Ht6fdB7Gp2LureGXu7hIZIhIzqZA3XGODWLonw3WDxNZ6h5e2MP5ygdM571q6f8VNJ8yKa70/VLeIxlfMNq7ANnnkDntWxbfEvw7IAsA1KTA48vT5m4/BaPb0+4exqdjpdcjaWykEbANEQc+2P/AK9cm1hPN5s23YoTYoPTcTyalufiLpH2ed4LHWZJTwqnTJgHPbnbTYPiFo7WypJp+tqSASv9lzHk8n+H1o9vT7i9jPsQXVnOiQTOhwcg+/qartbBN8zKQJcKc9ug/nTNX+IFhPKEj0vWiphwAdPlGG3Anjb6Dr71n3vj+1Z2M2hassbZ8tDZSDDD3xz60e2p9w9jPsbllaMyOiZYqgOPo3Jq1Hbhnk2xEZznjqOK5z/hZ2g21lHttNQS5C7JGNsygE9Rk/jVgfFbRhuC2GpMrHCn7M3C49ffFHtqfcfsanY0Y7R037FbLZ69hUqWDedH5ak7SAT2yckiucuPippP7821jflpF2kGBsoeKdp3xW0sWUEdxp2oLcsxDkW7EHGcMMdT7Ue2p9w9jU7F/UvDUV5Escke5vOBPtjJB/nWQPDMtmZwi7g7tIuRkh84/lV1Pippk11G0GlakQwKZW3ZsYyc4A5p1v8AE/RW1uWO9s76C3MUbqz2r7wwzn5cZxyOaPbU+4exqdjp/h/pP9l6fdTbArux2qPQf/Xqzrmmi81BJIoyZHRWfnp71mw/Erw60eLePU5OM4j06Y5/JfWli+Iei+crNaa0rhNuDpk//wATR7en3D2NTsfJf7U0DwfEW0jcHd/ZkWV9Pmf+teM17N+1Nq8Wt/EqC5toriKIWEaKJ4HhYjc5ztYA9+tYulfAz4iatpdnqOneHvOsryFLiCT7bbLvjdQynBkBGQRwRmtE01dGbTTszzOiuq0rwbdS+K9R0TWpRpj6XHPNfvtExhWFSXChTh24wBuAJPUDmtzSvA/hvULA6iniu9XT3vrbT4m/sjMpllVmw6edhQu05IZsjpk8UxHnNFejah8Nojd2droesPfzvrLaJcCW08hYpgAS6ne26PG75jtI2njHNaCeEdH8bXeuaro941lZ29w1taWFjYpPIIYogEmlQSI2HxyyK5LbyR6gHKfCf/kqfg3/ALDVl/6PSv0pr81vhP8A8lT8G/8AYasv/R6V+lNAHgH7a3/JLNK/7DUX/oieviqvtX9tb/klmlf9hqL/ANET18VUAFdZ8LQp+Ifh4SAFTeICPauTrpvh3Mbfxz4dkx0vovxywH9aAPusXdgJptsEW2OR2Rsc5C8H9aomOxutPtbOSJVij+TgcsDz+prGvLpY3hlQ/I0oQ/TBFVReyOIGMhQ9QB6jNAHSB7S3RYkt41ijRkGF7k9apX13Z6hPBK6Kfs2YsY5Jxx/PNYMWr+ZcSo7EFIwWH90jg/jWPNrEcKyyTFVa2RpXb1ycD+VAHf6Hq1jogllURIl2QpPTG1jjP61evvH0KaJcyq6/annEKr6BgcH9K8B1PxGHE0k8gVEdRGmeDkjiuP0vxg82p3jyuQiKZAp/vZIx9BigD6+0DxFCnhFLkyiTYfLO9s44P+FauheIbe8idJZB9ojC7h65A6V8qaN4mkvfB8yQTlGuZ1ZUJ5A2nP64ruPA+tyy3Ftc7vmYFHBPUkYB/TFAHvjatZyyg8fITscjocc4/CpLe9/fXu4gxLtZTn1HP615tPqLLexNG2fJJDjPqvpU2n6s1xDcKkhCMpAYnrjv+dAHX6xf2axGSRI3d1xucdD0rHgmtpZoVnjja3jDMP8Afbjj6Yrm5tSiktC7sXU4IPXocUxNRV0DbwoLYI7hu4oA7fUNRtIYlSGBUyRIxA6legqk08KbCYkYSjcxb1XGD+PNYUupK0StjhRgg9uf/r1ka5rgsrdFU5cx/u89CRyc0AdYNVs7a6uJokjDyTM2PfI5/pWb4r8ZWJVrWQIsdwQmcDpgk/yFeVah4oDyq4RlBkBXnn1/xNeafErxHI+oW7RO2CN6EHgrggg/oaAPcPAHi8L4iVorlpLWJSmzeSBz0PpXui6tbSWyzRSKQ0Xmrk9s4r4G+HettY3t3bB2BmhHJboQSSfqRXvug+JHbSbZJXKGK1C789ieV/HNAH0DcalaQorNOhDgkYOc8VBHqcDiIxuQZGG0HuteRDXoRZ2wG4ELjd6e9atlqZjs7FjL+/Bx+I4/rQB6HqmqJHGyRlWJVgQT2rNOp27qtwI48qxXGOegrhZdXae/UksGkXGAPU//AFjSSX7rDOqqQ65zz2zQB2KPYzxzM8aLKXLDA7tzn9P1o067tLNEmaJB5A+UBehPHH41xWm6yl08hR/kV2ifPqDx/KrUeoLLpsM3OzJkz3I7CgDZm1CzVmijiTM/mRNxzgjb+lWJNVtYoXtSFwG818d8KOf0ryrxDrLac0EglO4s3Tr8zd64zxL48/0uBYpWB3kEKeSue/4A0AepfELxHYWc0Txqq3UyIIlHGPm3cfrXfeCvEkMngu0upZTPJyGK9Wyepr4q8Y+MZtb8Tx3sE7tbxAKg6DIOa9l+FGqyLYXdv57PG7CRFY9E280AfS1rq1rOk7LKMRc8nt61AusW0l6lueXOCp+vevKl1H7FabyTuxv2jk8k1MniEG5dhglkZFPpgZoA9IGpWz2N4Y2jdpJGAXqGzwP5VkS3cDTSFY1PkMhKqvQgDGP51zGm6iscWEPybcg+/wD+umz3jwpJ+8H3iWyaAOn1PVYLmJhIFITAf3G4GqtpPZq2+4jidEVdgIHJByB+Ga5G61QOzQY2vvVQT3GCc/Q4qpPfGPSojFIpmiAZVJ+9znP6UAemR6pbC8kuFhj8yYYbjPC9Kz9P1S1tfIARDIFDnjocmuT0u/N5G1yWwH+bYP4cDkfnmqOoap5N1cQR4yICcjqODgUAevaRrVrcxYV9gjXJye1YOp+K47DXcyShbfuM8EYwCfxrw6x8dG214WquSXO11J5ReuPzNZXjDxlJdatqcS/eXCKewG4f4UAfR+keJLUXUcIdBHPI0ivnjFbN7rdpF8qSB2yPoecV8r6P4kuIZdLWeT93HISQx6Keg/SvRF17zI7aYvthBOSe+DgUAezPqdvC0au6lnc7D7U641W2gUFpQwLYyOcV5mNRE0ls7N/CD14A4NOv79hKzIRtYcn3z2/CgDr5dcjAWeOMAxBo0GeDkjn9BQdeGZGVEbHyNn0AOf51xmoXcls7BACoiLhuw471zaa7FJPcjeyvOVIycAYHNAHp9jrsAt5FOwyQMFVu4HOf6VBqGp2rxRzSJGiBwVwOrL/+s1wNvf8A2TTX+YSSyOTs78nioLrXVt7HyyfMePA8vuT3IoA7GfV7SO1iE4VP9ILjPT5myf5CvPb3xgmm+Imj0yYwLMdimMjgc/z6VxHjvxU6Wl7BaSnzQ7Sjd24/+ua8htNVuLLULe4llaYq3zBnzt5x/wDXoA/Qbw1rlpd6DZyLOm/aqMC2SDitVdRthbNIZRhBzk9TjP4184eBdbkaEK0qqjyBTg/dypP9BXaNq8n2QbwFfeEGTnOMc/rQB6YdctzcY3DCuY92en1/GmXGuWv2NWJ3SZBAPO09/wCteWWOuGK0u1kwGkkDAk9s4/nirtpdDzFEhxBj7h6jOaLAdhq76fdWrW7QQsnmbmUjvnOayhNbw24gIQpFcmVfUr1x9Oaybza8kb7mUugA59DWTc3yFCZJM7j5bAHp0/nQB08zWgnDW8CAtKs74GdxJwfw6Vcu9XtEihgjghFwjN5b7R94HP8AU1yNrqkMmoTxBiGhULnPBBHasfxDros0cgYeAswJ7/KP55/SgDv7DV4LG1hjaNRIkRd9o5UkkH881z/inXbKOC9u2WPzjFH8zDkqMkgfkK4h/E8trZ/bpE3JIr9e5xkH8MmvLPG3jA3GiDT0naS48xJAynkcHI+lAH0Z8NvEdn/a1vGG8tLh9sa7uCWBP6Y/WvTrzWLe0v3jkcAh41JznIINfEXgTxJeo2mKGG+zuIx8xO50POc+3SvWtN8TXN1qkl9JMWjeQRhCeOvH5UAcF+2HPHdfFKye3lV0GlRfMpyP9ZJXg5r1P9oe5Nz49jzglLNFz6/M1eWupU4YYNAF7QtZv9B1KO/0qfyLpFZdxRXVlYFWVlYFWUgkFSCCDzWnqHjXXtQRI7i7hWKOeG5SKG0hhjSSJSsZVUQBQAzcAYOckE1zlFAHT2HjnXLNr9lnika8knndniUFZpo2jeVSMYbazAdhnIGcVFoXjLXNC0/7FplzBFCJGljZ7SGSSF2UKzRyOheMkADKkHiudooA6v4T/wDJU/Bv/Yasv/R6V+lNfmt8J/8Akqfg3/sNWX/o9K/SmgDwD9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqACtXwy7xeINMkjJDLdRlSBnkMDWVW14QkEfifR2YAot5ETnp94UAfUp1NpbaK5BJVGMhT09P1/nWXqmo7dJgdmKC2co5B5JC1FNqcL6VcxghfmdUA6gBuD+Yrj/EV3cLocKxuC08jvnP3sLzQBvT6y51CSQHHmp8w9SSTj9K4+98QGSWeKaRy7W5kc9mUnAqEasp8oOx8yQDf/ALJYHA+uK4LUr2eaaV7hgkuzygo9AaAL2qao80cpQsQrpuPbIHPH1IrFa8uIru4lOBLIjRvxyATyac8gKMCSyOgX3J7H9KhZhJdE7hk8Nn2H/wBagDoPDeqi2to7WUfuxvYOeqnBwP513Xwp1lybSGZmASFjuPcljg/hXlVo6xzib7sYQsEbueldH8P777Nq6rLINnkbVHpk9PzoA+jLfU/L1CCKQ5laOFZm65LHAp+i6pvutQjnYA28xjA7d+P5V5veeIp4daijUKVFxYxDnlgTz+Wav6dq7S3XiGTK/ubtHGO5yQaAOyE7izuBCcrI22Mf3T1P86uSvjyYY1OVQMDjqcYz9eK47TbqRdPTyyXZmVmOfuvkk/pirk+oXK3ieWfmCkFu2eM0AdG+pbLNJGfMjQlmB7E4xXB+PvEK21xZIHwoYKwJ+7uGeKhl11To08pYO5GAPU7j/LbXnnj68e4ngeTG1QZBnvlBgfXk0AWvEHiF1ljSHO91IUjnD9B/M1yWuzRm1sFXO/ySGJPB54NQ+a8tw1yzEeXjHsSKr3VwkscCbeYUKnPWgB+nM4n82MlTtIHc9K9l0HVgYrW3uH+ZoxkemM4/UV4xDIIZimeMgBh2HBNal9rBi1Oyk3Pm3Uhyv8QySD+tAHt2r6+lvNEgIQSZcg9AQelb+laq1zb6PMBhmleKVffAOfzxXhfiHWhJNdWrMH8xBhj1jJwSa7HwHf3L6No7yTlpf7VlhBPG8BU5/SgD0a81iWPULqSMjakLLjPcH/65qa/1WWGxuA+N+wDdnk8DJrlFneTUruJ8JvlJYnpgc4/SmajdF7G4yxLKxkUHurMBigDftLuOztFYS5eaQuVPYnOCfxIqK88VwCaxiL7IN+0KTjO1CSPzriNS1WOCBrmUsGjyCnqMgZ/MVzOqzPBYxNLueRIZGLnoHIIz+RFAGt4i8SwXt9PI8jgFzHgHPUkZ+lcXf6glzD9nWXCi4EwXIzyoB569BWPJcyxWkMKLg8gkjk1DPJFhBHjqOe4GB/hQF7DFwkZwSP3mT3x15Fe0fB7VPtLB0f8AeRx7ZAw6nBzXiq/P93GSThfx6V3XwzvTpsl5MrKFJO8A9FCk/wCNAHv+o6vBHpTXSfM0ZPGOdwHHFc3YXp/4Se0RG3pM5yCeBlCf8KyX1MTaZEI3BLkNv6glh/8AWFcv4Y1h28b6RZjAxcTDJ6EKjY/X+VAHpmha+TpcUqSZBDxDPcqeGNbeqztJCUAKsSrbvUnGK800a/RNIsSuDvuWt3HowAY/zrvNRnzDGPM3koAAD93AGD+ZoAr+JdTFncQ3DJ0AY5PbHT8653UfECWkSPJIF3bsKexx3/lUHjK5M1lFhsmM4dT1I5/rXLT3Ec9hunUP50OVP+7/AJ/SgDsbLxPJb3jPE3ySWpYgdPlGf6GqXiDxWItS1nZJkrYCWPHPBxgj+VecX93c20t+jSeXBgLGvdgRgD8c1zcl5PPcmaRyZBH5XB6KOAP0oA09P1O4n1drpSTPO5LHPQY+X+tV5Nbkk1KWYnd5zxu/OQApOapWt4sEEmwsspKshA6Hn/GoZmCyARja33MH3oA7v7fDJL9onlLxCWLyIxwefm5/DNei3WsQnw/ECWWRGyoPHGTxXgUl5vvo5uQflDAeo4Fd9rmtrJcxwOwTyRFIMdGXnP8AP9KAPWbPUZbrWvDunpIyreWJkkx32jNbl9estvLICc4CR+xPX+VeVaBrRfxX4GuGYiR9PkRl7YyQD+ldNq2ps15CIG+QSYYnoo/+vQB2lzePcWKqGMbzKE57HaeP0rlNSkEUy7gPMgA+T1BHX8s1rXN4AscT8yh0+Uepz0rj/E1+Y7hXRS0xVdy9CeccfrQBbOrB55JE3jYu4L7nIFczqfiRY78yq4ZUjWPrnByBk/iKp6nqUlrqEYQDc8ylMHqgzn8q4K6uXkuZ4on2xmVpCxPOM5H9aANvxHqkGq6jcLHJy8YG/PykjqK4yM7w5dgAT3/iqZiqqII2Gwqenc44/WoWU7UiwASMn24oA9h8E6rH9jMpJMahVZR2+Xb/AD/nXoTao0OmXD5JAkwMnoDj/GvD/AmoxWXmpNwJSME9DwcfrXe6tqQa35J8slen9447fhQB1OmXw23WCWMkRYbu2SDWvdXiw6vYSAEzyqsf3uq9cY6fjXmehaukx1HDkqlmzcH/AGlzj8P51t6rfPLqWkT7uJYUD7T90knH9KTSe402tj0XWNQY20Ri+aeMIqgn35rn9Ru4mkUqcoiEls8Eg9Pr1qxqEnnQG4bKkuoOOmMcmuL12WWCI+VIrpvdmB+nBpiJH8QeTIw3AsWWIgdsdAf0rB8Y+I5h9oiUgyM6ugJ+6ig7vz5rEW4U39yplCh5RubPQkAZ/OsTxKJG1SY+YG8qPyCc+vJ/nQB1/iPxBHaWump5hkj8piyj3BI/nXlpfeYSxKkdD6c06Wdp8eY7EKAMsehwB/SojtViwPzbs9c8Ef40Ab3hG8Ntr0ZJURsmQSfvY5/xr0bQNRVzK0HIN7lB/s8c/wA68mtoQ9/ax52KCCwB/hPWtjQtTe0vN1tISDdM5U/3aALPxfmMnitGJ3MsCg/99Mao678RvFWveFLHw1quqefolkIlt7b7PEuwRrsT5lUMcLxyTnvTfiFIbnWo7jB/eQA4+hIrlDxQAlFFWLazubqO4ktreaaO3TzZmjQsIkyBuYjoMkDJ7kUAV6K04NB1i40ebVoNKv5dKhbbJepbO0KHjhnA2g8jqe9E+g6xb6PDq0+lX8WlTNtjvXtnWFzzwrkbSeD0PagDY+E//JU/Bv8A2GrL/wBHpX6U1+a3wn/5Kn4N/wCw1Zf+j0r9KaAPAP21v+SWaV/2Gov/AERPXxVX2r+2t/ySzSv+w1F/6Inr4qoAK0NEkji1axknYLEk6FjnoARWfSg4oA90vPEGixRIE1C1di53FZAcDGf5iuY1LW4LiC2t4ry23bGfzN/CNzx+NeZZPrRmgDtbu/sEt7mGGRHVpEVXVucqPv8A0zXPXE6NLL+9DbhgntnPP9Ky80UAW3lUKpTaTxjnoRS+YgL7ivTiqVFAF0SKJVaRgyquCAevtVjSLwWl7DOrAeXnr71lUoOKAOx/tZLvxXplxNMojE8Bck4CgMMk/lmup07WtMgvPEm67gWJrg+SxcYmUuxyPUdK8lyfWgmgD2jQvEmn2+nJFcajbJICTnzOpJOT+taU/iTS43vGi1axff8AvIx5o68cV4LmigDvF1iNUZFuo/muGVQTkBOcn9a5+51E3bH7U8bCLcqevOB+QArDyfU0ZPrQBelfHG5CuQcA/hmms4bytxG4DJIqnRQBYEgzkt0zk+tPMg3h2flVGNwzmqdLQBfkuBNOrSE7mY7n9R2Ndt4U1q1t9H0i1uLhImh1VpSWbGFZRlj7ZFedZoyfU0AezXPimxbVL1kvbcp5gKN5gwy7iD+nNXtU8QaVd2M0SarYoSAisJR90Hr+teF5PSigD0LxDf2upZt4ryBAqOhl8zggcr+ZrI1/VTIvlxToyNuyAc5yoHPtxXKZPrRknqaANB5EdpQZRx0Oc5+lMf7INPjC+d9tEh3NkeWUxxgdd2c+1UqM0AWY5GVgxKk9Tn61p6fcLbiV0lVQyEFScZJBFYVLk+tAHpPhvxBDDoU0cs8UdxGSIkkbBwFGPwzWJ4e1eODxfpl1K6pFA7BnY4zlTk/TmuRyfWjJHOTmgD1PTdfsjoFkJp4oZ1vZSULchNi4Yj3xXoEvinw/PbQMdXsVl/izKOue/wCGK+bM+9FAHsvirxHp11A0lre24lZPuLIDypz+vNccuoW/mptulELRYCF/9WW9PzOa4vJ9TRk+poA6LWNRS51AM8ivAAFXaew4yffNZtvLsUkEFyoU5HvnNZ+TRk+poAuGUIQAwKkjPHSgvuOA4z0yf51TyaKALQYZkOQcHjPr3q+12xhjZpQ7MAoy3KqMjB/nWNmjJ9TQB6Fouq2ra34K825hgjtEEc8jNgIN7dT24NdPqOv6bc3MuNRtUO4HIkAB57V4tmjNAH0Hd+KdHe4ilGq2eIVXkSjLEN/h/Kua8R67YXOsxlb63a3jjV9yOOTuI2/XBryHNFAHe6xqttLcBjPFJuf76NkJxz+Brk72ZDcPLGQzOT09MVnZPqaM5oAvSCJVQwSAMrE5J7f5zSGQyHLuo6/Njr6VSooA2bTUFgt3QiPAkWRe5GDXQ6p4h2i3a3nSSOVFwm7/AFbAY+b0NcJXc+AVsrnwv44gutLsp7iDSftUF5IrNNCwubdMJltoBDtzt3ds4yCAR+D76G2m1Zbq6jjhNjKib5ANxJBAHqeP0rVk1q0ij8PyRX6NcfZIUuQZAUXBPUdd4z+VbWhafZHSfD+lf2Vp82l6j4cv9RvL97RGnWeP7SQ6zkbk8swxLtBAOTkHdUmr6ZYtYa9o40qwi0nT9A06/s9QjtESdp5TbZczY3P5hmlG0kgYGANtKw7nSReKNElsJZZtbsvNOQsRmAwMccVxvinxDYz5mt72B25iISQHjbwav6z4J8CabeaxGYfE0iaZr8ehN/p8AMxfzD5oPkfKF8p/lwd2RyvOI7H4c+GIdR0/StWm1qW9vtW1HTEntpoo44xbEBXKNGxYkkZG4fXjBYjgLi/WXM0ckUbNhiu/t6fXBqhq1yJbqcwy5jZ+MN+R9673SPDOgHUPDfiCxhvl0NYLrUb62vpklYLav93eiKMSHy0xt4L4yetNvfDun674TvvElxLf3XiW5gm1S7U3CQiMmY/MIZIwZYyCD5iSHlsbflNAHnhkX5ACMkc896azZDHcuMcDPeqdFAGhFcBGjkZwTlQxzyF706G4S2kEiFWBZsqOwIwKzansrS5vpjDZW81zKEaQpEhdtqgsxwOwAJJ7AZoA09auRdz2JR1bbbIhxzg8kg/nXZ2H/CnhYWv9r/8ACf8A9peSn2r7J9j8nzdo37N3O3OcZ5x1riNL8Oa7q1jPe6Vo2p3tnBnzp7a1kkjjwMncyggcc81HDoOsXGjzavBpWoS6VCdsl6lu7QoeOGkA2g8jqe9AE8snh6LxJctFa6tdeHxI/kRNcRwXRT+Dc+x0B6ZwpHpiu3+HjvdaD46sbHUbfT9IvrAxWthqWt28W+4+0QMpIdowzCNX/ebAOo4zivPNX0q80e6S21GHyZnhiuFXcrZjkRZEOQSOVZTjqM84NUaAPZNC1CyGk+H9WOq2EOl6b4cv9OvLB7tFma4k+0gIICdziQzRNuAIGOSNtGv6hZNpXiLVl1Wwk0vUvDun6dZael2jzLPH9myjQg7k8swyncQAc8E7q8booA6v4T/8lT8G/wDYasv/AEelfpTX5rfCf/kqfg3/ALDVl/6PSv0poA8A/bW/5JZpX/Yai/8ARE9fFVfpp418HaF430qLTfE9j9usophcJH50kWJArKDlGB6MwxnHNcV/wz58MP8AoWf/ACfuv/jlAHwBRX3/AP8ADPnww/6Fn/yfuv8A45R/wz58MP8AoWf/ACfuv/jlAHwBRX3/AP8ADPnww/6Fn/yfuv8A45R/wz58Mf8AoWf/ACfuv/jlAHwdrOl3mi6lNYanD5N3DjfHuDYyoYcgkdCKo1+gl18Bvh1e3DXF9oU91cPjdNNqV07tgYGSZfQAfhUX/DPnww/6Fn/yfuv/AI5Uxvyrm3G7X02PijwNpdnqn/CQfbofN+y6RcXUPzMu2Rdu1uCM4yeDxXL1+glv8B/h1a+b9k0Ke381DFL5WpXS+Yh6o373lTxkVF/wz58Mf+hZ/wDJ+6/+OVMYyU5NvR2G2mkj4Bq7daXeWmm2OoXEOy0vvM+zyblO/YdrcA5GD64r7x/4Z8+GH/Qs/wDk/df/AByppfgP8OpYIbebQp5LeDPkwvqV0Ui3HLbR5vGTyap811b5iVtbn59V1Hw00uz1rxtpthqUPnWk3mb49xXOImYcgg9QO9fa/wDwz58MP+hZ/wDJ+6/+OVNafAf4dWVwlxY6FPa3CZ2zQ6ldI65GDgiX0JH41NWMp05Ri7Npjg0pJvY/Pqivv/8A4Z8+GH/Qs/8Ak/df/HKP+GfPhh/0LP8A5P3X/wAcrQk+Dv7LvP7F/tbyf+Jf9o+y+buX/Wbd23Gc9Oc4xVGv0F/4UN8Ovsn2T+wp/se/zfs/9pXXl78Y37fNxuxxn0qH/hnz4Yf9Cz/5P3X/AMcqY31uN26Hwp4WtYb7xNpFpdJvt57yGKRMkblZwCMjkcHtR4otYbHxNq9papst4LyaKNMk7VVyAMnk8DvX3dD8AfhrBKktv4deKaNgySR6jdBkYHIIPm8EGib4BfDWeV5bjw68s0jFnkk1G6LOx5JJ83kk1PK/ac19LDuuW3U/P2r1rpd5d6bfahbw77Sx8v7RJuUbN7bV4Jycn0zX3j/wz58MP+hZ/wDJ+6/+OVNH8Bvh1FbzW8OhTx28+POhTUroJLtOV3DzecHkVUua3u/13/ASt1Pz6or7/wD+GfPhh/0LP/k/df8Axyj/AIZ8+GH/AELP/k/df/HKoR8UeOdLs9L/AOEf+ww+V9q0i3upvmZt0jbtzck4zgcDiuXr9BLj4D/Dq68r7XoU8/lIIovN1K6by0HRF/e8KOcCov8Ahnz4Yf8AQs/+T91/8crOlGUYJSd2VNpu6Pg7RtLvNa1KGw02HzrubOyPcFzgFjySB0BqjX6C2nwH+HVlcLcWOhT2twmds0OpXSOuRg4Il9CR+NQ/8M+fDH/oWf8Ayfuv/jlV73N5f1/wBaW8z4ArqP7Ls/8AhWX9reT/AMTD+2Psvm7j/qvJ3bcZx15zjNfa/wDwz58MP+hZ/wDJ+6/+OVN/wob4dfZPsn9hT/Y9/m/Z/wC0rry9+Mb9vm43Y4z6VNSMpWs7aji0r3Pz6qxZWs19eW9pap5lxPIsUaZA3MxwBk8Dk96+9/8Ahnz4Yf8AQs/+T91/8cp8PwB+GsEqS2/h14po2DJJHqN0GRgcgg+bwQat3toSvM+BL21msb24tLpPLuIJGikTIO1lOCMjg8jtUFfoFN8AvhrPK8tx4deWaRi7yPqN0WdjyST5vJJpn/DPnww/6Fn/AMn7r/45Qr21B+R8UaBpdnd+CfFV/cQ77ux+yfZ5NxGzfIVbgHByPUGuXr9BY/gN8Oorea3h0KeO3nx50KaldBJdpyu4ebzg8iof+GfPhh/0LP8A5P3X/wAcqIRknJt7vT7kVJppW/rU+AKvanpd5pf2T7dD5X2q3S6h+ZW3Rtna3BOM4PB5r7x/4Z8+GH/Qs/8Ak/df/HKluPgP8OrryvtehT3HlIIovN1K6by0HRF/e8KOcCqfNdW2ErWPz7rqPhppdnrXjbTbDUofOtJvM3x7iucRMw5BB6gd6+1/+GfPhh/0LP8A5P3X/wAcqa0+A3w6srhJ7HQp7W4TO2aHUrpHXIwcES+hI/GpqxlOnKMXZtMcGoyTex+fVFff/wDwz58MP+hZ/wDJ+6/+OUf8M+fDD/oWf/J+6/8AjlaEnwdd6XeWmm2OoXEOy0vvM+zyblO/YdrcA5GD64qjX6Cy/Ab4dS28NvNoU8lvBnyYX1K6KRbjlto83jJ5PrUP/DPnww/6Fn/yfuv/AI5Uxvb3v67Dduh8AV1HxL0uz0XxtqVhpsPk2kPl7I9xbGYkY8sSepNfa/8Awz58MP8AoWf/ACfuv/jlTXfwG+HV7cPcX2hT3Vw+N002pXTu2BgZJl9AB+FS4y9opX0s/wBP8mNNcrXX/hz8+qvWul3l3pt9qFvDvtLHy/tEm5Rs3navBOTk+ma+8f8Ahnz4Yf8AQs/+T91/8cqWL4DfDqK3mt4dCmjt58edEmpXQSXacruHm84PI9KqXNb3f67/AICVup+fdFff/wDwz58Mf+hZ/wDJ+6/+OUf8M+fDD/oWf/J+6/8AjlUI+KPHOl2el/8ACP8A2GHyvtWj291N8zNukbdubknGcDgcVy9foLcfAf4dXXl/a9CnuPKQRR+bqV03loOiL+94Uc4FQ/8ADPnww/6Fn/yfuv8A45WdKMowSk7sqbTd0fB2jaXea1qUNhpkPnXc2dke5VzhSx5JA6A1b0PxT4g0GGSHQtd1XTYpG3ulndyQqzYxkhSMmvuy0+A/w6srhLix0Ke1uEztmh1K6R1yMHBEvoSPxqH/AIZ8+GH/AELP/k/df/HKr3uby/r/AIAtLeZ8Jwa9rFvo82kwarfxaVMd0lkly6wueOWQHaTwOo7V1Et3eTfByEzahqEkcGs+RFA13KYY08kvhYt2wHcScgZ5619if8M+fDD/AKFn/wAn7r/45U3/AAob4dfZPsn9hT/Y9/m/Z/7SuvL34xv2+bjdjjPpU1IylaztqOLSvc+CZ9Z1Sdp2n1K9kae4F3KXnYmScZxK2Ty43N8x5+Y+tWrPU9d1DVbKO31K/kv2uWa3Y3TBhNKQGYMTwzHGWyM9zX3N/wAM+fDD/oWf/J+6/wDjlPh+APw1glSW38OvFNGwZJI9RulZGHIIPm8EGrd7aErzPhefU9a0u1v9Amu5o7cE209sWDqu2QMyg84G9QTtOCVBOcCoj4j1s6L/AGOdZ1L+yP8Anx+1P5HXP+rzt689K+7ZvgF8NZ5XluPDryzSMXeSTUbos7HkknzeSTTP+GfPhh/0LP8A5P3X/wAcoV7ag/I+KNA0uzu/BPiq/uId93Y/ZPs8m4jZvlKtwDg5HrmuXr9BYvgP8Oorea3h0KeO3nx50KaldBJdpyu4ebzg8j0qH/hnz4Y/9Cz/AOT91/8AHKiEZJybe70+5fqVJppW/rU+AK9S+EtnquieJHF5qFtpWn6ho9zJItzqkNtHcpLbTJBkNIA/7wrxyVPJx1r6t/4Z8+GH/Qs/+T91/wDHKmuPgP8ADq68r7XoU1x5SCKLzdSum8tB0Rf3vCjnAqnzXVthK1j5E8E6Zq2mW39q2Gv6Quo6ZeyJZWMmt2sSxTYw9x+8lVWXhQpTcHxydow25o17ZxaboOpNq2nRabpfh3UNMvLA3sfmvcP9pGxYd26QSGWJt6grxyRtr6Z/4Z8+GH/Qs/8Ak/df/HKP+GfPhh/0LP8A5P3X/wAcqhHzp4tvdMvdFmfUJPDNzYnQ9Mh09rZ7aS/N6sdurBihMwVVEqsHwuAABnFb+sQeHNP+IF1aeJLXwfb2kPiRU0+C2S0Xy7RfNEouRH0T/VfLL8wbOAACK9tX9n74YqQR4aII5BGoXXH/AJFqW8+A3w4vrua6vdAluLqZzJLNLqV27yMTkszGXJJPc0AfMOieItF1G18MR6rYeEoft/2+HUythbQsiKp8nkKDEctww2s20ZJxXjFff/8Awz58MP8AoWf/ACfuv/jlH/DPnww/6Fn/AMn7r/45QB8V/Cf/AJKn4N/7DVl/6PSv0przXSfgb8OtI1Wz1LT/AA95N7ZzJcQSfbbltkiMGU4MhBwQDggivSqAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Echocardiographic still frame demonstrating the Doppler determination of pressure gradient across a membranous ventricular septal defect (VSD). The dotted cursor line denotes the angle of the continuous wave Doppler beam used to obtain the velocity across the ventricular septal defect. The velocity (v) is 3.6 m/sec and based upon the modified Bernoulli equation (pressure = 4 [v]",
"    <sup>",
"     2",
"    </sup>",
"    ), and the gradient between the left and right ventricles is 53 mmHg. Note that this envelope is m-shaped, and the use of a mean or end systolic gradient may be more appropriate in this patient.",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14839=[""].join("\n");
var outline_f14_31_14839=null;
var title_f14_31_14840="Epidemiology, risk factors and microbiology of infective endocarditis";
var content_f14_31_14840=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, risk factors and microbiology of infective endocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/31/14840/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14840/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/31/14840/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14840/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/31/14840/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14840/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/31/14840/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estimated 10,000 to 15,000 new cases of infective endocarditis (IE) are diagnosed in the United States each year [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the precise incidence of IE is difficult to ascertain because case definitions have varied from decade to decade, among different authors, and among different medical centers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/2\">",
"     2",
"    </a>",
"    ]. Furthermore, the incidence of predisposing conditions (eg, rheumatic heart disease and injection drug use) has varied over time and among different areas.",
"   </p>",
"   <p>",
"    As an example, the incidence of IE among patients admitted to hospitals in Philadelphia and the surrounding area was estimated to be 11.6 cases per 100,000 person-years from 1988 to 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/3\">",
"     3",
"    </a>",
"    ]. By contrast, the incidence of endocarditis in Olmsted County, Minnesota, during the period 1970 to 2006, was 5.0 to 7.9 cases per 100,000 person-years. The incidence of IE in men remained stable during this 36-year time span (ranging from 8.6 to 12.7",
"    <span class=\"nowrap\">",
"     cases/100,000",
"    </span>",
"    person-years) but the incidence of IE women increased from 1.4 cases to 6.7",
"    <span class=\"nowrap\">",
"     cases/100,000",
"    </span>",
"    person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Other studies have reported incidence rates ranging from 0.6 to 6.0 cases per 100,000 person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. One review of 15 population-based epidemiologic studies of IE found that crude incidence rates ranged from 1.4 to 6.2 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sex and age have an impact on the incidence of IE. Men predominate in most case series, with male-to-female ratios ranging from 3:2 to 9:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The epidemiology of endocarditis in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27896?source=see_link\">",
"     \"Infective endocarditis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    New trends in the epidemiology of IE have occurred during the past 30 years. Most of these changes relate to the numbers and types of susceptible hosts, rather than to shifts in the virulence of the infecting microorganisms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endocarditis is becoming more common in older adults [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/9,12,13\">",
"       9,12,13",
"      </a>",
"      ]. More than one-half of all IE cases in the United States and Europe occur in patients over the age of 60, and the median age of patients has increased steadily during the past 40 years [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/9\">",
"       9",
"      </a>",
"      ]. This trend is probably due to two factors: the decline in the incidence and importance of rheumatic heart disease as a risk factor for IE and the increasing proportion of elderly individuals in the general population. Older adult patients are more likely both to develop degenerative valve disease and to require valve replacement, both of which are associated with an increased risk of IE.",
"     </li>",
"     <li>",
"      Characteristics of patients with S. aureus IE vary by region. In the International Collaboration on Endocarditis-Prospective Cohort Study, patients in the United States were significantly more likely to be hemodialysis dependent, to have diabetes, to have a presumed intravascular device source, to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      , to be infected with methicillin-resistant S. aureus (MRSA), and to have persistent bacteremia [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The International Collaboration on Endocarditis-Merged Database (ICE-MD, a combination of seven existing electronic databases from five countries that contains data on cases of definite IE) analysis found that diabetes mellitus was an independent predictor of in-hospital mortality among patients hospitalized with IE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a second analysis of the ICE-MD of patients with native valve IE, 566 patients (34 percent) had IE due to S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/16\">",
"     16",
"    </a>",
"    ]. Compared with patients with IE due to other organisms, patients with S. aureus IE were significantly more likely to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Die (20 versus 12 percent)",
"     </li>",
"     <li>",
"      Experience an embolic event (60 versus 31 percent)",
"     </li>",
"     <li>",
"      Have a central nervous system event (20 versus 13 percent)",
"     </li>",
"     <li>",
"      Not undergo surgery (26 versus 39 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A multivariate analysis identified the following prognostic factors as independently associated with mortality in patients with S. aureus IE: increasing age (odds ratio [OR], 1.4; 95% CI 1.1-1.7), periannular abscess (OR, 2.4; 95% CI 1.1-5.6), heart failure (OR, 3.9; 95% CI 2.3-6.7), and absence of surgical therapy (OR, 2.3; 95% CI 1.3-4.2). In addition, there was regional variation in outcomes, which were probably multifactorial and not wholly understood.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with patients with S. aureus endocarditis, patients with enterococcal endocarditis in the International Collaboration on Endocarditis-Merged Database are less likely to embolize (26 versus 49 percent) and had a lower mortality (11 versus 27 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The local or regional incidence of IDU has had an impact on the overall incidence of endocarditis. As an example, the incidence of IE in IDU in Philadelphia and the surrounding areas has been estimated to be 5.3",
"      <span class=\"nowrap\">",
"       cases/100,000",
"      </span>",
"      person-years, accounting for nearly one-half of all recognized cases [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/3\">",
"       3",
"      </a>",
"      ]. Similar findings were noted in a study from a hospital in Los Angeles [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/18\">",
"       18",
"      </a>",
"      ]. Drug addiction as a cause of IE is most prominent in patients less than 40 years old [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prospective population-based observational study performed in France during 2008 found that the annual incidence of IE was 33.8 cases per million. The incidence was highest in men aged 75 to 79 years and the majority of patients had no known prior heart disease. Healthcare-associated IE accounted for 27 percent all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of microorganisms can cause infective endocarditis (IE); staphylococci and streptococci account for the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/20\">",
"     20",
"    </a>",
"    ]. Staphylococcal IE is substantially more common in healthcare-associated cases of IE. Streptococci remain common causes of community-acquired IE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/20\">",
"     20",
"    </a>",
"    ]. The International Collaboration on Endocarditis-Prospective Cohort Study identified the microbiologic etiology in 2781 patients from 58 sites in 25 countries with definite endocarditis as defined by Duke criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/14,21\">",
"     14,21",
"    </a>",
"    ]. Most patients had native valve IE (72 percent) and 23 percent were healthcare associated.",
"   </p>",
"   <p>",
"    Overall, staphylococci were the etiologic agent in 744 of 1779 (42 percent) and streptococci in 712 (40 percent). The pathogens included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      S. aureus &mdash; 31 percent",
"     </li>",
"     <li>",
"      Viridans group streptococci &mdash; 17 percent",
"     </li>",
"     <li>",
"      Enterococci &mdash; 11 percent",
"     </li>",
"     <li>",
"      Coagulase-negative staphylococci &mdash; 11 percent",
"     </li>",
"     <li>",
"      Streptococcus bovis &mdash; 7 percent",
"     </li>",
"     <li>",
"      Other streptococci &mdash; 5 percent",
"     </li>",
"     <li>",
"      Non-HACEK gram-negative bacteria &mdash; 2 percent",
"     </li>",
"     <li>",
"      Fungi &mdash; 2 percent",
"     </li>",
"     <li>",
"      HACEK &mdash; 2 percent; Organisms in this category include a number of fastidious gram-negative bacilli:",
"      <strong>",
"       H",
"      </strong>",
"      aemophilus aphrophilus;",
"      <strong>",
"       A",
"      </strong>",
"      ctinobacillus actinomycetemcomitans;",
"      <strong>",
"       C",
"      </strong>",
"      ardiobacterium hominis;",
"      <strong>",
"       E",
"      </strong>",
"      ikenella corrodens; and",
"      <strong>",
"       K",
"      </strong>",
"      ingella kingae.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The remaining cases included culture negative endocarditis (8 percent), polymicrobial (1 percent), and a variety of other organisms (3 percent).",
"   </p>",
"   <p>",
"    The higher incidence of S. aureus compared with viridans group streptococci is probably due to the fact that this study was conducted in large, tertiary care centers and may not reflect the epidemiology of IE in more rural communities.",
"   </p>",
"   <p>",
"    In a study from Minnesota of 150 patients with IE, for example, viridans group streptococci caused 60 of 150 infections; S. aureus caused 40 of 150 infections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/5\">",
"     5",
"    </a>",
"    ]. These results are of limited generalizability, however, because of the relatively small sample size and the demography of the cohort, which was dominated by middle-class white men with a low prevalence of injection drug use (IDU) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The changing epidemiology of S. aureus infections has undoubtedly impacted the epidemiology of IE due to S. aureus. Native valve IE due to CA-MRSA in young patients without known preexisting valvular heart disease is an important emerging infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The low rate of gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae as a cause of IE may be related in part to decreased adherence of these organisms to heart valves compared with the gram-positive organisms that account for most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/24\">",
"     24",
"    </a>",
"    ]. However, in some regions of the world, such as the Middle East, gram-negative bacteria such as Brucella are important causes of IE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors predispose to the development of IE. These include intravenous drug use (IDU), prosthetic heart valves, and structural heart disease. Other factors, especially those related to invasive procedures, have been postulated to increase the risk and form the theoretical basis for antimicrobial prophylaxis. However, a population based case control study from Philadelphia failed to identify pulmonary, cardiac, gastrointestinal, and genitourinary procedures or surgery as risk factors for the development of community-acquired endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients with teeth who did not floss were at slightly higher risk for endocarditis caused by mouth flora than those who did floss and those without teeth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Injection drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the injection itself, specific drugs of abuse may also be risk factors for the development of endocarditis, which often involves the right side of the heart. The pathogenic mechanisms accounting for an apparent association between injection drug use and right-sided endocarditis remain to be elucidated. One large study of injection drug users with fever found that those who used cocaine were significantly more likely to have endocarditis than those using other drugs, whereas another found that use of heroin, but not of other injection drugs, was associated with right-sided endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of right- versus left-sided endocarditis in IDU is controversial. The most significant risk factor for right-sided infective endocarditis is IDU; however, left-sided disease may be more common in addicts. In one series of 67 patients, left-sided involvement occurred in 57 percent of IDU compared with 40 percent with right-sided disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/29\">",
"     29",
"    </a>",
"    ]. The most common infecting organism is S. aureus, particularly in right-sided infection. One report described 132 cases of right-sided infective endocarditis in 121 IDUs; S. aureus was the culprit organism in 82 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/30\">",
"     30",
"    </a>",
"    ]. The vegetation was usually &ge;1 cm in diameter, and there was a marked increase in mortality associated with vegetations greater than 2 cm (33 versus 1.3 percent for smaller vegetations, p&lt;0.001).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prosthetic heart valves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prosthetic valve endocarditis comprises a small but important segment of IE cases that is likely to increase in future years, as more than 100,000 heart valves are implanted annually in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/31\">",
"     31",
"    </a>",
"    ]. Prosthetic valve endocarditis develops in 1 to 4 percent of valve recipients during the first year following valve replacement, and in approximately 1 percent per year thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/1,32\">",
"     1,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The type of prosthetic valve does not have an impact on the development of IE. This was demonstrated in a multicenter follow-up study of patients randomized to receive mechanical (n = 510) or bioprosthetic (n = 522) cardiac valves [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/32\">",
"     32",
"    </a>",
"    ]. The rate of prosthetic valve endocarditis was similar in both groups (0.8 cases per year of follow-up) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Structural heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately three-fourths of all patients with IE have a preexisting structural cardiac abnormality at the time that endocarditis begins [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/4,33\">",
"     4,33",
"    </a>",
"    ]. A report evaluating all cases of IE seen at Presbyterian Hospital in New York between 1938 and 1967 found that rheumatic heart disease was the common cardiac abnormality, being present in 39 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/34\">",
"     34",
"    </a>",
"    ]. In contrast, a later series from Tennessee found that rheumatic heart disease was present in only 6 percent of patients with IE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Degenerative valvular lesions such as mitral valve prolapse (usually with coexistent mitral regurgitation) have become relatively more important as a predisposing cause for IE. As an example, mitral valve prolapse was the underlying cardiac lesion in 22 and 29 percent of cases of IE in two reports [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. The risk of IE in patients with mitral valve prolapse and associated regurgitation is estimated to be five to eight times higher than that in the normal population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. However, mitral valve prolapse without mitral insufficiency is a more common abnormality that is associated with only a small risk of endocarditis.",
"   </p>",
"   <p>",
"    Other underlying disorders that are present in IE are aortic valve disease (stenosis, regurgitation, or both) in 12 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/38\">",
"     38",
"    </a>",
"    ] and congenital heart disease in 10 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/39\">",
"     39",
"    </a>",
"    ]. The most common predisposing congenital heart lesions are bicuspid aortic valves, patent ductus arteriosus, ventricular septal defect, coarctation of the aorta, and tetralogy of Fallot.",
"   </p>",
"   <p>",
"    The risk of IE appears to be dependent upon the specific congenital or acquired cardiac lesion. One study, for example, evaluated 2401 patients with congenital aortic stenosis, pulmonary stenosis, or a ventricular septal defect who were followed prospectively for 40,000 days [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/40\">",
"     40",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall incidence of endocarditis was 135",
"      <span class=\"nowrap\">",
"       cases/100,000",
"      </span>",
"      person-years [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The highest rates of endocarditis occurred in patients with aortic stenosis and ventricular septal defects (271 and 145",
"      <span class=\"nowrap\">",
"       cases/100,000",
"      </span>",
"      person-years, respectively). Among patients with aortic stenosis, the peak gradient across the aortic valve was linked with the risk of IE; the higher the gradient, the higher the risk of developing endocarditis. In another series, the risk of IE with aortic stenosis was approximately twice as high as with aortic regurgitation (73 versus",
"      <span class=\"nowrap\">",
"       40/100,000",
"      </span>",
"      person-years) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The lowest rate of endocarditis occurred with pulmonic stenosis; only 1 of 592 patients with this lesion developed IE during the follow-up period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of IE also appears to be very low in adults with congenital heart disease, inherently normal pulmonic and tricuspid valves, and pulmonary or tricuspid regurgitation due to pulmonary hypertension. In one series of 186 such patients who were followed for a mean of almost nine years, no cases of endocarditis occurred with the exception of a single habitual intravenous drug abuser [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     History of infective endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prior history of endocarditis is an important predisposing cause for IE. Recurrent endocarditis occurred in 4.5 percent of one large cohort of nonaddicts who survived their initial episode [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/43\">",
"     43",
"    </a>",
"    ]. Other studies have reported rates of IE recurrence ranging from 2.5 to 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nosocomial and healthcare-associated endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosocomial endocarditis has been defined as a diagnosis of IE made more than 72 hours after admission in patients with no evidence of IE on admission, or IE developing within 60 days of a prior hospital admission during which there was risk for bacteremia or IE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/45\">",
"     45",
"    </a>",
"    ]. Other authors have classified patients as having healthcare-associated or nosocomial IE using the same definitions as used to define healthcare-associated and nosocomial bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/5,46\">",
"     5,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10263?source=see_link\">",
"     \"Epidemiology of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Nosocomial IE is usually a complication of bacteremia induced by an invasive intravascular procedure or an intravenous catheter-related infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/45,47-49\">",
"     45,47-49",
"    </a>",
"    ]. It accounts for up to 20 percent of cases of IE in some areas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/3,45,50\">",
"     3,45,50",
"    </a>",
"    ]. Nosocomial IE may be more common in the elderly than in other age groups because elderly patients are more likely to be hospitalized and undergo invasive bacteremia-prone procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/13\">",
"     13",
"    </a>",
"    ]. In one report, healthcare-associated IE accounted for 50 percent of all cases in residents from Olmsted County, Minnesota, during the period 2001-2006. Community-acquired IE accounted for 42.5 percent of the total diagnosed cases, and 7.5 percent of the cases were considered to be nosocomial IE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hemodialysis patients are at significant risk for IE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Predisposing factors in this population include intravascular access, calcific valvular disease, and immune impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/52\">",
"     52",
"    </a>",
"    ]. The incidence of IE in hemodialysis patients has been estimated to be",
"    <span class=\"nowrap\">",
"     308/100,000",
"    </span>",
"    patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. However, the accuracy of such estimates is difficult to assess given potential bias related to variable use of echocardiography for evaluation of access-related bloodstream infections, the infrequency of postmortem exams in hemodialysis patients following bacteremia, inconsistent follow-up, and the retrospective design of most studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of cases of IE have been reported in patients with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. Some valves have been infected with unusual organisms such as Salmonella and Listeria [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. It has been suggested that HIV infection is an independent risk factor for IE in injection drug abusers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/57\">",
"     57",
"    </a>",
"    ]; however, this has not been confirmed in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other predisposing factors for IE include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Peritoneovenous shunts for the control of intractable ascites [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ventriculoatrial shunts for the management of hydrocephalus [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/59\">",
"       59",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IE has also been reported in patients undergoing liver, heart, and heart-lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, patients with ulcerative lesions of the colon due to carcinoma or inflammatory bowel disease have a poorly understood predilection to develop endocarditis secondary to Streptococcus bovis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14840/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29926?source=see_link&amp;anchor=H6#H6\">",
"     \"Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection\", section on 'Association with colonic neoplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=see_link\">",
"       \"Patient information: Endocarditis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2199457\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An estimated 10,000 to 15,000 new cases of infective endocarditis (IE) are diagnosed in the United States each year. However, the precise incidence of IE is difficult to ascertain because case definitions have varied from decade to decade, among different authors and among different medical centers. Furthermore, the incidence of predisposing conditions (eg, rheumatic heart disease and injection drug use) has varied over time and among different areas. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Men predominate in most case series of IE, with male-to-female ratios ranging from 3:2 to 9:1. IE has increasingly become a disease of the elderly. This trend is probably due to two factors: the decline in the incidence and importance of rheumatic heart disease as a risk factor for IE and the increasing proportion of older individuals in the population. Older adults are more likely both to develop degenerative valve disease and to require valve replacement, both of which are associated with an increased risk of IE. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with IE, diabetes mellitus and Staphylococcus aureus infection are associated with increased mortality. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of microorganisms can cause IE; staphylococci account for the majority of cases of healthcare-associated IE. However, staphylococci and streptococci occur in roughly equal proportions of patients with community-acquired IE. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Healthcare-associated IE accounts for approximately one in four cases of IE. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Nosocomial and healthcare-associated endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of factors predispose to the development of IE. These include intravenous drug use, prosthetic heart valves, structural heart disease, and a prior history of IE. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/1\">",
"      Bayer AS. Infective endocarditis. Clin Infect Dis 1993; 17:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/2\">",
"      Tleyjeh IM, Abdel-Latif A, Rahbi H, et al. A systematic review of population-based studies of infective endocarditis. Chest 2007; 132:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/3\">",
"      Berlin JA, Abrutyn E, Strom BL, et al. Incidence of infective endocarditis in the Delaware Valley, 1988-1990. Am J Cardiol 1995; 76:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/4\">",
"      Griffin MR, Wilson WR, Edwards WD, et al. Infective endocarditis. Olmsted County, Minnesota, 1950 through 1981. JAMA 1985; 254:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/5\">",
"      Correa de Sa DD, Tleyjeh IM, Anavekar NS, et al. Epidemiological trends of infective endocarditis: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc 2010; 85:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/6\">",
"      Smith RH, Radford DJ, Clark RA, Julian DG. Infective endocarditis: a survey of cases in the South-East region of Scotland, 1969-72. Thorax 1976; 31:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/7\">",
"      Hickey AJ, MacMahon SW, Wilcken DE. Mitral valve prolapse and bacterial endocarditis: when is antibiotic prophylaxis necessary? Am Heart J 1985; 109:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/8\">",
"      Williams, RC, Kunkel, HG. Rheumatoid factors and their disappearance following therapy in patients with subacute bacterial endocarditis. Arthritis Rheum 1962; 5:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/9\">",
"      Hill EE, Herijgers P, Claus P, et al. Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur Heart J 2007; 28:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/10\">",
"      Lerner PI, Weinstein L. Infective endocarditis in the antibiotic era. N Engl J Med 1966; 274:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/11\">",
"      Watanakunakorn C. Changing epidemiology and newer aspects of infective endocarditis. Adv Intern Med 1977; 22:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/12\">",
"      Cantrell M, Yoshikawa TT. Infective endocarditis in the aging patient. Gerontology 1984; 30:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/13\">",
"      Durante-Mangoni E, Bradley S, Selton-Suty C, et al. Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study. Arch Intern Med 2008; 168:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/14\">",
"      Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293:3012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/15\">",
"      Kourany WM, Miro JM, Moreno A, et al. Influence of diabetes mellitus on the clinical manifestations and prognosis of infective endocarditis: a report from the International Collaboration on Endocarditis-Merged Database. Scand J Infect Dis 2006; 38:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/16\">",
"      Miro JM, Anguera I, Cabell CH, et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 2005; 41:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/17\">",
"      McDonald JR, Olaison L, Anderson DJ, et al. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. Am J Med 2005; 118:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/18\">",
"      Bayer AS, Ward JI, Ginzton LE, Shapiro SM. Evaluation of new clinical criteria for the diagnosis of infective endocarditis. Am J Med 1994; 96:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/19\">",
"      Terpenning MS, Buggy BP, Kauffman CA. Infective endocarditis: clinical features in young and elderly patients. Am J Med 1987; 83:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/20\">",
"      Selton-Suty C, C&eacute;lard M, Le Moing V, et al. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis 2012; 54:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/21\">",
"      Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009; 169:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/22\">",
"      Quagliarello V. Infective endocarditis: global, regional, and future perspectives. JAMA 2005; 293:3061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/23\">",
"      Millar BC, Prendergast BD, Moore JE. Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis. J Antimicrob Chemother 2008; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/24\">",
"      Gould K, Ramirez-Ronda CH, Holmes RK, Sanford JP. Adherence of bacteria to heart valves in vitro. J Clin Invest 1975; 56:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/25\">",
"      Erbay AR, Erbay A, Canga A, et al. Risk factors for in-hospital mortality in infective endocarditis: five years' experience at a tertiary care hospital in Turkey. J Heart Valve Dis 2010; 19:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/26\">",
"      Strom BL, Abrutyn E, Berlin JA, et al. Risk factors for infective endocarditis: oral hygiene and nondental exposures. Circulation 2000; 102:2842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/27\">",
"      Chambers HF, Morris DL, T&auml;uber MG, Modin G. Cocaine use and the risk for endocarditis in intravenous drug users. Ann Intern Med 1987; 106:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/28\">",
"      Jain V, Yang MH, Kovacicova-Lezcano G, et al. Infective endocarditis in an urban medical center: association of individual drugs with valvular involvement. J Infect 2008; 57:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/29\">",
"      Graves MK, Soto L. Left-sided endocarditis in parenteral drug abusers: recent experience at a large community hospital. South Med J 1992; 85:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/30\">",
"      Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes. Ann Intern Med 1992; 117:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/31\">",
"      Grover FL, Cohen DJ, Oprian C, et al. Determinants of the occurrence of and survival from prosthetic valve endocarditis. Experience of the Veterans Affairs Cooperative Study on Valvular Heart Disease. J Thorac Cardiovasc Surg 1994; 108:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/32\">",
"      Millaire A, Van Belle E, de Groote P, et al. Obstruction of the left main coronary ostium due to an aortic vegetation: survival after early surgery. Clin Infect Dis 1996; 22:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/33\">",
"      McKinsey DS, Ratts TE, Bisno AL. Underlying cardiac lesions in adults with infective endocarditis. The changing spectrum. Am J Med 1987; 82:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/34\">",
"      Cherubin CE, Neu HC. Infective endocarditis at the Presbyterian Hospital in New York City from 1938-1967. Am J Med 1971; 51:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/35\">",
"      Weinberger I, Rotenberg Z, Zacharovitch D, et al. Native valve infective endocarditis in the 1970s versus the 1980s: underlying cardiac lesions and infecting organisms. Clin Cardiol 1990; 13:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/36\">",
"      Clemens JD, Horwitz RI, Jaffe CC, et al. A controlled evaluation of the risk of bacterial endocarditis in persons with mitral-valve prolapse. N Engl J Med 1982; 307:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/37\">",
"      Beton DC, Brear SG, Edwards JD, Leonard JC. Mitral valve prolapse: an assessment of clinical features, associated conditions and prognosis. Q J Med 1983; 52:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/38\">",
"      Michel PL, Acar J. Native cardiac disease predisposing to infective endocarditis. Eur Heart J 1995; 16 Suppl B:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/39\">",
"      Bansal RC. Infective endocarditis. Med Clin North Am 1995; 79:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/40\">",
"      Gersony WM, Hayes CJ, Driscoll DJ, et al. Bacterial endocarditis in patients with aortic stenosis, pulmonary stenosis, or ventricular septal defect. Circulation 1993; 87:I121.",
"     </a>",
"    </li>",
"    <li>",
"     Horstkotte, D. Prosthetic valve endocarditis. In: Infective Endocarditis, Horstkotte, D, Bodnar, E (Eds), IRC Publishers, London, 1991, p. 229.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/42\">",
"      Dodo H, Perloff JK, Child JS, et al. Are high-velocity tricuspid and pulmonary regurgitation endocarditis risk substrates? Am Heart J 1998; 136:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/43\">",
"      Tornos MP, Permanyer-Miralda G, Olona M, et al. Long-term complications of native valve infective endocarditis in non-addicts. A 15-year follow-up study. Ann Intern Med 1992; 117:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/44\">",
"      Carrel T, Schaffner A, Vogt P, et al. Endocarditis in intravenous drug addicts and HIV infected patients: possibilities and limitations of surgical treatment. J Heart Valve Dis 1993; 2:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/45\">",
"      Mart&iacute;n-D&aacute;vila P, Fort&uacute;n J, Navas E, et al. Nosocomial endocarditis in a tertiary hospital: an increasing trend in native valve cases. Chest 2005; 128:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/46\">",
"      Friedman ND, Kaye KS, Stout JE, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/47\">",
"      Finkelstein R, Sobel JD, Nagler A, Merzbach D. Staphylococcus aureus bacteremia and endocarditis: comparison of nosocomial and community-acquired infection. J Med 1984; 15:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/48\">",
"      Martino P, Micozzi A, Venditti M, et al. Catheter-related right-sided endocarditis in bone marrow transplant recipients. Rev Infect Dis 1990; 12:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/49\">",
"      Morpeth S, Murdoch D, Cabell CH, et al. Non-HACEK gram-negative bacillus endocarditis. Ann Intern Med 2007; 147:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/50\">",
"      Fern&aacute;ndez-Hidalgo N, Almirante B, Tornos P, et al. Contemporary epidemiology and prognosis of health care-associated infective endocarditis. Clin Infect Dis 2008; 47:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/51\">",
"      Nucifora G, Badano LP, Viale P, et al. Infective endocarditis in chronic haemodialysis patients: an increasing clinical challenge. Eur Heart J 2007; 28:2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/52\">",
"      Robinson DL, Fowler VG, Sexton DJ, et al. Bacterial endocarditis in hemodialysis patients. Am J Kidney Dis 1997; 30:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/53\">",
"      Abbott KC, Agodoa LY. Hospitalizations for bacterial endocarditis after initiation of chronic dialysis in the United States. Nephron 2002; 91:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/54\">",
"      Horstkotte D, Piper C, Niehues R, et al. Late prosthetic valve endocarditis. Eur Heart J 1995; 16 Suppl B:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/55\">",
"      Bestetti RB, Figueiredo JF, Da Costa JC. Salmonella tricuspid endocarditis in an intravenous drug abuser with human immunodeficiency virus infection. Int J Cardiol 1991; 30:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/56\">",
"      Riancho JA, Echevarr&iacute;a S, Napal J, et al. Endocarditis due to Listeria monocytogenes and human immunodeficiency virus infection. Am J Med 1988; 85:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/57\">",
"      Nahass RG, Weinstein MP, Bartels J, Gocke DJ. Infective endocarditis in intravenous drug users: a comparison of human immunodeficiency virus type 1-negative and -positive patients. J Infect Dis 1990; 162:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/58\">",
"      Valla D, Pariente EA, Degott C, et al. Right-sided endocarditis complicating peritoneovenous shunting for ascites. Arch Intern Med 1983; 143:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/59\">",
"      Daly JS, Worthington MG, Brenner DJ, et al. Rochalimaea elizabethae sp. nov. isolated from a patient with endocarditis. J Clin Microbiol 1993; 31:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/60\">",
"      Fowler VG, Durack DT. Infective endocarditis. Curr Opin Cardiol 1994; 9:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/61\">",
"      Klein RS, Recco RA, Catalano MT, et al. Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med 1977; 297:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14840/abstract/62\">",
"      Kreuzpaintner G, Horstkotte D, Heyll A, et al. Increased risk of bacterial endocarditis in inflammatory bowel disease. Am J Med 1992; 92:391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2151 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14840=[""].join("\n");
var outline_f14_31_14840=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2199457\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Injection drug use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      History of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nosocomial and healthcare-associated endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2199457\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10263?source=related_link\">",
"      Epidemiology of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27896?source=related_link\">",
"      Infective endocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29926?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=related_link\">",
"      Patient information: Endocarditis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_31_14841="Diagnosis and staging of non-small cell lung cancer";
var content_f14_31_14841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and staging of non-small cell lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/31/14841/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14841/contributors\">",
"     Karl W Thomas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14841/contributors\">",
"     Michael K Gould, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/31/14841/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14841/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/31/14841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14841/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/31/14841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient presents with suspected non-small cell lung cancer (NSCLC), testing is indicated to confirm the diagnosis, identify the histologic type, and determine the disease stage. The disease stage is a measure of the extent of disease, which is used to determine prognosis and guide management.",
"   </p>",
"   <p>",
"    The diagnosis and staging of NSCLC is described here. The tumor node metastasis (TNM) system for staging NSCLC is discussed separately. In addition, the clinical manifestations, initial evaluation, treatment, and prognosis of lung cancer are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY AND PHYSICAL EXAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who present with suspected NSCLC should have a complete and meticulous history and physical examination performed. The purpose of the history and physical examination is to identify symptoms or physical findings suggestive of locally extensive or metastatic disease, assess pulmonary health status, identify significant comorbidities, and assess overall health status. Each impacts the therapeutic options, patient's ability to tolerate treatment, and disease course in ways that are independent of the disease stage [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=see_link\">",
"     \"Survival estimates in advanced terminal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\", section on 'Prognosis of NSCLC'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most symptoms and signs (eg, cough, hemoptysis, postobstructive pneumonia) are nonspecific. However, some suggest extensive disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic symptoms, such as weight loss, anorexia, fatigue, fever, or depression.",
"     </li>",
"     <li>",
"      New or worsening dyspnea may be due to a malignant pleural effusion (M1a disease).",
"     </li>",
"     <li>",
"      Bone pain (eg, rib, back) may be due to bone metastasis (M1b disease). It is typically well-localized, continuous, aching, and severe.",
"     </li>",
"     <li>",
"      Dysphagia may be due to bulky mediastinal disease (N2 or N3 disease) or esophageal invasion (T4 disease).",
"     </li>",
"     <li>",
"      Neurologic abnormalities (eg, headaches, syncope, weakness, cognitive impairment) may be due to neurologic metastasis (M1b disease).",
"     </li>",
"     <li>",
"      Horner's syndrome (ipsilateral ptosis, anhidrosis, and miosis) may be due to invasion of the last cervical or first thoracic segment of the sympathetic trunk (T4 disease). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/58/14250?source=see_link\">",
"       \"Pancoast's syndrome and superior (pulmonary) sulcus tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hoarseness may be due to entrapment of the left recurrent laryngeal nerve (T4, N2, or N3 disease). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16009?source=see_link\">",
"       \"Hoarseness in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Superior vena cava syndrome may be due to compression of the superior vena cava by tumor or mediastinal lymph nodes. Alternatively, it may be due to thrombosis caused by tumor or nodal invasion through the luminal surface (T4, N2, or N3 disease). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=see_link\">",
"       \"Malignancy-related superior vena cava syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pericardial tamponade may be due to pericardial invasion (T4 disease) or a malignant pericardial effusion (M1a disease). Manifestations include dyspnea, chest discomfort or fullness, peripheral edema, and sinus tachycardia, accompanied by elevated jugular venous pressure and pulsus paradoxus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=see_link\">",
"       \"Pericardial disease associated with malignancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Enlarged supraclavicular and scalene lymph nodes may be due to metastasis (N3 disease).",
"     </li>",
"     <li>",
"      Hepatomegaly or right upper quadrant pain may be due to hepatic metastasis (M1b disease).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The T, N, and M descriptors are reviewed below and in the table (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    NSCLC can cause paraneoplastic syndromes. These are characterized by endocrinopathy, neurodegenerative disorders, metabolic abnormalities, hematologic disease, or skeletal syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=see_link\">",
"     \"Malignancy and rheumatic disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paraneoplastic syndromes do not necessarily indicate metastatic disease. Thus, their presence does not obviate the need for complete staging. Patients with paraneoplastic syndromes should receive disease stage-appropriate therapy and should not be denied specific treatments on the basis of paraneoplastic symptoms alone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/3\">",
"     3",
"    </a>",
"    ]. Paraneoplastic syndromes commonly associated with lung cancer are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef51311 \" href=\"UTD.htm?29/61/30685\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with suspected NSCLC should undergo measurement of a complete blood count, serum electrolytes, calcium, alkaline phosphatase, albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, and creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/4\">",
"     4",
"    </a>",
"    ]. The purpose of the laboratory studies is to identify abnormalities that may be due to locally extensive or metastatic disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver function test abnormalities could be due to liver metastasis and should prompt evaluation of the liver with contrast-enhanced computed tomography (CT) or ultrasonography.",
"     </li>",
"     <li>",
"      Calcium elevation could be due to bone metastasis and should prompt a radionuclide bone scan or positron emission tomography (PET). It may also be a paraneoplastic manifestation of the primary tumor.",
"     </li>",
"     <li>",
"      Elevation of the alkaline phosphatase could be due to liver or bone metastasis. It should prompt an evaluation for bone metastasis by radionuclide bone scan or PET scan if the gammaglutamyl transpeptidase (GGT) is not elevated, or contrast-enhanced CT or ultrasound of the liver if the GGT is also elevated.",
"     </li>",
"     <li>",
"      Anemia could be due to metastatic disease and requires additional evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"       \"Approach to the adult patient with anemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tumor markers obtained from serum or tumor tissue have prognostic significance in some situations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Similarly, the use of genetic testing of the tumor to detect specific mutations or to determine specific gene expression profiles may provide estimates of disease behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/8\">",
"     8",
"    </a>",
"    ]. Serum tumor markers have not been shown to have broad clinical utility in patients with NSCLC and their routine use is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\", section on 'Prognosis of NSCLC'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with suspected NSCLC should undergo contrast-enhanced computed tomography (CT) that extends through the lungs, liver, and adrenal glands. CT is ideal for tumor node metastasis (TNM) staging (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Staging'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It can characterize the primary tumor and define its relationship to the chest wall and mediastinal structures",
"     </li>",
"     <li>",
"      It can identify mediastinal lymph nodes that are enlarged and suspicious for malignant involvement",
"     </li>",
"     <li>",
"      It can detect contralateral lung, chest wall, or upper abdominal lesions that are suspicious for metastasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients require additional imaging. This may include whole body positron emission tomography (PET), integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging, CT of the brain, magnetic resonance imaging (MRI), and radionuclide bone scintigraphy. Each of these modalities and a recommended approach to imaging patients with suspected NSCLC are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=see_link\">",
"     \"Role of imaging in the staging of non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormal findings on imaging tests should be confirmed by tissue sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/9\">",
"     9",
"    </a>",
"    ]. The exception is when imaging alone presents overwhelming evidence of metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TISSUE SAMPLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSCLC cannot be diagnosed or accurately staged via noninvasive methods alone. Histopathologic data obtained by tissue sampling is required.",
"   </p>",
"   <p>",
"    It should be emphasized that sampling the primary tumor is diagnostic only. In contrast, sampling abnormalities that may be related to metastatic sites (eg, enlarged lymph nodes, pleural effusion) can be diagnostic and provide additional staging information. In general, the sampling target should be the lesion that will establish the highest disease stage. Sampling both the primary tumor and the potentially metastatic lesion is occasionally required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several options for sampling a primary tumor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging-guided percutaneous needle aspiration or biopsy",
"     </li>",
"     <li>",
"      Endobronchial ultrasound (EBUS)-guided forceps biopsy",
"     </li>",
"     <li>",
"      Conventional flexible bronchoscopy with forceps biopsy, blind transbronchial fine needle aspiration (TBNA), or both",
"     </li>",
"     <li>",
"      Electromagnetic navigational bronchoscopy (ENB)-guided forceps biopsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Imaging-guided percutaneous needle aspiration or biopsy tend to have the highest diagnostic accuracy. However, the bronchoscopic techniques permit evaluation and sampling of the mediastinal lymph nodes during the same procedure. Among the bronchoscopic techniques, EBUS-guided sampling appears to be superior to conventional flexible bronchoscopic sampling of small lesions (&lt;3 cm), but is similar for larger lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/10\">",
"     10",
"    </a>",
"    ]. ENB-guided sampling is a promising technique for sampling small peripheral lesions, when performed by a trained operator [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3642?source=see_link\">",
"     \"Transbronchial needle aspiration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19976?source=see_link\">",
"     \"Endobronchial ultrasound: Indications, advantages, and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43427?source=see_link\">",
"     \"Endobronchial ultrasound: Technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Selection of a sampling technique should take tumor location (central versus peripheral), safety, availability, ease, local expertise, and diagnostic accuracy into consideration.",
"   </p>",
"   <p>",
"    For patients who have multiple comorbidities or contraindications to invasive biopsy, sputum cytology should be considered, especially for patients with centrally located tumors. Cytologic specimens are as reliable as histopathologic specimens for diagnosis of NSCLC, but are positive in only 20 to 25 percent of patients with proven lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-surgical approaches, surgical approaches, or both may be used to obtain a tissue sample from patients with suspected lymph node metastasis. Successful application of the non-surgical approaches may eliminate the need for a surgical staging procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14224361\">",
"    <span class=\"h3\">",
"     Non-surgical approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-surgical approaches include needle aspiration or needle biopsy for sampling peripheral lymph nodes, and EBUS-guided TBNA, transesophageal endoscopic ultrasound-guided fine needle aspiration (EUS-FNA), or conventional bronchoscopy with blind TBNA for sampling mediastinal lymph nodes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Needle aspiration or biopsy of peripheral lymph nodes &ndash; For patients with palpable cervical or supraclavicular lymphadenopathy, needle aspiration or biopsy is a simple, bedside procedure that can establish a diagnosis and identify N3 disease (",
"      <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Endobronchial ultrasound &ndash; EBUS-guided TBNA can sample mediastinal lymph nodes, especially those that are located in the paratracheal, subcarinal, or hilar lymph node stations (",
"      <a class=\"graphic graphic_figure graphicRef63771 \" href=\"UTD.htm?0/10/167\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/13-16\">",
"       13-16",
"      </a>",
"      ]. In a prospective cohort study of 108 patients, real-time EBUS-guided TBNA detected malignant lymph node involvement with a sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of 95, 100, 100, 90, and 96 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/17\">",
"       17",
"      </a>",
"      ]. These results have been consistently reproduced in cohorts of patients who underwent EBUS-guided lymph node biopsy for mediastinal staging of suspected lung carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/14,18\">",
"       14,18",
"      </a>",
"      ]. The test characteristics are superior to blind TBNA [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/19\">",
"       19",
"      </a>",
"      ]. EBUS-guided TBNA is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19976?source=see_link\">",
"       \"Endobronchial ultrasound: Indications, advantages, and complications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43427?source=see_link\">",
"       \"Endobronchial ultrasound: Technical aspects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transesophageal endoscopic ultrasound &ndash; EUS-FNA can sample mediastinal lymph nodes, especially those that are posterior or inferior (subcarinal, aortopulmonary, paraesophageal, pulmonary ligament) (",
"      <a class=\"graphic graphic_figure graphicRef63771 \" href=\"UTD.htm?0/10/167\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/20\">",
"       20",
"      </a>",
"      ]. In a prospective cohort study of 104 patients, EUS-FNA detected malignant lymph node involvement with a sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 92, 100, 100, 94, and 97 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/21\">",
"       21",
"      </a>",
"      ]. EUS-FNA is reviewed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/16/12552?source=see_link\">",
"       \"Endoscopic ultrasound-guided fine-needle aspiration in the mediastinum\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transbronchial needle aspiration &ndash; Blind TBNA can be safely and rapidly performed during flexible or rigid bronchoscopy. It is particularly well-suited for sampling paratracheal (stations 4R,4L), subcarinal (station 7), and hilar (stations 10R,10L) lymph nodes, especially by experienced operators (",
"      <a class=\"graphic graphic_figure graphicRef73945 \" href=\"UTD.htm?19/28/19914\">",
"       figure 2",
"      </a>",
"      ). Blind TBNA detects malignant mediastinal lymph node involvement with a sensitivity of 39 percent when the prevalence of lymph node metastasis is low [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/22\">",
"       22",
"      </a>",
"      ]. The sensitivity increases to 78 percent when the prevalence of lymph node metastasis is high. This sensitivity dictates that negative results be confirmed by mediastinoscopy or during surgical resection. Microscopic examination of the aspirate by a cytopathologist during the procedure increases the sensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/23\">",
"       23",
"      </a>",
"      ]. Blind TBNA is generally believed to be inferior to EBUS-guided TBNA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3642?source=see_link\">",
"       \"Transbronchial needle aspiration\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Combined modalities &ndash; No single non-surgical procedure can access all potentially involved lymph node stations. However, using more than one modality increases diagnostic yield by increasing the breadth of lymph node stations that can be sampled. In a prospective cohort study of 138 patients with suspected lung cancer (including 42 patients with confirmed lymph node metastasis), the sensitivity of EBUS-guided biopsy plus EUS-guided biopsy was 93 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/24\">",
"       24",
"      </a>",
"      ]. This was higher than that for EBUS-guided biopsy alone (69 percent), EUS-guided biopsy alone (69 percent), TBNA (36 percent), TBNA plus EBUS-guided biopsy (76 percent), or TBNA plus EUS-guided biopsy (79 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14224369\">",
"    <span class=\"h3\">",
"     Surgical approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical approaches include mediastinoscopy and thoracoscopy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical mediastinoscopy &ndash; Cervical mediastinoscopy is a surgical procedure that can be performed with few complications. It detects malignant involvement of the following lymph node stations with high sensitivity: upper paratracheal (stations 2R, 2L), right paratracheal (station 4R), and left paratracheal superior to the aortic arch (",
"      <a class=\"graphic graphic_figure graphicRef73945 \" href=\"UTD.htm?19/28/19914\">",
"       figure 2",
"      </a>",
"      ). The left paratracheal (station 4L), anterior subcarinal (station 7), and bilateral hilar nodes (stations 10R, 10L) may be accessible as well [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/25\">",
"       25",
"      </a>",
"      ]. The majority of patients with NSCLC will not require or receive surgical mediastinoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/26\">",
"       26",
"      </a>",
"      ]. However, its good diagnostic yield, safety, and patient tolerance make cervical mediastinoscopy a reasonable approach to lymph node staging. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32183?source=see_link\">",
"       \"Surgical management of mediastinal lymphadenopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anterior mediastinotomy &ndash; Left parasternal anterior mediastinotomy (Chamberlain procedure) is an alternative surgical approach for mediastinal lymph node sampling. It can be used to sample any of the following mediastinal lymph node stations: left paratracheal (station 4L), paraaortic (station 6), subaortic (station 5), and subcarinal nodes (station 7) (",
"      <a class=\"graphic graphic_figure graphicRef73945 \" href=\"UTD.htm?19/28/19914\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32183?source=see_link&amp;anchor=H412278#H412278\">",
"       \"Surgical management of mediastinal lymphadenopathy\", section on 'Anterior mediastinotomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thoracoscopy &ndash; Thoracoscopy can be used to sample azygos (station 4R), subaortic (station 5), paraaortic (station 6), paraesophageal (station 8), or pulmonary ligament (station 9) lymph nodes (",
"      <a class=\"graphic graphic_figure graphicRef73945 \" href=\"UTD.htm?19/28/19914\">",
"       figure 2",
"      </a>",
"      ). Thoracoscopy can also be used to evaluate the extent of invasion by the primary tumor, especially when there is possible mediastinal invasion, chest wall invasion, or pleural involvement because direct visual inspection of suspicious areas gives more reliable information than radiologic studies [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. In a prospective cohort study of 64 patients with suspected stage IIIB NSCLC (as defined by the 6th edition of the tumor node metastasis staging system), thoracoscopy improved the accuracy of preoperative staging [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/29\">",
"       29",
"      </a>",
"      ]. Among the 10 patients with a negative result on their pleural fluid cytology, six (60 percent) were found to have malignant pleural involvement. Among the 30 patients with mediastinal infiltration suspected on the basis of a CT scan, 15 (50 percent) were down-staged to stage IIIA or stage II. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41414?source=see_link\">",
"       \"An overview of medical thoracoscopy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42933?source=see_link\">",
"       \"Indications for diagnostic thoracoscopy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14224385\">",
"    <span class=\"h3\">",
"     Comparison",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-surgical and surgical approaches to mediastinal nodal staging have been compared. A clinical trial enrolled 241 patients with suspected NSCLC in whom mediastinal staging was indicated because of a centrally located tumor or abnormal findings on computed tomography (CT) or positron emission tomography (PET) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/30\">",
"     30",
"    </a>",
"    ]. The patients were randomly assigned to undergo either EBUS-FNA plus EUS-FNA (endosonography group) or mediastinoscopy, with or without anterior mediastinotomy or VATS (mediastinoscopy group). The endosonography group underwent subsequent mediastinoscopy when the non-surgical sampling was negative. Thoracotomy with lymph node dissection was performed in both groups when there was no evidence of mediastinal tumor spread. Endosonography plus mediastinoscopy was more sensitive for detecting mediastinal metastasis than mediastinoscopy (94 versus 79 percent), but the sensitivity of endosonography alone (85 percent) was similar to that mediastinoscopy. Unnecessary thoracotomy was performed more often among patients who underwent mediastinoscopy alone than endosonography plus mediastinoscopy (18 versus 7 percent), although the rate of complications were similar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pleural effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural effusions are present in up to one-third of patients with NSCLC at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/4\">",
"     4",
"    </a>",
"    ]. While some effusions may be parapneumonic or sympathetic, the majority are due to malignant pleural disease (M1a disease). The T, N, and M descriptors are reviewed below (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Confirmation that a pleural effusion is malignant is mandatory in all patients with NSCLC if this determination influences the disease stage. Cytologic examination of 50 to 100 mL of pleural fluid obtained by thoracentesis will detect approximately 65 percent of malignant effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second thoracentesis should be performed if the initial thoracentesis is negative. An estimated 30 percent of second thoracenteses are positive when the results of the initial thoracentesis are falsely negative [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/31\">",
"     31",
"    </a>",
"    ]. Thoracoscopy should be performed if two thoracenteses are negative [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/12,32\">",
"     12,32",
"    </a>",
"    ]. The sensitivity of thoracoscopy for pleural metastasis is approximately 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/4,25,33\">",
"     4,25,33",
"    </a>",
"    ]. Thoracoscopy has the added advantage of being able to evaluate for chest wall invasion, mediastinal invasion, or malignant mediastinal lymph node involvement. Closed pleural biopsy does little to increase diagnostic yield [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=see_link\">",
"     \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adrenal nodule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal gland nodules or masses may be found by CT in 3 to 4 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. In patients with lung cancer, most adrenal nodules are benign adenomas. Fewer than half are metastases. All adrenal lesions in patients with suspected lung cancer require directed evaluation if it will determine the disease stage. A malignant adrenal nodule is considered distant metastasis (M1b disease). The T, N, and M descriptors are reviewed below (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Conventional CT and MRI imaging of adrenal lesions permits initial characterization of adrenal nodules. However, these radiographic modalities lack a high degree of sensitivity or specificity for the characterization of metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protocols that measure the washout of attenuation following the administration of intravenous contrast may significantly improve the sensitivity and specificity of CT for characterizing adrenal lesions. This was illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 151 patients with 166 adrenal masses, CT using an adrenal imaging protocol identified adrenal adenomas with a sensitivity and specificity of 98 and 92 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/39\">",
"       39",
"      </a>",
"      ]. The prevalence of adrenal adenomas in the population was 77 percent.",
"     </li>",
"     <li>",
"      In a study of 99 patients with 112 adrenal masses, CT using a slightly different adrenal protocol and density threshold detected malignancy with a sensitivity and specificity of 100 and 95 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/40\">",
"       40",
"      </a>",
"      ]. The prevalence of malignancy in the population was 15 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PET imaging may also improve the sensitivity, specificity, and accuracy of adrenal gland imaging. In a series of 94 patients with 113 adrenal masses, the sensitivity, specificity, and accuracy of PET imaging for detection of metastatic disease was 93, 90, and 92 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An adrenal gland biopsy should be performed if confirmation of the adrenal pathology will determine the disease stage and treatment options. Image-guided fine needle biopsy with endoscopic ultrasound (EUS-FNA) or CT-guided percutaneous needle biopsy is the most common approach. EUS-FNA is particularly well suited to left-adrenal gland biopsy and has been shown to frequently alter the staging and management of patients, most often leading to downstaging and surgery in otherwise operable patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is usually enough information to determine the disease stage once the history, physical examination, laboratory testing, imaging, and tissue sampling are complete. Staging is based upon the tumor node metastasis (TNM) staging system, which grades the primary tumor characteristics (T), presence or absence of regional lymph node involvement (N), and presence or absence of distant metastasis (M) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The combination of T, N, and M grades determines the overall disease stage (stage I through IV).",
"   </p>",
"   <p>",
"    The 7th edition of the TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ) is the most recent version, replacing the 6th edition (",
"    <a class=\"graphic graphic_table graphicRef74820 \" href=\"UTD.htm?19/43/20157\">",
"     table 3",
"    </a>",
"    ) as of January 1, 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/45\">",
"     45",
"    </a>",
"    ]. The major change in the 7th edition is the reclassification of malignant pleural effusions and separate tumor nodule(s) (previously called satellite nodules). Other changes include new size cut-offs and new subdivisions of the T1 (into T1a and T1b), T2 (into T2a and T2b), and M1 (into M1a and M1b) descriptors (",
"    <a class=\"graphic graphic_table graphicRef68104 \" href=\"UTD.htm?13/4/13388\">",
"     table 4",
"    </a>",
"    ). The TNM staging system for NSCLC is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Four types of staging can be performed in patients with NSCLC. All are based on the TNM staging system:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical-diagnostic stage is based upon medical history, physical examination, laboratory testing, radiologic testing, tissue sampling, and any other investigation undertaken prior to primary therapy. It is assigned the prefix c (eg, cT3N2M0). A limitation of clinical-diagnostic staging is that the stage is sometimes related to the intensity of the evaluation.",
"     </li>",
"     <li>",
"      The surgical-pathologic stage is based on the clinical-diagnostic stage plus histopathologic data from the resected tumor. It provides confirmation of the T descriptor, N descriptor, and histologic type. In addition, it takes into account the histologic grade, resection margins, and presence or absence of lymphovascular invasion [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/46\">",
"       46",
"      </a>",
"      ]. The surgical-pathologic stage is assigned the prefix p (eg, pT3N2M0).",
"     </li>",
"     <li>",
"      A retreatment stage is assigned if there is recurrence of disease and a new treatment program is planned.",
"     </li>",
"     <li>",
"      An autopsy stage is recorded when a patient dies and has a postmortem examination performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical-diagnostic staging is the focus of this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3958612\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic examination of the tissue sample(s) obtained by the various methods outlined above is used to confirm the presence of lung cancer and determine its subtype. The pathology of lung malignancies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link\">",
"     \"Pathology of lung malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     APPROACH TO DIAGNOSIS AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with suspected NSCLC should have a history and physical examination performed, as well as laboratory testing and computed tomography (CT) of the chest with intravenous contrast. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'History and physical exam'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Laboratory testing'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Based upon this initial evaluation, most patients require additional imaging. This may include whole body positron emission tomography (PET), integrated",
"    <span class=\"nowrap\">",
"     CT/PET,",
"    </span>",
"    bone scanning, magnetic resonance imaging (MRI) of the chest wall or brain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CT of the brain. Each of these modalities and a recommended approach to imaging patients with suspected NSCLC are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=see_link\">",
"     \"Role of imaging in the staging of non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major purpose of the history, physical examination, laboratory testing, and imaging is to identify target lesions for tissue sampling. Tissue sampling is necessary because histopathologic data is required to confirm the diagnosis of NSCLC and to accurately determine the disease stage. Noninvasive techniques, such as imaging alone, are insufficient. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Tissue sampling'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The sampling target should be the lesion that will establish the highest disease stage, assuming that the lesion is not inaccessible or particularly high risk (eg, brain metastasis). As an example, a patient whose chest CT demonstrates a left upper lobe mass with right paratracheal lymph node enlargement should have the paratracheal lymph nodes sampled because this can both confirm NSCLC and establish N3 disease, whereas sampling the mass can only confirm NSCLC and an additional procedure is required to complete the staging. The sampling technique should be chosen on the basis of tumor location (central versus peripheral), local expertise, safety, availability, ease, diagnostic accuracy, and patient preference.",
"   </p>",
"   <p>",
"    If initial tissue sampling confirms the diagnosis of lung carcinoma, then the disease stage should be determined according to the tumor node metastasis (TNM) staging system for NSCLC (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ). However, if initial tissue sampling provides inconclusive results or the clinical stage of disease remains unclear, then a second procedure may be indicated. The selection of a second biopsy procedure should favor procedures with a higher diagnostic sensitivity (ie, image-guided or surgical sampling). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who may be a candidate for surgical resection of the NSCLC should undergo complete pulmonary function testing and consultation with a cardiothoracic surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14841/abstract/47\">",
"     47",
"    </a>",
"    ]. Whether surgical resection will be deemed appropriate depends on a variety of factors, including the disease stage and the patient's general medical condition. Patients with borderline pulmonary function or worrisome cardiorespiratory symptoms should also undergo functional cardiopulmonary testing or a myocardial perfusion study, respectively.",
"   </p>",
"   <p>",
"    An exception to this approach applies to patients who are good surgical candidates, have a primary lesion that is very suspicious for malignancy, and whose noninvasive evaluation found no evidence that the disease has spread beyond the primary lesion. Such patients may undergo surgical resection of the lesion without prior tissue sampling. In this situation, NSCLC is confirmed and staged after the histopathology from the surgical resection is known. The rationale for this approach is that, in such patients, the benefit of early resection (ie, cure) outweighs both the surgical risks and the possibility of false-negative or false-positive clinical-diagnostic staging.",
"   </p>",
"   <p>",
"    The management of confirmed NSCLC is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link\">",
"     \"Management of stage I and stage II non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=see_link\">",
"     \"Management of stage III non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=see_link\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/44/3779?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/22/41314?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/63/17396?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a patient presents with suspected non-small cell lung cancer (NSCLC), the diagnosis should be confirmed and both the histologic type and disease stage should be determined. The disease stage is a measure of the extent of disease, which is used to determine prognosis and guide management. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with suspected NSCLC should undergo a history, physical examination, laboratory testing, and computed tomography (CT) of the chest with intravenous contrast. Most patients require additional imaging as directed by their unique characteristics. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Approach to diagnosis and staging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'History and physical exam'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Laboratory testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Imaging'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=see_link\">",
"       \"Role of imaging in the staging of non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An important goal of the evaluation of suspected NSCLC is to identify a target lesion for tissue sampling. Ideally, the diagnosis and invasive confirmation of stage can be accomplished in a single procedure. Therefore, the sampling target should be the lesion that will establish the highest disease stage, assuming that the lesion is not inaccessible or particularly high risk. If initial tissue sampling provides inconclusive results or the clinical stage of disease remains unclear, then a second procedure may be indicated. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Approach to diagnosis and staging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Tissue sampling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An exception to this approach applies to patients who are good surgical candidates, have a primary lesion that is very suspicious for malignancy, and have no evidence of spread of disease beyond the primary lesion based on noninvasive evaluation. Such patients may undergo surgical resection of the lesion without prior tissue sampling. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Approach to diagnosis and staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is usually enough information to determine the disease stage once the history, physical examination, laboratory testing, imaging, and tissue sampling are complete. Staging is based upon the tumor node metastasis (TNM) staging system for NSCLC (",
"      <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Approach to diagnosis and staging'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"       \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/1\">",
"      Ross PJ, Ashley S, Norton A, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 2004; 90:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/2\">",
"      Colinet B, Jacot W, Bertrand D, et al. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index. Br J Cancer 2005; 93:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/3\">",
"      Spiro SG, Gould MK, Colice GL, American College of Chest Physicians. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132:149S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/4\">",
"      Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med 1997; 156:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/5\">",
"      Tamura M, Oda M, Tsunezuka Y, et al. Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer. Chest 2004; 126:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/6\">",
"      Rubins JB, Dunitz J, Rubins HB, et al. Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer. J Thorac Cardiovasc Surg 1998; 116:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/7\">",
"      Ferrigno D, Buccheri G. Clinical applications of serum markers for lung cancer. Respir Med 1995; 89:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/8\">",
"      Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/9\">",
"      Silvestri GA, Gould MK, Margolis ML, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132:178S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/10\">",
"      Paone G, Nicastri E, Lucantoni G, et al. Endobronchial ultrasound-driven biopsy in the diagnosis of peripheral lung lesions. Chest 2005; 128:3551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/11\">",
"      Gildea TR, Mazzone PJ, Karnak D, et al. Electromagnetic navigation diagnostic bronchoscopy: a prospective study. Am J Respir Crit Care Med 2006; 174:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/12\">",
"      Rivera MP, Mehta AC, American College of Chest Physicians. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:131S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/13\">",
"      Silvestri GA, Hoffman BJ, Bhutani MS, et al. Endoscopic ultrasound with fine-needle aspiration in the diagnosis and staging of lung cancer. Ann Thorac Surg 1996; 61:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/14\">",
"      Herth FJ, Eberhardt R, Vilmann P, et al. Real-time endobronchial ultrasound guided transbronchial needle aspiration for sampling mediastinal lymph nodes. Thorax 2006; 61:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/15\">",
"      Herth FJ, Ernst A, Eberhardt R, et al. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically normal mediastinum. Eur Respir J 2006; 28:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/16\">",
"      Yasufuku K, Nakajima T, Motoori K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest 2006; 130:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/17\">",
"      Yasufuku K, Chiyo M, Koh E, et al. Endobronchial ultrasound guided transbronchial needle aspiration for staging of lung cancer. Lung Cancer 2005; 50:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/18\">",
"      Vincent BD, El-Bayoumi E, Hoffman B, et al. Real-time endobronchial ultrasound-guided transbronchial lymph node aspiration. Ann Thorac Surg 2008; 85:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/19\">",
"      Herth F, Becker HD, Ernst A. Conventional vs endobronchial ultrasound-guided transbronchial needle aspiration: a randomized trial. Chest 2004; 125:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/20\">",
"      Larsen SS, Vilmann P, Krasnik M, et al. Endoscopic ultrasound guided biopsy versus mediastinoscopy for analysis of paratracheal and subcarinal lymph nodes in lung cancer staging. Lung Cancer 2005; 48:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/21\">",
"      Eloubeidi MA, Cerfolio RJ, Chen VK, et al. Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans. Ann Thorac Surg 2005; 79:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/22\">",
"      Holty JE, Kuschner WG, Gould MK. Accuracy of transbronchial needle aspiration for mediastinal staging of non-small cell lung cancer: a meta-analysis. Thorax 2005; 60:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/23\">",
"      Davenport RD. Rapid on-site evaluation of transbronchial aspirates. Chest 1990; 98:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/24\">",
"      Wallace MB, Pascual JM, Raimondo M, et al. Minimally invasive endoscopic staging of suspected lung cancer. JAMA 2008; 299:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/25\">",
"      Mentzer SJ, Swanson SJ, DeCamp MM, et al. Mediastinoscopy, thoracoscopy, and video-assisted thoracic surgery in the diagnosis and staging of lung cancer. Chest 1997; 112:239S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/26\">",
"      Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung cancer patients. Ann Thorac Surg 2005; 80:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/27\">",
"      Wain JC. Video-assisted thoracoscopy and the staging of lung cancer. Ann Thorac Surg 1993; 56:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/28\">",
"      Roberts JR, Blum MG, Arildsen R, et al. Prospective comparison of radiologic, thoracoscopic, and pathologic staging in patients with early non-small cell lung cancer. Ann Thorac Surg 1999; 68:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/29\">",
"      De Giacomo T, Rendina EA, Venuta F, et al. Thoracoscopic staging of IIIB non-small cell lung cancer before neoadjuvant therapy. Ann Thorac Surg 1997; 64:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/30\">",
"      Annema JT, van Meerbeeck JP, Rintoul RC, et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA 2010; 304:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/31\">",
"      Light RW, Erozan YS, Ball WC Jr. Cells in pleural fluid. Their value in differential diagnosis. Arch Intern Med 1973; 132:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/32\">",
"      British Thoracic Society, Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax 2001; 56:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/33\">",
"      Menzies R, Charbonneau M. Thoracoscopy for the diagnosis of pleural disease. Ann Intern Med 1991; 114:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/34\">",
"      Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc 1985; 60:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/35\">",
"      Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 2006; 29:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/36\">",
"      Lam KY, Lo CY. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol (Oxf) 2002; 56:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/37\">",
"      Ettinghausen SE, Burt ME. Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer. J Clin Oncol 1991; 9:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/38\">",
"      Porte HL, Ernst OJ, Delebecq T, et al. Is computed tomography guided biopsy still necessary for the diagnosis of adrenal masses in patients with resectable non-small-cell lung cancer? Eur J Cardiothorac Surg 1999; 15:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/39\">",
"      Caoili EM, Korobkin M, Francis IR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 2002; 222:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/40\">",
"      Blake MA, Kalra MK, Sweeney AT, et al. Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay. Radiology 2006; 238:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/41\">",
"      Kumar R, Xiu Y, Yu JQ, et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 2004; 45:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/42\">",
"      Bodtger U, Vilmann P, Clementsen P, et al. Clinical impact of endoscopic ultrasound-fine needle aspiration of left adrenal masses in established or suspected lung cancer. J Thorac Oncol 2009; 4:1485.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC Cancer Staging Manual, 6th ed, Greene FL, Page DL, Fleming ID, et al (Eds), Springer-Verlag, New York 2002. p.435.",
"    </li>",
"    <li>",
"     UICC TNM Classification of Malignant Tumors, 6th Ed, Sobin L, Wittekind C (Eds), Wiley-Liss, New York 2002. p.272.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/45\">",
"      Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/46\">",
"      Schwartz AM, Henson DE, American College of Chest Physicians. Diagnostic surgical pathology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:78S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14841/abstract/47\">",
"      Colice GL, Shafazand S, Griffin JP, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132:161S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4632 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14841=[""].join("\n");
var outline_f14_31_14841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY AND PHYSICAL EXAM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TISSUE SAMPLING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Primary tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14224361\">",
"      - Non-surgical approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14224369\">",
"      - Surgical approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14224385\">",
"      - Comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pleural effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adrenal nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3958612\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      APPROACH TO DIAGNOSIS AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4632\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4632|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/10/167\" title=\"figure 1\">",
"      Mediastinal LN approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/28/19914\" title=\"figure 2\">",
"      IASLC lymph node map",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4632|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/41/37533\" title=\"table 1\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/61/30685\" title=\"table 2\">",
"      Paraneoplastic syndromes associated with lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/43/20157\" title=\"table 3\">",
"      Lung cancer TMN staging 6th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/4/13388\" title=\"table 4\">",
"      Changes 7th ed TNM lung ca",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41414?source=related_link\">",
"      An overview of medical thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=related_link\">",
"      Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19976?source=related_link\">",
"      Endobronchial ultrasound: Indications, advantages, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43427?source=related_link\">",
"      Endobronchial ultrasound: Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/16/12552?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration in the mediastinum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16009?source=related_link\">",
"      Hoarseness in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42933?source=related_link\">",
"      Indications for diagnostic thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=related_link\">",
"      Management of stage I and stage II non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=related_link\">",
"      Management of stage III non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=related_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=related_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=related_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/58/14250?source=related_link\">",
"      Pancoast's syndrome and superior (pulmonary) sulcus tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/44/3779?source=related_link\">",
"      Patient information: Non-small cell lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/22/41314?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/63/17396?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=related_link\">",
"      Pericardial disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=related_link\">",
"      Role of imaging in the staging of non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32183?source=related_link\">",
"      Surgical management of mediastinal lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=related_link\">",
"      Survival estimates in advanced terminal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3642?source=related_link\">",
"      Transbronchial needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=related_link\">",
"      Tumor node metastasis (TNM) staging system for non-small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_31_14842="Treatment selection for moderate to severe plaque psoriasis in special populations";
var content_f14_31_14842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment selection for moderate to severe plaque psoriasis in special populations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/31/14842/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14842/contributors\">",
"     April W Armstrong, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/31/14842/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14842/contributors\">",
"     Kristina Callis Duffin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/31/14842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/31/14842/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/31/14842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9475333\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapy is the primary mode of treatment for plaque psoriasis in patients with limited skin involvement. Patients with moderate to severe plaque psoriasis (considered here as psoriasis involving more than 5 to 10 percent of the body surface area) usually require an alternative approach to therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of psoriasis\", section on 'Choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major treatment options for patients with moderate to severe psoriasis include phototherapy and a variety of systemic medications. Because the risks associated with treatment may be altered by the presence of additional medical disorders, treatment selection must involve consideration of the patient&rsquo;s underlying diseases.",
"   </p>",
"   <p>",
"    The approach to the treatment of plaque psoriasis in patients with hepatitis B, hepatitis C, human immunodeficiency virus (HIV) infection, latent tuberculosis, and internal malignancy will be reviewed here. A general review of psoriasis therapy is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link\">",
"     \"Treatment of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220664025\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major categories of treatments used for moderate to severe plaque psoriasis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ultraviolet light phototherapy",
"      </strong>",
"      (psoralen plus ultraviolet A [PUVA] and narrowband or broadband ultraviolet B [UVB]) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment of psoriasis\", section on 'Ultraviolet light'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=see_link\">",
"       \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26775?source=see_link\">",
"       \"UVB therapy (broadband and narrowband)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Conventional oral agents",
"      </strong>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"       acitretin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H30#H30\">",
"       \"Treatment of psoriasis\", section on 'Systemic therapies'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Biologic agents",
"      </strong>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"       ustekinumab",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H36#H36\">",
"       \"Treatment of psoriasis\", section on 'Biologic agents'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because some psoriasis therapies have side effects that can be detrimental in patients with certain underlying diseases, the approach to therapy is altered in some populations. For example, the safety of a potentially hepatotoxic drug, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , is a concern when treating patients with hepatitic disorders. In addition, the potential adverse effects of immunosuppressive therapy on patients with chronic infections or malignancies must be considered.",
"   </p>",
"   <p>",
"    The determination of the optimal approach to the treatment of psoriasis in patients with comorbidities, such as hepatitis B, hepatitis C, HIV infection, latent tuberculosis, and malignancy is hampered by limited data on the safety of these treatments in the psoriasis population. As a result, proposed guidelines for the management of these patients have been based upon a combination of published data from patients with psoriasis, data from studies of similar treatment regimens for other diseases, and expert consensus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/1-7\">",
"     1-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9475340\">",
"    <span class=\"h1\">",
"     CHRONIC HEPATITIS B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus (HBV) infection is one of the most common chronic viral infections in humans, affecting more than 350 million people worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Although symptoms may occur, chronic HBV infection frequently is asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\", section on 'Chronic hepatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HBV infection is divided into phases that reflect the interplay between virus replication and the host immune response (",
"    <a class=\"graphic graphic_figure graphicRef69344 \" href=\"UTD.htm?41/25/42398\">",
"     figure 1",
"    </a>",
"    ). Laboratory studies are useful for determining the phase of the disease (",
"    <a class=\"graphic graphic_table graphicRef60627 graphicRef60827 \" href=\"UTD.htm?7/35/7742\">",
"     table 1A-B",
"    </a>",
"    ). In patients with chronic HBV infection, hepatitis B surface antigen (HBsAg) and IgG hepatitis B core antibodies (IgG anti-HBc) persist in serum. Hepatitis e antigen (HBeAg), a marker of viral replication and infectivity that is usually associated with high levels of HBV DNA in serum and active liver disease, also may be detected. Upon recovery from HBV infection, HBsAg is no longer detectable in serum. However, patients with prior infection remain positive for IgG anti-HBc. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential for immunosuppressant-induced reactivation of HBV infection and morbidity from drugs with hepatic side effects are the major concerns that influence psoriasis therapy in patients with chronic hepatitis B. Although neither psoriasis nor HBV infection are uncommon conditions, data on the safety of psoriasis therapies in patients with both diseases are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174248504\">",
"    <span class=\"h2\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunosuppressive effects of ultraviolet light are believed to play a role in the efficacy of UVB phototherapy in psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/10\">",
"     10",
"    </a>",
"    ]. Although the risk for reactivation of HBV infection due to phototherapy has not been evaluated, the systemic effects of treatment are likely minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/2\">",
"     2",
"    </a>",
"    ]. Treatment with UVB phototherapy is generally considered to be safe in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of psoriasis\", section on 'Ultraviolet light'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absence of the need for the administration of topical or systemic psoralens has led to a preference for UVB phototherapy (particularly narrowband UVB phototherapy) as the preferred mode of phototherapy for moderate to severe psoriasis. Although two one-year studies of patients without hepatitis failed to find statistically significant histological differences in pre-PUVA and post-PUVA liver biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], there have been several reports of liver injury after PUVA therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. In addition, severe liver disease is a relative contraindication for treatment with PUVA (",
"    <a class=\"graphic graphic_table graphicRef83207 \" href=\"UTD.htm?23/37/24155\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=see_link\">",
"     \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220663779\">",
"    <span class=\"h2\">",
"     Conventional oral agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Reactivation of HBV infection resulting in fulminant hepatic failure has been documented in case reports of patients treated with methotrexate for rheumatologic diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/18-21\">",
"       18-21",
"      </a>",
"      ]. This finding raises concern about the safety of methotrexate therapy in patients with hepatitis B, particularly given the existence of other therapeutic options. A 2012 consensus statement from the Medical Board of the National Psoriasis Foundation advised that methotrexate should",
"      <strong>",
"       not",
"      </strong>",
"      be prescribed in this population [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/1,22\">",
"       1,22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"       \"Major side effects of low-dose methotrexate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"       Acitretin",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Unlike other systemic therapies for psoriasis, acitretin is not an immunosuppressant [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Therefore, despite a lack of data on the safety of acitretin use in HBV-infected patients, acitretin is not thought to increase the risk for reactivation of HBV infection.",
"      <br/>",
"      <br/>",
"      Elevation of liver enzymes is a common side effect of acitretin therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/25\">",
"       25",
"      </a>",
"      ], though severe hepatotoxic reactions are rare [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/24,26\">",
"       24,26",
"      </a>",
"      ]. A two-year study of pretreatment and posttreatment liver biopsies in patients treated with acitretin for psoriasis failed to find clinically significant toxic effects on the liver, suggesting that hepatitic tolerance of the drug may be good in healthy patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/25\">",
"       25",
"      </a>",
"      ]. Whether patients with chronic HBV infection have increased risk for hepatotoxic effects from acitretin is uncertain.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      The safety of cyclosporine in patients with psoriasis and hepatitis B has not been specifically evaluated. However, the immunosuppressive properties of cyclosporine raise concern for the possibility of reactivation of HBV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/27\">",
"       27",
"      </a>",
"      ]. Cyclosporine was not considered an acceptable option for therapy for psoriasis in a 2009 consensus of experts [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220663786\">",
"    <span class=\"h2\">",
"     Biologic agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1503100\">",
"    <span class=\"h3\">",
"     TNF-alpha inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologic TNF-alpha inhibitors usually do not induce direct hepatotoxic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/28\">",
"     28",
"    </a>",
"    ]. Transaminase elevations develop only occasionally [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, reactivation of HBV infection is the major concern for use of these drugs in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link&amp;anchor=H7#H7\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\", section on 'Rheumatalogic disorders treated with anti-TNF agents, methotrexate, and other biologics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reactivation of HBV infection in patients treated with TNF-alpha inhibitors may be related to a suppressive role of endogenous TNF-alpha on replication of HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/4\">",
"     4",
"    </a>",
"    ]. HBsAg-positive patients have the greatest risk for disease reactivation. Reactivation occurs less frequently in HBsAg negative patients who have a prior history of hepatitis B and is rare in HBsAg-negative patients who have achieved full immunologic recovery (anti-HBs-positive and anti-HBc-positive (",
"    <a class=\"graphic graphic_table graphicRef60827 \" href=\"UTD.htm?2/45/2781\">",
"     table 1B",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/4,28,30\">",
"     4,28,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of clarity on the exact level of risk for HBV reactivation due to TNF-alpha inhibitor therapy for psoriasis reflects the consistent exclusion of patients with HBV infection from trials evaluating the efficacy and safety of these therapies. Isolated cases of reactivation of HBV infection in HBsAg-positive patients treated with TNF-alpha inhibitors for psoriasis have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/4\">",
"     4",
"    </a>",
"    ]. As an example, in one series of seven HBsAg-positive patients with psoriasis or psoriatic arthritis who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    for an average of 29 months, three patients, including one who had undetectable HBV DNA levels prior to treatment, developed reactivation of HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/31\">",
"     31",
"    </a>",
"    ]. Antiviral prophylaxis was given to only one patient; reactivation of HBV infection did not occur in this patient.",
"   </p>",
"   <p>",
"    As a result of the paucity of treatment data in patients with moderate to severe psoriasis and hepatitis B, much of the knowledge of the use of these agents in the setting of HBV infection stems from literature published in patients with conditions other than psoriasis. Most reported cases of HBV reactivation have occurred in patients who were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    for rheumatologic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], suggesting that infliximab may be the TNF-alpha inhibitor that is most likely to cause HBV reactivation. It is unclear whether the disproportionate number of reports for infliximab compared with other TNF-alpha inhibitors is related to its longer half-life or greater drug potency [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1503282\">",
"    <span class=\"h3\">",
"     Ustekinumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are scarce on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    and HBV infection. Although successful treatment of a patient with chronic hepatitis B (HBsAg-positive and anti-HBc-positive) with ustekinumab plus an antiviral agent has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/34\">",
"     34",
"    </a>",
"    ], reactivation of HBV infection has been documented in a patient who was HBsAg negative, anti-HBc positive, and anti-HBs positive prior to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174248692\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, patients who are found to have hepatitis B on pretreatment laboratory screening should be referred to a hepatologist for further evaluation and consideration for antiviral therapy.",
"   </p>",
"   <p>",
"    Because of concern for the potential adverse effects of systemic therapies for psoriasis in this population, we favor phototherapy (with or without adjunctive topical therapy) as the treatment of choice for patients with moderate to severe psoriasis and chronic hepatitis B, with narrowband UVB followed by broadband UVB as our preferred treatment options [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/2\">",
"     2",
"    </a>",
"    ]. If phototherapy and topical therapy are not possible or effective, we consider cautious treatment with TNF-alpha inhibitors or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    . We avoid treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    due to concern for hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/1\">",
"     1",
"    </a>",
"    ] and avoid the routine use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    due to concerns about the drug&rsquo;s immunosuppressive effects.",
"   </p>",
"   <p>",
"    Definitive guidelines for the management of HBV-infected patients treated with TNF-alpha inhibitors are lacking. Patients who will be treated with TNF-alpha inhibitors should be managed in conjunction with a hepatologist [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/1\">",
"     1",
"    </a>",
"    ]. For HBsAg-positive patients with chronic inactive hepatitis B, we agree with the recommendations of others that antiviral prophylaxis should be initiated two to four weeks before the start of treatment with the TNF-alpha inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/1,36\">",
"     1,36",
"    </a>",
"    ]. Liver function tests and viral load should be monitored closely (eg, monthly or bimonthly for six months, then every three months thereafter) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the lower risk for HBV reactivation in patients who are HBsAg-negative and anti-HBc positive, some authors have suggested that these patients may not require antiviral prophylaxis during treatment with a TNF-alpha inhibitor, though they should continue to be monitored closely for reactivation of HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/4,28\">",
"     4,28",
"    </a>",
"    ]. In addition, since the majority of reported cases of reactivation of HBV infection occurred during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , some authors have suggested using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , a non-antibody TNF-alpha inhibitor, as the preferred TNF-alpha inhibitor for the treatment of psoriasis in patients with chronic or resolved HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    in patients with HBV infection are limited, and caution is necessary if the drug is used in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/23\">",
"     23",
"    </a>",
"    ]. We follow patients with chronic hepatitis B who are treated with acitretin closely for laboratory evidence of liver toxicity and co-manage these patients with a hepatologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9475347\">",
"    <span class=\"h1\">",
"     CHRONIC HEPATITIS C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C is a common blood-borne infection that infects approximately 200 million people worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/37\">",
"     37",
"    </a>",
"    ]. Similar to hepatitis B, the primary concerns for the treatment of moderate to severe psoriasis in hepatitis C virus (HCV)-infected patients are exacerbation of the infection and drug-induced hepatotoxicity. Of note, interferon, a treatment commonly used for hepatitis C, may exacerbate psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H974087\">",
"    <span class=\"h2\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the safety of phototherapy in patients with HCV infection has not been specifically studied, UVB phototherapy generally is considered safe in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/3\">",
"     3",
"    </a>",
"    ]. PUVA is an additional therapeutic option; however, as noted above, there have been several reports of liver injury after PUVA therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/13-17\">",
"     13-17",
"    </a>",
"    ], and severe liver disease is considered a relative contraindication for PUVA (",
"    <a class=\"graphic graphic_table graphicRef83207 \" href=\"UTD.htm?23/37/24155\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H174248504\">",
"     'Phototherapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of psoriasis\", section on 'Ultraviolet light'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=see_link\">",
"     \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220663801\">",
"    <span class=\"h2\">",
"     Conventional oral agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Methotrexate is contraindicated for the treatment of psoriasis in patients with hepatitis C due to an increased risk for hepatotoxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"       \"Major side effects of low-dose methotrexate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"       Acitretin",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      The safety of acitretin therapy in patients with hepatitis C has not been studied. Liver function test abnormalities, and occasionally, long-term hepatotoxic effects, can occur during treatment with acitretin [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/25\">",
"       25",
"      </a>",
"      ]. As noted above, a two-year study of pretreatment and posttreatment liver biopsies in patients without hepatitis who were treated with acitretin for psoriasis failed to find clinically significant toxic effects on the liver [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/25\">",
"       25",
"      </a>",
"      ]. Whether patients with hepatitis C are at increased risk for hepatic side effects of acitretin is uncertain. (See",
"      <a class=\"local\" href=\"#H220663779\">",
"       'Conventional oral agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Traditionally, cyclosporine has been avoided in the treatment of psoriasis in patients with hepatitis C due to concerns that the drug&rsquo;s immunosuppressive effects might exacerbate the infection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/3\">",
"       3",
"      </a>",
"      ]. However, in vitro studies have found that cyclosporine has suppressive effects on HCV replication [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/39-41\">",
"       39-41",
"      </a>",
"      ]. In addition, case reports have documented improvements in both transaminase levels and psoriasis during treatment with cyclosporine in patients with hepatitis C [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/42-45\">",
"       42-45",
"      </a>",
"      ]. These findings suggest that cyclosporine therapy may be tolerated and beneficial for some patients with psoriasis and hepatitis C. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=see_link&amp;anchor=H15#H15\">",
"       \"Investigational therapies for hepatitis C virus infection\", section on 'Cyclophilin inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220663808\">",
"    <span class=\"h2\">",
"     Biologic agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106913731\">",
"    <span class=\"h3\">",
"     TNF-alpha inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data on biologic therapy in patients with hepatitis C are limited, the available data from studies in patients with psoriasis and other diseases suggest that patients with chronic hepatitis C may tolerate TNF-alpha inhibitor therapy. Interestingly, a small randomized trial found that patients who were given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    as an adjunct to interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for the treatment of hepatitis C were more likely to achieve clearance of HCV RNA than patients who received interferon, ribavirin, and a placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link&amp;anchor=H11#H11\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\", section on 'Hepatitis C'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , the biologic agent most studied in patients with psoriasis and hepatitis C, primarily consists of case reports and small retrospective studies. A systematic review of published reports between 1990 and 2010 identified 22 case reports of patients treated with etanercept for psoriasis or psoriatic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/47\">",
"     47",
"    </a>",
"    ]. The review found that viral loads or transaminase levels remained stable in 17 of these patients and decreased in four patients during treatment with etanercept. Only one patient developed an increase in viral load.",
"   </p>",
"   <p>",
"    Additional case reports and small retrospective studies have documented successful use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    for psoriasis in patients with hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/47-55\">",
"     47-55",
"    </a>",
"    ]. As an example, a retrospective study of 20 adults with psoriasis and hepatitis C who were treated with etanercept (18 patients), adalimumab (4 patients),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    (3 patients),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infliximab (1 patient), found that these biologic agents were well-tolerated by most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, in 2004, the United States Food and Drug Administration (FDA) added a warning to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    package insert that described rare reports of acute liver failure, jaundice, hepatitis, and cholestasis from postmarketing data [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/56\">",
"     56",
"    </a>",
"    ]. Autoimmune hepatitis was diagnosed in some of the patients. The package inserts of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    do not have similar warnings [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1504190\">",
"    <span class=\"h3\">",
"     Ustekinumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    appeared to be safe and effective in three patients over a mean follow-up period of 15 months in a retrospective study, the possibility that IL-12 may have a role in host defense against HCV contributes to uncertainty regarding the safety of its use in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/34\">",
"     34",
"    </a>",
"    ]. Additional studies will be useful for determining the safety of ustekinumab therapy in patients with hepatitis C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515664\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The paucity of data on the treatment of psoriasis in patients with hepatitis C makes the identification of the best approach to the treatment of these patients difficult. We agree with the first and second-line therapeutic approach outlined by the Medical Board of the National Psoriasis Foundation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/3\">",
"     3",
"    </a>",
"    ]. For patients with moderate to severe psoriasis and hepatitis C, we use UVB phototherapy in combination with topical therapy as our preferred first-line treatment. Treatment options for patients who cannot be effectively treated with these modalities include biologic TNF-alpha inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    , and PUVA phototherapy, though data on the safety of these interventions are limited.",
"   </p>",
"   <p>",
"    We consult a hepatologist prior to starting treatment with a TNF-alpha inhibitor. Patients treated with TNF-alpha inhibitors also should have baseline and periodic assessments of HCV viral load and liver enzymes (eg, every three months) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/1,28\">",
"     1,28",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     Acitretin",
"    </a>",
"    should be used with caution in this population, with periodic monitoring of liver function status [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite evidence suggesting that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    may inhibit replication of HCV, until further evidence confirms its safety in the hepatitis C population, we agree with the Medical Board of the National Psoriasis Foundation&rsquo;s designation of this drug as a third-line agent for psoriasis in patients with hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/3\">",
"     3",
"    </a>",
"    ]. Further study is required for conclusions regarding the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    for psoriasis in patients with hepatitis C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9475354\">",
"    <span class=\"h1\">",
"     HUMAN IMMUNODEFICIENCY VIRUS INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with human immunodeficiency virus (HIV) infection may be more likely to have severe psoriasis than patients without HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/6\">",
"     6",
"    </a>",
"    ]. In some patients, psoriasis is the initial presenting sign of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/5\">",
"     5",
"    </a>",
"    ]. The immunosuppressive effects of psoriasis therapies are the major concern in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515703\">",
"    <span class=\"h2\">",
"     Antiretroviral drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis in HIV-infected patients may improve with antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/5,57-62\">",
"     5,57-62",
"    </a>",
"    ]. As an example, in an open-label study in which 24 patients with HIV-associated psoriasis were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , 90 percent of the 19 patients who were followed for at least eight weeks achieved either partial or complete improvement of psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220663823\">",
"    <span class=\"h2\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phototherapy can be effective for HIV-associated psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/2,63-65\">",
"     2,63-65",
"    </a>",
"    ]. Although ultraviolet radiation has been linked to activation of HIV in some in vitro and animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/66-68\">",
"     66-68",
"    </a>",
"    ], small case series and uncontrolled studies suggest that phototherapy administered to HIV-positive patients is well-tolerated and not associated with significant changes in viral load, CD4+, and CD8+ T cells during or after therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/63,65,69,70\">",
"     63,65,69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220663830\">",
"    <span class=\"h2\">",
"     Conventional oral agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"       Acitretin",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Acitretin is an attractive therapeutic option for psoriasis in patients with HIV because it is not an immunosuppressant. In a 20-week uncontrolled study in which 11 HIV-positive men with moderate to severe psoriasis (including seven men with plaque-type psoriasis) were treated with acitretin (up to 100 mg per day), four patients achieved at least 75 percent reduction in the Psoriasis Area and Severity Index [PASI] score and an additional two patients achieved at least 51 to 75 percent improvement. Two of the three patients who discontinued treatment stopped treatment due to worsening psoriasis. The third patient stopped treatment due to a myocardial infarction that was presumed to be unrelated to acitretin therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/71\">",
"       71",
"      </a>",
"      ]. Of note, typical doses of acitretin for the treatment of psoriasis range from 25 to 50 mg per day; higher doses are often poorly tolerated due to side effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H33#H33\">",
"       \"Treatment of psoriasis\", section on 'Retinoids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Methotrexate is not commonly used for psoriasis in HIV-infected patients due to concern about the drug&rsquo;s immunosuppressive effects [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/5,63,72\">",
"       5,63,72",
"      </a>",
"      ]. Although case reports have documented successful treatment in the setting of HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/72\">",
"       72",
"      </a>",
"      ], the risks and benefits of therapy must be weighed carefully prior to treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/5\">",
"       5",
"      </a>",
"      ]. Treatment with methotrexate is usually reserved for refractory cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"       \"Major side effects of low-dose methotrexate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Case reports have documented the successful use of cyclosporine for psoriasis in patients with HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]. However, as with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , the immunosuppressive effects are a concern. Treatment with cyclosporine is primarily reserved for short courses (up to 12 weeks) of treatment in patients with refractory disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link&amp;anchor=H17#H17\">",
"       \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Side effects'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Some authors have suggested an initial starting dose of 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of cyclosporine if the drug is used in this population [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/5\">",
"       5",
"      </a>",
"      ]. Trough levels of cyclosporine should be monitored carefully in patients taking protease inhibitors, since these agents may increase the bioavailability of cyclosporine [",
"      <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220663844\">",
"    <span class=\"h2\">",
"     Biologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited on the safety of biologic therapies in patients with HIV infection. Several cases of successful use of biologic TNF-alpha inhibitors for psoriasis or rheumatologic conditions in patients with HIV have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/76-80\">",
"     76-80",
"    </a>",
"    ]. Viral counts and immune status remained stable in these patients. However, one report documented the eventual discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    due to the occurrence of multiple infections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional case report has described successful treatment of psoriasis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/81\">",
"     81",
"    </a>",
"    ]. The patient achieved great improvement in psoriasis and treatment was well-tolerated.",
"   </p>",
"   <p>",
"    Further studies are necessary to determine the role biologic therapy should play in the management of psoriasis in patients with HIV infection. Concomitant antiretroviral therapy is suggested to decrease the likelihood of opportunistic infections during biologic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/5,6,76,82\">",
"     5,6,76,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515897\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other drugs that have been reported to be useful in individual patients with HIV and psoriasis include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"     nicotinamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    has been reported to be beneficial for psoriasis and for HIV independently; however, the drug has not been evaluated in patients with both conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H220663963\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HIV and moderate to severe psoriasis are best managed by coordinated care with a dermatologist and infectious disease specialist. We agree with the recommendations from the Medical Board of the National Psoriasis Foundation that first-line therapies for patients with HIV and psoriasis are phototherapy and antiretrovirals, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    is an appropriate second-line treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/6\">",
"     6",
"    </a>",
"    ]. Therapies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and TNF-alpha inhibitors should be reserved for severe refractory cases and should be used cautiously; the status of the HIV infection should be monitored closely during treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9475361\">",
"    <span class=\"h1\">",
"     LATENT TUBERCULOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive treatment may result in reactivation of latent tuberculosis (TB) infection. Thus, screening for TB infection is recommended prior to the administration of immunosuppressive therapies for psoriasis (eg, biologic agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/7\">",
"     7",
"    </a>",
"    ]. TNF-alpha plays a particularly important role in the immune defense against TB infection, raising particular concern about the use of TNF-alpha inhibitor therapy in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link&amp;anchor=H3#H3\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\", section on 'Tnf-alpha and host defenses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening is performed through a patient interview and testing via a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    or interferon-gamma release assay. A chest x-ray should be performed if the screening test is positive. Screening for TB infection is not necessary prior to treatment with topical agents, phototherapy, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    since these therapies do not appear to increase the risk for reactivation of TB infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have latent TB should be given treatment for this condition to reduce the risk for tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Opinions vary on how long patients must be on treatment for latent TB before TNF-alpha inhibitor therapy can be initiated. While some authors recommend completing the full course of prophylactic TB therapy prior to biologic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/85\">",
"     85",
"    </a>",
"    ], other sources, including the Medical Board of the National Psoriasis Foundation, suggest initiation of immunologic therapies after the first one to two months of prophylactic TB treatment if it is required by the clinical condition [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/2,7,86,87\">",
"     2,7,86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the National Psoriasis Foundation&rsquo;s approach. While the full course of prophylactic TB treatment can be completed before initiating a biologic agent, we consider acceptable the initiation of biologic therapy following at least one month of TB treatment such that the patient will then continue TB treatment concurrently with biologic therapy. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk for TB reactivation among patients who are treated with prophylactic therapy prior to the start of biologic therapy appears to be low [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/83,88,89\">",
"     83,88,89",
"    </a>",
"    ]. The risk for mycobacterial infections in patients treated with TNF-alpha inhibitors is reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9475368\">",
"    <span class=\"h1\">",
"     MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunosuppressive effects of systemic agents for psoriasis are the primary safety concerns for systemic psoriasis therapy in patients with a history internal malignancy. The best approach to the treatment varies based upon the severity of psoriasis and the type of malignancy. Consultation with the patient&rsquo;s oncologist and a thorough discussion with the patient about the risk-benefit ratios of the therapeutic options should take place prior to deciding on a treatment.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    may increase the risk for lymphoproliferative disorders. There is lingering uncertainty about the malignancy risk imparted by biologic agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link&amp;anchor=H14365930#H14365930\">",
"     \"Major side effects of low-dose methotrexate\", section on 'Lymphoproliferative disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link&amp;anchor=H23#H23\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Risk of malignancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H42#H42\">",
"     \"Treatment of psoriasis\", section on 'Ustekinumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43001?source=see_link&amp;anchor=H3467089#H3467089\">",
"     \"Comorbid disease in psoriasis\", section on 'Malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-immunosuppressive therapies, such as phototherapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    , are generally considered safe treatment options for patients with current or prior lymphoreticular or solid tumor malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with a history of melanoma or multiple nonmelanoma skin cancers are an exception since these conditions are relative contraindications for phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/31/14842/abstract/10\">",
"     10",
"    </a>",
"    ]. Of note, patients with a history of multiple squamous cell skin cancers may benefit from the suppressive effect of acitretin on the development of these lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H32#H32\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Oral retinoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39205739\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of psoriasis in pregnant women is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/4/41030?source=see_link\">",
"     \"Management of psoriasis in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52453712\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with moderate to severe psoriasis (psoriasis involving more than 5 to 10 percent of the body surface area) generally require phototherapy or systemic therapies for optimal management of the disease. The potential adverse effects of these therapies must be considered carefully in patients with comorbidities. (See",
"      <a class=\"local\" href=\"#H220664025\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of psoriasis\", section on 'Choice of therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The determination of the best approach to the management of psoriasis in patients with hepatitis B, hepatitis C, human immunodeficiency virus (HIV) infection, latent tuberculosis, and internal malignancy is challenging because data on psoriasis therapy in these populations are limited. Recommendations for the management of these patients are based upon data from patients with psoriasis, patients with other disorders treated with similar therapies, and expert opinion. (See",
"      <a class=\"local\" href=\"#H220664025\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      UVB phototherapy is a treatment for psoriasis that has negligible effects on hepatitic tissue and systemic immunity. UVB phototherapy is a safe treatment for psoriasis in patients with chronic hepatitis B, chronic hepatitis C, HIV infection, latent tuberculosis, and internal malignancy. (See",
"      <a class=\"local\" href=\"#H9475340\">",
"       'Chronic hepatitis B'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9475347\">",
"       'Chronic hepatitis C'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9475354\">",
"       'Human immunodeficiency virus infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9475361\">",
"       'Latent tuberculosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9475368\">",
"       'Malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"       Acitretin",
"      </a>",
"      is a systemic therapy for psoriasis that lacks immunosuppressive effects. This treatment can be beneficial in patients with infections or other disorders that may be exacerbated by immunosuppression. However, acitretin may have adverse hepatic effects. (See",
"      <a class=\"local\" href=\"#H9475354\">",
"       'Human immunodeficiency virus infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9475361\">",
"       'Latent tuberculosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9475368\">",
"       'Malignancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9475340\">",
"       'Chronic hepatitis B'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9475347\">",
"       'Chronic hepatitis C'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TNF-alpha inhibitor therapy may have beneficial effects on hepatitis C virus (HCV) infection and has been tolerated by patients with hepatitis C. Further studies are necessary to confirm the safety of TNF-alpha inhibitor therapy for psoriasis in the setting of hepatitis C. (See",
"      <a class=\"local\" href=\"#H106913731\">",
"       'TNF-alpha inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TNF-alpha plays an important role in immune defense against tuberculosis. Patients with psoriasis should be screened for latent tuberculosis prior to treatment with a TNF-alpha inhibitor and treatment for latent tuberculosis should begin prior to therapy. Although it has been less frequently performed in clinical practice, screening for latent tuberculosis also is advised prior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      therapy. (See",
"      <a class=\"local\" href=\"#H9475361\">",
"       'Latent tuberculosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/1\">",
"      Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012; 148:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/2\">",
"      Strober B, Berger E, Cather J, et al. A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol 2009; 61:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/3\">",
"      Frankel AJ, Van Voorhees AS, Hsu S, et al. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 61:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/4\">",
"      Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol 2012; 67:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/5\">",
"      Morar N, Willis-Owen SA, Maurer T, Bunker CB. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis 2010; 10:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/6\">",
"      Menon K, Van Voorhees AS, Bebo BF Jr, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/7\">",
"      Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008; 59:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/8\">",
"      Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003; 39 Suppl 1:S64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/9\">",
"      Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/10\">",
"      Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/11\">",
"      Zachariae H, Kragballe K, S&oslash;gaard H. Liver biopsy in PUVA-treated patients. Acta Derm Venereol 1979; 59:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/12\">",
"      Nyfors A, Dahl-Nyfors B, Hopwood D. Liver biopsies from patients with psoriasis related to photochemotherapy (PUVA): findings before and after 1 year of therapy in twelve patients. A blind study and review of literature on hepatotoxicity of PUVA. J Am Acad Dermatol 1986; 14:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/13\">",
"      Pariser DM, Wyles RJ. Toxic hepatitis from oral methoxsalen photochemotherapy (PUVA). J Am Acad Dermatol 1980; 3:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/14\">",
"      Markin RS, Donovan JP, Shaw BW Jr, Zetterman RK. Fulminant hepatic failure after methotrexate and PUVA therapy for psoriasis. J Clin Gastroenterol 1993; 17:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/15\">",
"      Bjellerup M, Bruze M, Krook G, Ljunggren B. Toxic hepatitis after PUVA. J Am Acad Dermatol 1981; 4:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/16\">",
"      Stephens RB, Cooper A. Hepatitis from 5-methoxypsoralen occurring in a patient with previous flucloxacillin hepatitis. Australas J Dermatol 1999; 40:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/17\">",
"      Bjellerup M, Bruze M, Hansson A, et al. Liver injury following administration of 8-methoxypsoralen during PUVA therapy. Acta Derm Venereol 1979; 59:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/18\">",
"      Watanabe K, Takase K, Ohno S, et al. Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Mod Rheumatol 2012; 22:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/19\">",
"      Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol 2007; 25:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/20\">",
"      Flowers MA, Heathcote J, Wanless IR, et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990; 112:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/21\">",
"      Ito S, Nakazono K, Murasawa A, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001; 44:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/22\">",
"      King LE. Letter: Complications during methotrexate therapy for psoriasis. Arch Dermatol 1975; 111:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/23\">",
"      Lee CS, Li K. A review of acitretin for the treatment of psoriasis. Expert Opin Drug Saf 2009; 8:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/24\">",
"      Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999; 41:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/25\">",
"      Roenigk HH Jr, Callen JP, Guzzo CA, et al. Effects of acitretin on the liver. J Am Acad Dermatol 1999; 41:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/26\">",
"      van Ditzhuijsen TJ, van Haelst UJ, van Dooren-Greebe RJ, et al. Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin). J Hepatol 1990; 11:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/27\">",
"      Sandrini S, Callea F, Cristinelli L, et al. Viral hepatitis in HBsAg-positive renal transplant patients treated with cyclosporin and steroids. Nephrol Dial Transplant 1990; 5:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/28\">",
"      Vigan&ograve; M, Degasperi E, Aghemo A, et al. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012; 12:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/29\">",
"      Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/30\">",
"      Cassano N, Mastrandrea V, Principi M, et al. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents 2011; 25:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/31\">",
"      Cho YT, Chen CH, Chiu HY, Tsai TF. Use of anti-tumor necrosis factor-&alpha; therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol 2012; 39:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/32\">",
"      Stine JG, Bass M, Ibrahim D, et al. Dermatologists' awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-&alpha; inhibitor therapy. South Med J 2011; 104:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/33\">",
"      Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/34\">",
"      Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol 2013; 168:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/35\">",
"      Koskinas J, Tampaki M, Doumba PP, Rallis E. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient. Br J Dermatol 2013; 168:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/36\">",
"      Fotiadou C, Lazaridou E, Ioannides D. Safety of anti-tumour necrosis factor-&alpha; agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol 2011; 25:471.",
"     </a>",
"    </li>",
"    <li>",
"     Lanvanchy D, McMahon B. Worldwide prevalence and prevention of hepatitis C. In: Hepatitis C, Liang TJ, Hoofnagle JH (Eds), Academic Press, San Diego 2000. p.185.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/38\">",
"      Afshar M, Martinez AD, Gallo RL, Hata TR. Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: A review and analysis of 36 cases. J Eur Acad Dermatol Venereol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/39\">",
"      Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/40\">",
"      Nakagawa M, Sakamoto N, Enomoto N, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004; 313:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/41\">",
"      Liu JP, Ye L, Wang X, et al. Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytes. Transpl Infect Dis 2011; 13:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/42\">",
"      Bomm L, Zimmermann C, Souto R, et al. Use of cyclosporin in a patient with hepatitis C and pustular psoriasis. An Bras Dermatol 2011; 86:S193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/43\">",
"      Di Lernia V. Treatment of psoriasis in patients with hepatitis C virus infection. Clin Exp Dermatol 2011; 36:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/44\">",
"      Giovanna Brunasso AM, Michetti P, Fancelli L, Massone C. Cyclosporine as monotherapy for psoriasis in the setting of chronic HCV infection: a forgotten therapeutical option. Hepat Mon 2012; 12:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/45\">",
"      Imafuku S, Tashiro A, Furue M. Ciclosporin treatment of psoriasis in a patient with chronic hepatitis C. Br J Dermatol 2007; 156:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/46\">",
"      Zein NN, Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/47\">",
"      Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011; 50:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/48\">",
"      De Simone C, Paradisi A, Capizzi R, et al. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006; 54:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/49\">",
"      Di Lernia V, Guareschi E. Successful treatment of hand and foot psoriasis with infliximab. Dermatol Online J 2010; 16:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/50\">",
"      Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004; 51:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/51\">",
"      Prignano F, Ricceri F, Pescitelli L, et al. Tumour necrosis factor-&alpha; antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol 2011; 164:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/52\">",
"      Aslanidis S, Vassiliadis T, Pyrpasopoulou A, et al. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007; 26:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/53\">",
"      Pitarch G, Sanchez-Carazo JL, Mahiques L, et al. Treatment of psoriasis with adalimumab. Clin Exp Dermatol 2007; 32:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/54\">",
"      Zanni M, Missale G, Santilli D, Di Nuzzo S. Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis&nbsp;C virus infection: clinical and virological study in three patients. Eur J Dermatol 2011; 21:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/55\">",
"      Gandhi RK, Pickup T, Sheth PB. Is etanercept safe for treating plaque psoriasis in a patient with chronic hepatitis C virus infection? Arch Dermatol 2010; 146:1151.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm166901.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/57\">",
"      Duvic M, Crane MM, Conant M, et al. Zidovudine improves psoriasis in human immunodeficiency virus-positive males. Arch Dermatol 1994; 130:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/58\">",
"      Fischer T, Schw&ouml;rer H, Vente C, et al. Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy. AIDS 1999; 13:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/59\">",
"      Mahajan VK, Sharma NL, Sarin S, et al. Triple antiretroviral therapy improves psoriasis associated with human immunodeficiency virus infection: a clinico-therapeutic experience. J Eur Acad Dermatol Venereol 2008; 22:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/60\">",
"      Vittorio Luigi De Socio G, Simonetti S, Stagni G. Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. Scand J Infect Dis 2006; 38:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/61\">",
"      Kaplan MH, Sadick NS, Wieder J, et al. Antipsoriatic effects of zidovudine in human immunodeficiency virus-associated psoriasis. J Am Acad Dermatol 1989; 20:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/62\">",
"      Arnett FC, Reveille JD, Duvic M. Psoriasis and psoriatic arthritis associated with human immunodeficiency virus infection. Rheum Dis Clin North Am 1991; 17:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/63\">",
"      Breuer-McHam J, Marshall G, Adu-Oppong A, et al. Alterations in HIV expression in AIDS patients with psoriasis or pruritus treated with phototherapy. J Am Acad Dermatol 1999; 40:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/64\">",
"      Chernyshov P. Testing for HIV prior to methotrexate administration. Is it an obligatory procedure? Int J Dermatol 2006; 45:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/65\">",
"      Meola T, Soter NA, Ostreicher R, et al. The safety of UVB phototherapy in patients with HIV infection. J Am Acad Dermatol 1993; 29:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/66\">",
"      Rosenberg ZF, Fauci AS. Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression. Immunol Today 1990; 11:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/67\">",
"      Cavard C, Zider A, Vernet M, et al. In vivo activation by ultraviolet rays of the human immunodeficiency virus type 1 long terminal repeat. J Clin Invest 1990; 86:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/68\">",
"      Stein B, Kr&auml;mer M, Rahmsdorf HJ, et al. UV-induced transcription from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and UV-induced secretion of an extracellular factor that induces HIV-1 transcription in nonirradiated cells. J Virol 1989; 63:4540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/69\">",
"      Fotiades J, Lim HW, Jiang SB, et al. Efficacy of ultraviolet B phototherapy for psoriasis in patients infected with human immunodeficiency virus. Photodermatol Photoimmunol Photomed 1995; 11:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/70\">",
"      Pech&egrave;re M, Yerly S, Lemonnier E, et al. Impact of PUVA therapy on HIV viremia: a pilot study. Dermatology 1997; 195:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/71\">",
"      Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol 1997; 133:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/72\">",
"      Maurer TA, Zackheim HS, Tuffanelli L, Berger TG. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol 1994; 31:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/73\">",
"      Allen BR. Use of cyclosporin for psoriasis in HIV-positive patient. Lancet 1992; 339:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/74\">",
"      Tourne L, Durez P, Van Vooren JP, et al. Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine. J Am Acad Dermatol 1997; 37:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/75\">",
"      Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2010; 62:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/76\">",
"      Sellam J, Bouvard B, Masson C, et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine 2007; 74:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/77\">",
"      Bartke U, Venten I, Kreuter A, et al. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br J Dermatol 2004; 150:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/78\">",
"      Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/79\">",
"      Lee ES, Heller MM, Kamangar F, et al. Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study. J Drugs Dermatol 2012; 11:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/80\">",
"      Aboulafia DM, Bundow D, Wilske K, Ochs UI. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000; 75:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/81\">",
"      Paparizos V, Rallis E, Kirsten L, Kyriakis K. Ustekinumab for the treatment of HIV psoriasis. J Dermatolog Treat 2012; 23:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/82\">",
"      Nordgaard-Lassen I, Dahlerup JF, Belard E, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J 2012; 59:C4480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/83\">",
"      Carmona L, G&oacute;mez-Reino JJ, Rodr&iacute;guez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/84\">",
"      Perez J, Kupper H, Spencer-Green G. Impact of screening for latent TB prior to initiation of anti-TNF therapy in North America and Europe. Ann Rheum Dis 2005; 64:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/85\">",
"      Sivamani RK, Goodarzi H, Garcia MS, et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clin Rev Allergy Immunol 2013; 44:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/86\">",
"      Amerio P, Amoruso G, Bardazzi F, et al. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. J Dermatolog Treat 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/87\">",
"      Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/88\">",
"      Aggarwal R, Manadan AM, Poliyedath A, et al. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol 2009; 36:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/31/14842/abstract/89\">",
"      Tsai TF, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol 2012; 167:1145.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15279 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14842=[""].join("\n");
var outline_f14_31_14842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H52453712\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9475333\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H220664025\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9475340\">",
"      CHRONIC HEPATITIS B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174248504\">",
"      Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H220663779\">",
"      Conventional oral agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H220663786\">",
"      Biologic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1503100\">",
"      - TNF-alpha inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1503282\">",
"      - Ustekinumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174248692\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9475347\">",
"      CHRONIC HEPATITIS C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H974087\">",
"      Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H220663801\">",
"      Conventional oral agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H220663808\">",
"      Biologic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H106913731\">",
"      - TNF-alpha inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1504190\">",
"      - Ustekinumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H515664\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9475354\">",
"      HUMAN IMMUNODEFICIENCY VIRUS INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H515703\">",
"      Antiretroviral drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H220663823\">",
"      Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H220663830\">",
"      Conventional oral agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H220663844\">",
"      Biologic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H515897\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H220663963\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9475361\">",
"      LATENT TUBERCULOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9475368\">",
"      MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39205739\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H52453712\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15279\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15279|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/25/42398\" title=\"figure 1\">",
"      Serology acute and chronic HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15279|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/60/41932\" title=\"table 1A\">",
"      Serologic markers HBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/45/2781\" title=\"table 1B\">",
"      Interpretation of the Hepatitis B panel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/37/24155\" title=\"table 2\">",
"      PUVA contraindications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43001?source=related_link\">",
"      Comorbid disease in psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=related_link\">",
"      Investigational therapies for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/4/41030?source=related_link\">",
"      Management of psoriasis in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=related_link\">",
"      Psoralen plus ultraviolet A (PUVA) photochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26775?source=related_link\">",
"      UVB therapy (broadband and narrowband)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_31_14843="Doses IV antimicrobials";
var content_f14_31_14843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intravenous antimicrobials for pneumococcal pneumonia in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Antimicrobial",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose",
"      </td>",
"      <td class=\"subtitle1\">",
"       Interval",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Penicillin G",
"      </td>",
"      <td>",
"       2 to 3 million units",
"      </td>",
"      <td>",
"       Every 4 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ampicillin",
"      </td>",
"      <td>",
"       2 grams",
"      </td>",
"      <td>",
"       Every 6 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ampicillin/sulbactam",
"      </td>",
"      <td>",
"       2 grams ampicillin plus 1 gram sulbactam",
"      </td>",
"      <td>",
"       Every 6 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amoxicillin/clavulanate",
"      </td>",
"      <td>",
"       1 gram amoxicillin plus 0.125 grams clavulanate",
"      </td>",
"      <td>",
"       Every 6 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cefotaxime",
"      </td>",
"      <td>",
"       2 grams",
"      </td>",
"      <td>",
"       Every 6 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ceftriaxone",
"      </td>",
"      <td>",
"       1 gram",
"      </td>",
"      <td>",
"       Every 12 hours",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14843=[""].join("\n");
var outline_f14_31_14843=null;
var title_f14_31_14844="Hemoperfusion in poisons";
var content_f14_31_14844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common agents for which hemoperfusion may enhance elimination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Barbiturates&nbsp;&nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenobarbital",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Primidone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sedative-hypnotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Meprobamate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Methaqualone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Glutethimide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ethchlorvynol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenytoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Disopyramide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chloramphenicol",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Amanita mushrooms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbamazepine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Valproate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Procainamide + N-acetylprocainamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chloral hydrate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dapsone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methotrexate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenylbutazone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon tetrachloride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paraquat",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14844=[""].join("\n");
var outline_f14_31_14844=null;
var title_f14_31_14845="Carcinogenesis in Barretts";
var content_f14_31_14845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carcinogenesis in Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 251px; height: 251px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14845=[""].join("\n");
var outline_f14_31_14845=null;
var title_f14_31_14846="Maximal flow volume curve IPF";
var content_f14_31_14846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Maximal expiratory flow volume (MEFV curve) in idiopathic pulmonary fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 368px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A: shown are the MEFV curves at presentation in a 42-year old nonsmoking man with a normal chest roentgenogram and lung biopsy-proven idiopathic pulmonary fibrosis. The FEV1 and FVC values are low relative to the predicted values, but the FEV1 to FVC ratio is increased. However, at any given lung volume, the flow rates are higher than expected because of elevated driving pressure due to an increased elastic recoil. B: shows the MEFV curve for a patient with chronic obstructive lung disease. The FEV1 and FVC values are low relative to the predicted values, and the lung volumes are increased.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14846=[""].join("\n");
var outline_f14_31_14846=null;
var title_f14_31_14847="Passive stretch tenosynovitis";
var content_f14_31_14847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Passive stretching sign for active tenosynovitis of the finger (trigger finger)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hands are placed in the palms up position, and the affected finger is passively stretched in the extended position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_31_14847=[""].join("\n");
var outline_f14_31_14847=null;
